<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Australian Living Guideline for Inflammatory Arthritis</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Source+Sans+3:wght@300;400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    <style>
        :root {
            --primary-blue: #1e3a5f;
            --primary-teal: #0d9488;
            --primary-teal-light: #14b8a6;
            --primary-teal-dark: #0f766e;
            --accent-yellow: #eab308;
            --accent-orange: #f97316;
            --text-dark: #1f2937;
            --text-medium: #4b5563;
            --text-light: #6b7280;
            --bg-cream: #fefdfb;
            --bg-light: #f8fafc;
            --bg-blue-light: #f0f9ff;
            --border-light: #e5e7eb;
            --border-medium: #d1d5db;
            --white: #ffffff;
            --shadow-md: 0 4px 6px -1px rgba(0,0,0,0.1);
            --shadow-lg: 0 10px 15px -3px rgba(0,0,0,0.1);
            --radius-sm: 6px;
            --radius-md: 10px;
            --radius-lg: 16px;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Source Sans 3', -apple-system, BlinkMacSystemFont, sans-serif; color: var(--text-dark); line-height: 1.6; background-color: var(--bg-cream); }
        header { background: var(--white); border-bottom: 1px solid var(--border-light); position: sticky; top: 0; z-index: 1000; }
        .header-top { background: var(--primary-blue); padding: 8px 0; }
        .header-top-content { max-width: 1200px; margin: 0 auto; padding: 0 24px; display: flex; justify-content: flex-end; gap: 24px; }
        .header-top a { color: rgba(255,255,255,0.85); text-decoration: none; font-size: 13px; font-weight: 500; }
        .header-top a:hover { color: var(--white); }
        .header-main { max-width: 1200px; margin: 0 auto; padding: 16px 24px; display: flex; justify-content: space-between; align-items: center; flex-wrap: wrap; gap: 16px; }
        .logo-title { font-family: 'Source Serif 4', Georgia, serif; font-size: 22px; font-weight: 600; color: var(--primary-blue); }
        .logo-subtitle { font-size: 13px; color: var(--text-light); }
        nav { display: flex; gap: 8px; flex-wrap: wrap; }
        .nav-item { position: relative; }
        .nav-link { display: flex; align-items: center; gap: 6px; padding: 10px 16px; color: var(--text-medium); text-decoration: none; font-size: 15px; font-weight: 500; border-radius: var(--radius-sm); transition: all 0.2s; }
        .nav-link:hover { color: var(--primary-teal); background: var(--bg-light); }
        .nav-link svg { width: 14px; height: 14px; transition: transform 0.2s; }
        .nav-item:hover .nav-link svg { transform: rotate(180deg); }
        .dropdown { position: absolute; top: 100%; left: 0; min-width: 220px; background: var(--white); border-radius: var(--radius-md); box-shadow: var(--shadow-lg); border: 1px solid var(--border-light); opacity: 0; visibility: hidden; transform: translateY(10px); transition: all 0.2s; padding: 8px; z-index: 100; }
        .nav-item:hover .dropdown { opacity: 1; visibility: visible; transform: translateY(0); }
        .dropdown a { display: block; padding: 10px 14px; color: var(--text-medium); text-decoration: none; font-size: 14px; border-radius: var(--radius-sm); }
        .dropdown a:hover { background: var(--bg-light); color: var(--primary-teal); }
        .hero { background: linear-gradient(135deg, var(--primary-blue) 0%, #2d5a87 100%); padding: 80px 24px; }
        .hero-content { max-width: 1200px; margin: 0 auto; }
        .hero h1 { font-family: 'Source Serif 4', Georgia, serif; font-size: clamp(28px, 5vw, 44px); font-weight: 600; color: var(--white); margin-bottom: 20px; max-width: 700px; line-height: 1.2; }
        .hero-description { font-size: 19px; color: rgba(255,255,255,0.9); max-width: 600px; line-height: 1.7; margin-bottom: 32px; }
        .hero-badges { display: flex; flex-wrap: wrap; gap: 12px; margin-bottom: 32px; }
        .hero-badge { display: inline-flex; align-items: center; gap: 8px; padding: 8px 16px; background: rgba(255,255,255,0.15); border-radius: 100px; color: var(--white); font-size: 14px; font-weight: 500; }
        .hero-badge svg { width: 16px; height: 16px; }
        .hero-cta { display: inline-flex; align-items: center; gap: 10px; padding: 14px 28px; background: var(--primary-teal); color: var(--white); text-decoration: none; font-size: 16px; font-weight: 600; border-radius: var(--radius-md); transition: all 0.2s; box-shadow: 0 4px 14px rgba(13,148,136,0.4); }
        .hero-cta:hover { background: var(--primary-teal-light); transform: translateY(-2px); }
        .hero-cta svg { width: 18px; height: 18px; }
        .whats-new-section { padding: 48px 24px; background: var(--bg-light); border-bottom: 1px solid var(--border-light); }
        .whats-new-container { max-width: 1200px; margin: 0 auto; }
        .whats-new-header { display: flex; justify-content: space-between; align-items: center; margin-bottom: 24px; flex-wrap: wrap; gap: 16px; }
        .whats-new-header h2 { font-family: 'Source Serif 4', Georgia, serif; font-size: 24px; font-weight: 600; color: var(--primary-blue); display: flex; align-items: center; gap: 10px; }
        .whats-new-header h2 svg { width: 24px; height: 24px; color: var(--primary-teal); }
        .whats-new-link { font-size: 14px; font-weight: 600; color: var(--primary-teal); text-decoration: none; display: flex; align-items: center; gap: 6px; }
        .whats-new-link:hover { text-decoration: underline; }
        .whats-new-link svg { width: 16px; height: 16px; }
        .whats-new-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(300px, 1fr)); gap: 20px; }
        .whats-new-item { background: var(--white); border: 1px solid var(--border-light); border-radius: var(--radius-md); padding: 20px 24px; display: flex; gap: 16px; transition: all 0.2s; cursor: pointer; }
        .whats-new-item:hover { border-color: var(--primary-teal); box-shadow: var(--shadow-md); }
        .whats-new-badge { flex-shrink: 0; width: 44px; height: 44px; border-radius: var(--radius-sm); display: flex; align-items: center; justify-content: center; }
        .whats-new-badge.new { background: linear-gradient(135deg, #10b981 0%, #059669 100%); }
        .whats-new-badge.updated { background: linear-gradient(135deg, #3b82f6 0%, #2563eb 100%); }
        .whats-new-badge svg { width: 22px; height: 22px; color: var(--white); }
        .whats-new-content { flex: 1; min-width: 0; }
        .whats-new-label { font-size: 11px; font-weight: 700; text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 4px; }
        .whats-new-label.new { color: #059669; }
        .whats-new-label.updated { color: #2563eb; }
        .whats-new-title { font-size: 15px; font-weight: 600; color: var(--text-dark); line-height: 1.4; margin-bottom: 6px; }
        .whats-new-meta { font-size: 13px; color: var(--text-light); }
        .conditions-section { padding: 60px 24px; background: var(--white); }
        .conditions-container { max-width: 1200px; margin: 0 auto; }
        .section-header { text-align: center; margin-bottom: 40px; }
        .section-header h2 { font-family: 'Source Serif 4', Georgia, serif; font-size: 32px; font-weight: 600; color: var(--primary-blue); margin-bottom: 12px; }
        .section-header p { font-size: 17px; color: var(--text-medium); max-width: 600px; margin: 0 auto; }
        .filter-section { margin-bottom: 40px; }
        .filter-row { display: flex; justify-content: center; gap: 8px; margin-bottom: 16px; flex-wrap: wrap; }
        .filter-label { font-size: 13px; font-weight: 600; color: var(--text-light); text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 12px; text-align: center; }
        .condition-tab { padding: 12px 24px; background: var(--bg-light); border: 2px solid transparent; border-radius: var(--radius-md); font-size: 14px; font-weight: 600; color: var(--text-medium); cursor: pointer; transition: all 0.2s; }
        .condition-tab:hover { border-color: var(--border-medium); color: var(--text-dark); }
        .condition-tab.active { background: var(--primary-teal); color: var(--white); border-color: var(--primary-teal); }
        .search-container { max-width: 500px; margin: 0 auto 32px; position: relative; }
        .search-input { width: 100%; padding: 14px 20px 14px 48px; font-size: 16px; border: 2px solid var(--border-light); border-radius: var(--radius-md); background: var(--white); color: var(--text-dark); transition: all 0.2s; }
        .search-input:focus { outline: none; border-color: var(--primary-teal); box-shadow: 0 0 0 3px rgba(13,148,136,0.1); }
        .search-input::placeholder { color: var(--text-light); }
        .search-icon { position: absolute; left: 16px; top: 50%; transform: translateY(-50%); width: 20px; height: 20px; color: var(--text-light); pointer-events: none; }
        .search-clear { position: absolute; right: 12px; top: 50%; transform: translateY(-50%); width: 24px; height: 24px; border: none; background: var(--bg-light); border-radius: 50%; cursor: pointer; display: none; align-items: center; justify-content: center; color: var(--text-medium); }
        .search-clear:hover { background: var(--border-light); }
        .search-clear.visible { display: flex; }
        .no-results { text-align: center; padding: 60px 20px; color: var(--text-light); }
        .no-results h3 { font-size: 18px; color: var(--text-medium); margin-bottom: 8px; }
        .tag-filters { display: flex; justify-content: center; gap: 8px; flex-wrap: wrap; max-width: 900px; margin: 0 auto; }
        .tag-filter { padding: 6px 14px; background: var(--white); border: 1px solid var(--border-light); border-radius: 100px; font-size: 13px; font-weight: 500; color: var(--text-medium); cursor: pointer; transition: all 0.2s; }
        .tag-filter:hover { border-color: var(--primary-teal); color: var(--primary-teal); }
        .tag-filter.active { background: var(--primary-blue); color: var(--white); border-color: var(--primary-blue); }
        .recommendations-grid { display: grid; grid-template-columns: repeat(auto-fill, minmax(340px, 1fr)); gap: 24px; }
        .recommendation-card { background: var(--white); border: 1px solid var(--border-light); border-radius: var(--radius-lg); overflow: hidden; transition: all 0.3s; cursor: pointer; }
        .recommendation-card:hover { border-color: var(--primary-teal); box-shadow: var(--shadow-lg); transform: translateY(-4px); }
        .recommendation-card.hidden { display: none; }
        .card-header { padding: 20px 24px; border-bottom: 1px solid var(--border-light); display: flex; justify-content: space-between; align-items: flex-start; gap: 16px; }
        .card-category { font-size: 12px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; color: var(--primary-teal); margin-bottom: 8px; }
        .card-title { font-family: 'Source Serif 4', Georgia, serif; font-size: 18px; font-weight: 600; color: var(--text-dark); line-height: 1.4; }
        .card-strength { flex-shrink: 0; display: flex; flex-direction: column; align-items: center; gap: 4px; }
        .strength-indicator { width: 48px; height: 48px; border-radius: 50%; display: flex; align-items: center; justify-content: center; }
        .strength-indicator.conditional-for { background: linear-gradient(135deg, var(--accent-yellow) 0%, #ca8a04 100%); }
        .strength-indicator.conditional-against { background: linear-gradient(135deg, var(--accent-orange) 0%, #ea580c 100%); }
        .strength-indicator svg { width: 24px; height: 24px; color: var(--white); }
        .strength-label { font-size: 10px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.3px; color: var(--text-light); text-align: center; }
        .card-body { padding: 20px 24px; }
        .card-recommendation { font-size: 15px; color: var(--text-medium); line-height: 1.6; margin-bottom: 16px; }
        .card-tags { display: flex; flex-wrap: wrap; gap: 8px; }
        .card-tag { padding: 4px 10px; background: var(--bg-light); border-radius: 100px; font-size: 12px; font-weight: 500; color: var(--text-light); }
        .card-footer { padding: 16px 24px; background: var(--bg-light); display: flex; justify-content: space-between; align-items: center; }
        .card-link { display: inline-flex; align-items: center; gap: 6px; color: var(--primary-teal); text-decoration: none; font-size: 14px; font-weight: 600; }
        .card-link:hover { gap: 10px; }
        .card-link svg { width: 16px; height: 16px; }
        .card-updated { font-size: 12px; color: var(--text-light); }
        .modal-overlay { position: fixed; top: 0; left: 0; right: 0; bottom: 0; background: rgba(0,0,0,0.5); z-index: 2000; display: none; align-items: center; justify-content: center; padding: 24px; backdrop-filter: blur(4px); }
        .modal-overlay.active { display: flex; }
        .modal-content { background: var(--white); border-radius: var(--radius-lg); max-width: 900px; width: 100%; max-height: 90vh; overflow: hidden; display: flex; flex-direction: column; box-shadow: 0 25px 50px -12px rgba(0,0,0,0.25); }
        .modal-header { padding: 24px 32px; border-bottom: 1px solid var(--border-light); display: flex; justify-content: space-between; align-items: flex-start; gap: 20px; }
        .modal-category { font-size: 13px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; color: var(--primary-teal); margin-bottom: 8px; }
        .modal-title { font-family: 'Source Serif 4', Georgia, serif; font-size: 24px; font-weight: 600; color: var(--text-dark); line-height: 1.3; }
        .modal-close { width: 40px; height: 40px; border: none; background: var(--bg-light); border-radius: 50%; cursor: pointer; display: flex; align-items: center; justify-content: center; flex-shrink: 0; }
        .modal-close:hover { background: var(--border-light); }
        .modal-close svg { width: 20px; height: 20px; color: var(--text-medium); }
        .modal-tabs { display: flex; flex-wrap: wrap; padding: 0 32px; border-bottom: 1px solid var(--border-light); background: var(--bg-light); overflow-x: auto; min-height: 50px; }
        .modal-tab { padding: 16px 20px; font-size: 14px; font-weight: 600; color: var(--text-light); cursor: pointer; border: none; border-bottom: 3px solid transparent; margin-bottom: -1px; white-space: nowrap; background: none; }
        .modal-tab:hover { color: var(--text-medium); background: rgba(0,0,0,0.02); }
        .modal-tab.active { color: var(--primary-teal); border-bottom-color: var(--primary-teal); background: var(--white); }
        .modal-body { padding: 32px; overflow-y: auto; flex: 1; }
        .tab-content { display: none; }
        .tab-content.active { display: block; }
        .recommendation-box { background: var(--bg-blue-light); border-left: 5px solid var(--primary-teal); padding: 24px 28px; border-radius: 0 var(--radius-md) var(--radius-md) 0; margin-bottom: 24px; }
        .recommendation-box p { font-family: 'Source Serif 4', Georgia, serif; font-size: 18px; font-weight: 600; color: var(--primary-blue); line-height: 1.7; margin-bottom: 16px; }
        .recommendation-box p:last-child { margin-bottom: 0; }
        .remark-box { background: var(--bg-light); padding: 16px 20px; border-radius: var(--radius-md); margin-bottom: 24px; border: 1px solid var(--border-light); }
        .remark-box p { font-size: 15px; color: var(--text-medium); line-height: 1.7; font-style: italic; margin-bottom: 12px; }
        .remark-box p:last-child { margin-bottom: 0; }
        .strength-badge { display: inline-flex; align-items: center; gap: 8px; padding: 8px 14px; border-radius: 100px; font-size: 13px; font-weight: 600; margin-bottom: 20px; }
        .strength-badge.conditional-for { background: rgba(234,179,8,0.15); color: #a16207; }
        .strength-badge.conditional-against { background: rgba(249,115,22,0.15); color: #c2410c; }
        .content-section { margin-bottom: 28px; }
        .content-section:last-child { margin-bottom: 0; }
        .content-section h3 { font-size: 18px; font-weight: 600; color: var(--text-dark); margin-bottom: 16px; }
        .content-section p { font-size: 15px; color: var(--text-medium); line-height: 1.8; margin-bottom: 16px; }
        .content-section p:last-child { margin-bottom: 0; }
        .content-section ul { padding-left: 24px; margin: 16px 0; }
        .content-section li { font-size: 15px; color: var(--text-medium); line-height: 1.7; margin-bottom: 10px; padding-left: 4px; }
        .content-section li:last-child { margin-bottom: 0; }
        .content-section strong { color: var(--text-dark); }
        .etd-domain { margin-bottom: 24px; padding: 20px; background: var(--bg-light); border-radius: var(--radius-md); border: 1px solid var(--border-light); }
        .etd-domain:last-child { margin-bottom: 0; }
        .etd-domain-header { display: flex; justify-content: space-between; align-items: center; margin-bottom: 12px; flex-wrap: wrap; gap: 8px; }
        .etd-domain-title { font-size: 16px; font-weight: 600; color: var(--text-dark); }
        .etd-rating { display: inline-block; padding: 4px 12px; background: var(--white); border: 1px solid var(--border-medium); border-radius: 100px; font-size: 12px; font-weight: 600; color: var(--text-medium); }
        .etd-domain-text { font-size: 14px; color: var(--text-medium); line-height: 1.8; }
        .etd-domain-text p { margin-bottom: 12px; }
        .etd-domain-text p:last-child { margin-bottom: 0; }
        .etd-domain-text ul { padding-left: 20px; margin: 12px 0; }
        .etd-domain-text li { margin-bottom: 8px; line-height: 1.7; }
        .modal-footer { padding: 20px 32px; border-top: 1px solid var(--border-light); display: flex; justify-content: space-between; align-items: center; background: var(--bg-light); flex-wrap: wrap; gap: 16px; }
        .magicapp-link { display: inline-flex; align-items: center; gap: 8px; padding: 12px 20px; background: var(--primary-blue); color: var(--white); text-decoration: none; font-size: 14px; font-weight: 600; border-radius: var(--radius-md); }
        .magicapp-link:hover { background: #2d5a87; }
        .magicapp-link svg { width: 16px; height: 16px; }
        .feedback-link { display: inline-flex; align-items: center; gap: 6px; padding: 10px 16px; color: var(--text-medium); text-decoration: none; font-size: 13px; font-weight: 500; border: 1px solid var(--border-light); border-radius: var(--radius-md); transition: all 0.2s; }
        .feedback-link:hover { border-color: var(--primary-teal); color: var(--primary-teal); background: var(--bg-light); }
        .feedback-link svg { width: 14px; height: 14px; }
        .modal-footer-left { display: flex; align-items: center; gap: 16px; flex-wrap: wrap; }
        .modal-footer-right { display: flex; align-items: center; gap: 12px; flex-wrap: wrap; }
        .data-placeholder { text-align: center; padding: 40px; background: var(--bg-light); border-radius: var(--radius-md); border: 2px dashed var(--border-medium); }
        .data-placeholder p { color: var(--text-light); font-size: 15px; }
        .panel-info { margin-bottom: 28px; }
        .panel-info h3 { font-size: 16px; font-weight: 600; color: var(--text-dark); margin-bottom: 16px; display: flex; align-items: center; gap: 8px; }
        .panel-info h3 svg { width: 20px; height: 20px; color: var(--primary-teal); }
        .panel-members { display: flex; flex-wrap: wrap; gap: 10px; }
        .panel-member { display: inline-flex; align-items: center; gap: 8px; padding: 8px 14px; background: var(--bg-light); border-radius: 100px; font-size: 14px; color: var(--text-medium); border: 1px solid var(--border-light); }
        .panel-member.chair { background: var(--primary-blue); color: var(--white); border-color: var(--primary-blue); }
        .panel-member-role { font-size: 11px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.3px; opacity: 0.7; }
        .info-item { display: flex; gap: 12px; margin-bottom: 16px; padding: 16px; background: var(--bg-light); border-radius: var(--radius-md); }
        .info-item:last-child { margin-bottom: 0; }
        .info-icon { flex-shrink: 0; width: 40px; height: 40px; background: var(--white); border-radius: var(--radius-sm); display: flex; align-items: center; justify-content: center; border: 1px solid var(--border-light); }
        .info-icon svg { width: 20px; height: 20px; color: var(--primary-teal); }
        .info-content { flex: 1; }
        .info-label { font-size: 12px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; color: var(--text-light); margin-bottom: 4px; }
        .info-value { font-size: 15px; color: var(--text-dark); }
        .info-value a { color: var(--primary-teal); text-decoration: none; }
        .info-value a:hover { text-decoration: underline; }
        .about-section { padding: 80px 24px; background: var(--bg-light); }
        .about-container { max-width: 1200px; margin: 0 auto; display: grid; grid-template-columns: 1fr 1fr; gap: 60px; align-items: center; }
        .about-content h2 { font-family: 'Source Serif 4', Georgia, serif; font-size: 32px; font-weight: 600; color: var(--primary-blue); margin-bottom: 20px; }
        .about-content p { font-size: 16px; color: var(--text-medium); line-height: 1.8; margin-bottom: 16px; }
        .about-features { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; }
        .feature-card { padding: 24px; background: var(--white); border-radius: var(--radius-md); border: 1px solid var(--border-light); }
        .feature-icon { width: 48px; height: 48px; background: linear-gradient(135deg, var(--primary-teal) 0%, var(--primary-teal-dark) 100%); border-radius: var(--radius-md); display: flex; align-items: center; justify-content: center; margin-bottom: 16px; }
        .feature-icon svg { width: 24px; height: 24px; color: var(--white); }
        .feature-card h3 { font-size: 16px; font-weight: 600; color: var(--text-dark); margin-bottom: 8px; }
        .feature-card p { font-size: 14px; color: var(--text-light); line-height: 1.6; margin: 0; }
        .partners-section { padding: 60px 24px; background: var(--white); border-top: 1px solid var(--border-light); }
        .partners-container { max-width: 1200px; margin: 0 auto; text-align: center; }
        .partners-label { font-size: 13px; font-weight: 600; text-transform: uppercase; letter-spacing: 1px; color: var(--text-light); margin-bottom: 24px; }
        .partners-logos { display: flex; justify-content: center; align-items: center; gap: 32px; flex-wrap: wrap; }
        .partner-text { font-size: 14px; font-weight: 600; color: var(--text-light); padding: 12px 20px; border: 1px solid var(--border-light); border-radius: var(--radius-sm); }
        footer { background: var(--primary-blue); padding: 60px 24px 30px; color: var(--white); }
        .footer-container { max-width: 1200px; margin: 0 auto; }
        .footer-grid { display: grid; grid-template-columns: 2fr 1fr 1fr 1fr; gap: 48px; margin-bottom: 48px; }
        .footer-brand h3 { font-family: 'Source Serif 4', Georgia, serif; font-size: 20px; font-weight: 600; margin-bottom: 16px; }
        .footer-brand p { font-size: 14px; color: rgba(255,255,255,0.7); line-height: 1.7; }
        .footer-column h4 { font-size: 14px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 16px; }
        .footer-column a { display: block; color: rgba(255,255,255,0.7); text-decoration: none; font-size: 14px; padding: 6px 0; }
        .footer-column a:hover { color: var(--white); }
        .footer-bottom { padding-top: 30px; border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center; flex-wrap: wrap; gap: 16px; }
        .footer-copyright { font-size: 13px; color: rgba(255,255,255,0.5); }
        .footer-links { display: flex; gap: 24px; }
        .footer-links a { color: rgba(255,255,255,0.5); text-decoration: none; font-size: 13px; }
        .footer-links a:hover { color: var(--white); }
        @media (max-width: 1024px) { .about-container { grid-template-columns: 1fr; gap: 40px; } .footer-grid { grid-template-columns: 1fr 1fr; } }
        @media (max-width: 768px) { .recommendations-grid { grid-template-columns: 1fr; } .about-features { grid-template-columns: 1fr; } .footer-grid { grid-template-columns: 1fr; gap: 32px; } .modal-content { max-height: 100vh; border-radius: 0; } .modal-header, .modal-body, .modal-footer { padding-left: 20px; padding-right: 20px; } }
    </style>
</head>
<body>
    <header>
        <div class="header-top">
            <div class="header-top-content">
                <a href="https://anzmusc.org" target="_blank">ANZMUSC</a>
                <a href="https://rheumatology.org.au" target="_blank">Australian Rheumatology Association</a>
                <a href="https://musculoskeletal.cochrane.org" target="_blank">Cochrane Musculoskeletal</a>
            </div>
        </div>
        <div class="header-main">
            <div class="logo">
                <div class="logo-title">Australian Living Guideline</div>
                <div class="logo-subtitle">Pharmacological Management of Inflammatory Arthritis</div>
            </div>
            <nav>
                <div class="nav-item">
                    <a href="#" class="nav-link">About <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.23 7.21a.75.75 0 011.06.02L10 11.168l3.71-3.938a.75.75 0 111.08 1.04l-4.25 4.5a.75.75 0 01-1.08 0l-4.25-4.5a.75.75 0 01.02-1.06z" clip-rule="evenodd"/></svg></a>
                    <div class="dropdown">
                        <a href="#">How to Use This Guideline</a>
                        <a href="#">Who We Are</a>
                        <a href="panellists.html">Panel Members</a>
                        <a href="#">Methodology</a>
                        <a href="#">Funding & Support</a>
                        <a href="#">Conflicts of Interest</a>
                    </div>
                </div>
                <div class="nav-item">
                    <a href="#" class="nav-link">Resources <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.23 7.21a.75.75 0 011.06.02L10 11.168l3.71-3.938a.75.75 0 111.08 1.04l-4.25 4.5a.75.75 0 01-1.08 0l-4.25-4.5a.75.75 0 01.02-1.06z" clip-rule="evenodd"/></svg></a>
                    <div class="dropdown">
                        <a href="#">Glossary</a>
                        <a href="#">Abbreviations</a>
                        <a href="#">External Links</a>
                        <a href="#">Consumer Information</a>
                    </div>
                </div>
                <a href="#recommendations" class="nav-link">Recommendations</a>
                <a href="#" class="nav-link">Contact</a>
            </nav>
        </div>
    </header>

    <section class="hero">
        <div class="hero-content">
            <h1>Evidence-based guidance for inflammatory arthritis treatment</h1>
            <p class="hero-description">Helping Australian clinicians and patients make informed decisions about the pharmacological management of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.</p>
            <div class="hero-badges">
                <span class="hero-badge"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M16.403 12.652a3 3 0 000-5.304 3 3 0 00-3.75-3.751 3 3 0 00-5.305 0 3 3 0 00-3.751 3.75 3 3 0 000 5.305 3 3 0 003.75 3.751 3 3 0 005.305 0 3 3 0 003.751-3.75zm-2.546-4.46a.75.75 0 00-1.214-.883l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd"/></svg> NHMRC Approved</span>
                <span class="hero-badge"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm.75-13a.75.75 0 00-1.5 0v5c0 .414.336.75.75.75h4a.75.75 0 000-1.5h-3.25V5z" clip-rule="evenodd"/></svg> Living Guideline</span>
                <span class="hero-badge"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> 18 Recommendations</span>
            </div>
            <a href="#recommendations" class="hero-cta">Browse Recommendations <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M2 10a.75.75 0 01.75-.75h12.59l-2.1-1.95a.75.75 0 111.02-1.1l3.5 3.25a.75.75 0 010 1.1l-3.5 3.25a.75.75 0 11-1.02-1.1l2.1-1.95H2.75A.75.75 0 012 10z" clip-rule="evenodd"/></svg></a>
        </div>
    </section>

    <section class="whats-new-section">
        <div class="whats-new-container">
            <div class="whats-new-header">
                <h2>
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm.75-13a.75.75 0 00-1.5 0v5c0 .414.336.75.75.75h4a.75.75 0 000-1.5h-3.25V5z" clip-rule="evenodd"/></svg>
                    What's New
                </h2>
            </div>
            <div class="whats-new-grid">
                <!-- New recommendation: Laboratory safety monitoring -->
                <div class="whats-new-item" onclick="openModal('rec-10')">
                    <div class="whats-new-badge new">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                    </div>
                    <div class="whats-new-content">
                        <div class="whats-new-label new">New Recommendation</div>
                        <div class="whats-new-title">Laboratory safety monitoring in people with inflammatory arthritis</div>
                        <div class="whats-new-meta">September 2025 • RA, PsA, axSpA</div>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <section class="conditions-section" id="recommendations">
        <div class="conditions-container">
            <div class="section-header">
                <h2>Recommendations by Condition</h2>
                <p>Filter recommendations by condition or topic, or browse all recommendations below.</p>
            </div>
            <div class="filter-section">
                <div class="search-container">
                    <svg class="search-icon" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M9 3.5a5.5 5.5 0 100 11 5.5 5.5 0 000-11zM2 9a7 7 0 1112.452 4.391l3.328 3.329a.75.75 0 11-1.06 1.06l-3.329-3.328A7 7 0 012 9z" clip-rule="evenodd"/></svg>
                    <input type="text" class="search-input" id="search-input" placeholder="Search recommendations...">
                    <button class="search-clear" id="search-clear" onclick="clearSearch()">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" width="14" height="14"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg>
                    </button>
                </div>
                <div class="filter-label">Filter by Condition</div>
                <div class="filter-row">
                    <button class="condition-tab active" data-condition="all">All Recommendations</button>
                    <button class="condition-tab" data-condition="ra">Rheumatoid Arthritis</button>
                    <button class="condition-tab" data-condition="psa">Psoriatic Arthritis</button>
                    <button class="condition-tab" data-condition="axspa">Axial Spondyloarthritis</button>
                </div>
                <div class="filter-label" style="margin-top: 24px;">Filter by Topic</div>
                <div class="tag-filters">
                    <button class="tag-filter" data-tag="bdmards">bDMARDs</button>
                    <button class="tag-filter" data-tag="csdmards">csDMARDs</button>
                    <button class="tag-filter" data-tag="dmard-ir">DMARD-IR</button>
                    <button class="tag-filter" data-tag="flare">Flare</button>
                    <button class="tag-filter" data-tag="glucocorticoids">Glucocorticoids</button>
                    <button class="tag-filter" data-tag="low disease activity">Low Disease Activity</button>
                    <button class="tag-filter" data-tag="methotrexate">Methotrexate</button>
                    <button class="tag-filter" data-tag="monitoring">Monitoring</button>
                    <button class="tag-filter" data-tag="opioids">Opioids</button>
                    <button class="tag-filter" data-tag="pain">Pain</button>
                    <button class="tag-filter" data-tag="perioperative">Perioperative</button>
                    <button class="tag-filter" data-tag="remission">Remission</button>
                    <button class="tag-filter" data-tag="tapering">Tapering</button>
                    <button class="tag-filter" data-tag="tnfi">TNFi</button>
                </div>
            </div>
            <div class="recommendations-grid" id="recommendations-grid">
                <!-- Card: Initial DMARD Therapy -->
                <div class="recommendation-card" data-conditions="ra" data-tags="methotrexate triple therapy dmard-naïve" onclick="openModal('rec-0')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Initial DMARD Therapy</div>
                            <div class="card-title">Initial DMARD therapy for people with rheumatoid arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for">
                                <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg>
                            </div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Consider using methotrexate in combination with other DMARDs as initial therapy in people with rheumatoid arthritis.</p>
                        <div class="card-tags">
                            <span class="card-tag" data-tag="methotrexate">Methotrexate</span>
                            <span class="card-tag" data-tag="triple therapy">Triple Therapy</span>
                            <span class="card-tag" data-tag="dmard-naïve">DMARD-Naïve</span>
                        </div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Subcutaneous/intramuscular methotrexate versus ora -->
                <div class="recommendation-card" data-conditions="ra" data-tags="methotrexate csdmards" onclick="openModal('rec-1')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">DMARD Therapy</div>
                            <div class="card-title">Subcutaneous/intramuscular methotrexate versus oral methotrexate for people with rheumatoid arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">We conditionally recommend oral administration for people with rheumatoid arthritis who are commencing treatment with methotrexate. 

In people who have had an inadequate response or who have been int...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="methotrexate">Methotrexate</span><span class="card-tag" data-tag="csdmards">csDMARDs</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Choice of DMARD in people with rheumatoid arthriti -->
                <div class="recommendation-card" data-conditions="ra" data-tags="dmard-ir tnfi bdmards" onclick="openModal('rec-2')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">bDMARD-IR</div>
                            <div class="card-title">Choice of DMARD in people with rheumatoid arthritis who have not responded to TNFi</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with RA who have had an inadequate response to one TNFi, consider switching therapy to an alternative b/tsDMARD. Consider either a different TNFi or a b/tsDMARD with a different mechanism of...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="dmard-ir">DMARD-IR</span><span class="card-tag" data-tag="tnfi">TNFi</span><span class="card-tag" data-tag="bdmards">bDMARDs</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Rheumatoid arthritis: Dose reduction or discontinu -->
                <div class="recommendation-card" data-conditions="ra" data-tags="tapering remission low disease activity csdmards" onclick="openModal('rec-3')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Rheumatoid arthritis: Dose reduction or discontinuation of conventional synthetic DMARDs</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with RA who have been in sustained low disease activity or remission for at least 6 months, consider a trial of reduction in the dose of csDMARD. 

Abrupt discontinuation of csDMARDs is not ...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="tapering">Tapering</span><span class="card-tag" data-tag="remission">Remission</span><span class="card-tag" data-tag="low disease activity">Low Disease Activity</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Mar 2025</span>
                    </div>
                </div>
                <!-- Card: Psoriatic Arthritis: Dose reduction or discontinua -->
                <div class="recommendation-card" data-conditions="psa" data-tags="tapering remission low disease activity csdmards" onclick="openModal('rec-4')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Psoriatic Arthritis: Dose reduction or discontinuation of conventional synthetic DMARDs</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with psoriatic arthritis who have been in sustained low disease activity or remission for at least 6 months (including adequate control of skin disease), consider a trial of reduction in the...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="tapering">Tapering</span><span class="card-tag" data-tag="remission">Remission</span><span class="card-tag" data-tag="low disease activity">Low Disease Activity</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Aug 2025</span>
                    </div>
                </div>
                <!-- Card: Rheumatoid Arthritis: Dose reduction or discontinu -->
                <div class="recommendation-card" data-conditions="ra" data-tags="tapering remission low disease activity bdmards" onclick="openModal('rec-5')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Rheumatoid Arthritis: Dose reduction or discontinuation of biologic or targeted synthetic DMARDs</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with RA who have been in sustained low disease activity or remission for at least 6 months, consider stepwise reduction in the dose of b/tsDMARD. Continue dose reduction until cessation is a...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="tapering">Tapering</span><span class="card-tag" data-tag="remission">Remission</span><span class="card-tag" data-tag="low disease activity">Low Disease Activity</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2025</span>
                    </div>
                </div>
                <!-- Card: Axial Spondyloarthritis: Dose reduction or discont -->
                <div class="recommendation-card" data-conditions="axspa" data-tags="tapering remission low disease activity bdmards" onclick="openModal('rec-6')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Axial Spondyloarthritis: Dose reduction or discontinuation of biologic DMARDs</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with axial spondyloarthritis who have been in sustained low disease activity or remission for at least 6 months, consider reduction in the dose of bDMARD. Continue at the lower dose as long ...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="tapering">Tapering</span><span class="card-tag" data-tag="remission">Remission</span><span class="card-tag" data-tag="low disease activity">Low Disease Activity</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2025</span>
                    </div>
                </div>
                <!-- Card: Psoriatic Arthritis: Dose reduction or discontinua -->
                <div class="recommendation-card" data-conditions="psa" data-tags="tapering remission low disease activity bdmards" onclick="openModal('rec-7')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Psoriatic Arthritis: Dose reduction or discontinuation of biologic or targeted synthetic DMARDs</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-against"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4 10a.75.75 0 01.75-.75h10.5a.75.75 0 010 1.5H4.75A.75.75 0 014 10z" clip-rule="evenodd"/></svg></div>
                            <span class="strength-label">Conditional<br/>Against</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely reduce the dose of b/tsDMARDs in patients with psoriatic arthritis who are in low disease activity or remission. Abrupt cessation of b/tsDMARDs is not recommended.</p>
                        <div class="card-tags"><span class="card-tag" data-tag="tapering">Tapering</span><span class="card-tag" data-tag="remission">Remission</span><span class="card-tag" data-tag="low disease activity">Low Disease Activity</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2025</span>
                    </div>
                </div>
                <!-- Card: Dose reduction or discontinuation of b/tsDMARDs ve -->
                <div class="recommendation-card" data-conditions="ra" data-tags="tapering remission low disease activity bdmards csdmards" onclick="openModal('rec-8')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Dose reduction or discontinuation of b/tsDMARDs versus dose reduction or discontinuation of csDMARDs in people with rheumatoid arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with rheumatoid arthritis who have achieved sustained low disease activity or remission with a combination of csDMARDs and b/tsDMARDs and who wish to reduce their medication burden, consider...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="tapering">Tapering</span><span class="card-tag" data-tag="remission">Remission</span><span class="card-tag" data-tag="low disease activity">Low Disease Activity</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Aug 2025</span>
                    </div>
                </div>
                <!-- Card: Perioperative adjustment of DMARDs in people with  -->
                <div class="recommendation-card" data-conditions="ra psa axspa" data-tags="perioperative csdmards bdmards" onclick="openModal('rec-9')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Perioperative</div>
                            <div class="card-title">Perioperative adjustment of DMARDs in people with inflammatory arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely discontinue csDMARDs in the perioperative period.  

Do not routinely discontinue bDMARDs in the perioperative period; consider temporary discontinuation in individuals with a high ri...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="perioperative">Perioperative</span><span class="card-tag" data-tag="csdmards">csDMARDs</span><span class="card-tag" data-tag="bdmards">bDMARDs</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Laboratory safety monitoring in people with inflam -->
                <div class="recommendation-card" data-conditions="ra psa axspa" data-tags="monitoring csdmards" onclick="openModal('rec-10')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Monitoring</div>
                            <div class="card-title">Laboratory safety monitoring in people with inflammatory arthritis using conventional synthetic DMARDs</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In people with inflammatory arthritis who are taking conventional synthetic DMARDs (methotrexate, leflunomide, sulfasalazine), we recommend a stratified approach to laboratory safety monitoring:  

Pe...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="monitoring">Monitoring</span><span class="card-tag" data-tag="csdmards">csDMARDs</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Perioperative adjustment of glucocorticoids in peo -->
                <div class="recommendation-card" data-conditions="ra psa axspa" data-tags="perioperative glucocorticoids" onclick="openModal('rec-11')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Perioperative</div>
                            <div class="card-title">Perioperative adjustment of glucocorticoids in people with inflammatory arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-against"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4 10a.75.75 0 01.75-.75h10.5a.75.75 0 010 1.5H4.75A.75.75 0 014 10z" clip-rule="evenodd"/></svg></div>
                            <span class="strength-label">Conditional<br/>Against</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely use additional ‘stress dose’ glucocorticoids in people taking regular glucocorticoids for inflammatory arthritis who are undergoing elective surgery. Continue the usual oral glucocort...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="perioperative">Perioperative</span><span class="card-tag" data-tag="glucocorticoids">Glucocorticoids</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Aug 2025</span>
                    </div>
                </div>
                <!-- Card: Opioids for pain in rheumatoid arthritis -->
                <div class="recommendation-card" data-conditions="ra" data-tags="opioids pain" onclick="openModal('rec-12')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Pain Management</div>
                            <div class="card-title">Opioids for pain in rheumatoid arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-against"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4 10a.75.75 0 01.75-.75h10.5a.75.75 0 010 1.5H4.75A.75.75 0 014 10z" clip-rule="evenodd"/></svg></div>
                            <span class="strength-label">Conditional<br/>Against</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely use opioids for the treatment of pain in rheumatoid arthritis.
A brief course of a short-acting opioid may be considered for severe pain when other analgesic options have failed.</p>
                        <div class="card-tags"><span class="card-tag" data-tag="opioids">Opioids</span><span class="card-tag" data-tag="pain">Pain</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Opioids for pain in axial spondyloarthritis -->
                <div class="recommendation-card" data-conditions="axspa" data-tags="opioids pain" onclick="openModal('rec-13')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Pain Management</div>
                            <div class="card-title">Opioids for pain in axial spondyloarthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-against"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4 10a.75.75 0 01.75-.75h10.5a.75.75 0 010 1.5H4.75A.75.75 0 014 10z" clip-rule="evenodd"/></svg></div>
                            <span class="strength-label">Conditional<br/>Against</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely use opioids for the treatment of pain in axial spondyloarthritis.</p>
                        <div class="card-tags"><span class="card-tag" data-tag="opioids">Opioids</span><span class="card-tag" data-tag="pain">Pain</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Opioids for pain in psoriatic arthritis -->
                <div class="recommendation-card" data-conditions="psa" data-tags="opioids pain" onclick="openModal('rec-14')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Pain Management</div>
                            <div class="card-title">Opioids for pain in psoriatic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-against"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4 10a.75.75 0 01.75-.75h10.5a.75.75 0 010 1.5H4.75A.75.75 0 014 10z" clip-rule="evenodd"/></svg></div>
                            <span class="strength-label">Conditional<br/>Against</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely use opioids for the treatment of pain in psoriatic arthritis.</p>
                        <div class="card-tags"><span class="card-tag" data-tag="opioids">Opioids</span><span class="card-tag" data-tag="pain">Pain</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Dec 2024</span>
                    </div>
                </div>
                <!-- Card: Short-term use of glucocorticoids for treating fla -->
                <div class="recommendation-card" data-conditions="ra" data-tags="glucocorticoids flare" onclick="openModal('rec-15')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Glucocorticoids</div>
                            <div class="card-title">Short-term use of glucocorticoids for treating flare in RA</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Consider using short-term glucocorticoids for the treatment of rheumatoid arthritis flare in people with previously well-controlled disease, via either a systemic (oral, intramuscular or intravenous) ...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="glucocorticoids">Glucocorticoids</span><span class="card-tag" data-tag="flare">Flare</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Sep 2025</span>
                    </div>
                </div>
                <!-- Card: Long-term use of low dose glucocorticoids in RA -->
                <div class="recommendation-card" data-conditions="ra" data-tags="glucocorticoids" onclick="openModal('rec-16')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Glucocorticoids</div>
                            <div class="card-title">Long-term use of low dose glucocorticoids in RA</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-against"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4 10a.75.75 0 01.75-.75h10.5a.75.75 0 010 1.5H4.75A.75.75 0 014 10z" clip-rule="evenodd"/></svg></div>
                            <span class="strength-label">Conditional<br/>Against</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely use glucocorticoids as a long-term (&gt;6 months) adjunct to DMARDs for the treatment of rheumatoid arthritis.</p>
                        <div class="card-tags"><span class="card-tag" data-tag="glucocorticoids">Glucocorticoids</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Sep 2025</span>
                    </div>
                </div>
                <!-- Card: Short-term bridging glucocorticoids in addition to -->
                <div class="recommendation-card" data-conditions="ra" data-tags="glucocorticoids csdmards" onclick="openModal('rec-17')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Glucocorticoids</div>
                            <div class="card-title">Short-term bridging glucocorticoids in addition to DMARD therapy in RA</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Consider using a short course of glucocorticoids in people with active rheumatoid arthritis who are initiating, switching or adding DMARD therapy, using the lowest effective dose until DMARDs take eff...</p>
                        <div class="card-tags"><span class="card-tag" data-tag="glucocorticoids">Glucocorticoids</span><span class="card-tag" data-tag="csdmards">csDMARDs</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated Sep 2025</span>
                    </div>
                </div>            </div>
        </div>
    </section>

    <section class="about-section">
        <div class="about-container">
            <div class="about-content">
                <h2>About This Living Guideline</h2>
                <p>This guideline presents the best available, current scientific evidence for pharmacological management of the most common forms of inflammatory arthritis: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).</p>
                <p>As a living guideline, recommendations are updated in near real-time as new evidence emerges. Topics and questions identified as having highest clinical relevance are prioritised, including DMARD choice, switching, combination therapy, down-titration, and perioperative use.</p>
            </div>
            <div class="about-features">
                <div class="feature-card"><div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm.75-13a.75.75 0 00-1.5 0v5c0 .414.336.75.75.75h4a.75.75 0 000-1.5h-3.25V5z" clip-rule="evenodd"/></svg></div><h3>Living Evidence</h3><p>Recommendations updated as new practice-changing evidence becomes available.</p></div>
                <div class="feature-card"><div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M16.403 12.652a3 3 0 000-5.304 3 3 0 00-3.75-3.751 3 3 0 00-5.305 0 3 3 0 00-3.751 3.75 3 3 0 000 5.305 3 3 0 003.75 3.751 3 3 0 005.305 0 3 3 0 003.751-3.75zm-2.546-4.46a.75.75 0 00-1.214-.883l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd"/></svg></div><h3>GRADE Methodology</h3><p>Rigorous evidence assessment using internationally recognised standards.</p></div>
                <div class="feature-card"><div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg></div><h3>Expert Panel</h3><p>Developed by rheumatologists, researchers, and consumer representatives.</p></div>
                <div class="feature-card"><div class="feature-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3.505 2.365A41.369 41.369 0 019 2c1.863 0 3.697.124 5.495.365 1.247.167 2.18 1.108 2.435 2.268a4.45 4.45 0 00-.577-.069 43.141 43.141 0 00-4.706 0C9.229 4.696 7.5 6.727 7.5 8.998v2.24c0 1.413.67 2.735 1.76 3.562l-2.98 2.98A.75.75 0 015 17.25v-3.443c-.501-.048-1-.106-1.495-.172C2.033 13.438 1 12.162 1 10.72V5.28c0-1.441 1.033-2.717 2.505-2.914z"/><path d="M14 6c-.762 0-1.52.02-2.271.062C10.157 6.148 9 7.472 9 8.998v2.24c0 1.519 1.147 2.839 2.71 2.935.214.013.428.024.642.034.2.009.385.09.518.224l2.35 2.35a.75.75 0 001.28-.531v-2.07c1.453-.195 2.5-1.463 2.5-2.915V8.998c0-1.526-1.157-2.85-2.729-2.936A41.645 41.645 0 0014 6z"/></svg></div><h3>Shared Decision Making</h3><p>Supporting informed discussions between clinicians and patients.</p></div>
            </div>
        </div>
    </section>

    <section class="partners-section">
        <div class="partners-container">
            <div class="partners-label">Produced in collaboration with</div>
            <div class="partners-logos">
                <span class="partner-text">ANZMUSC</span>
                <span class="partner-text">Australian Rheumatology Association</span>
                <span class="partner-text">Cochrane Musculoskeletal</span>
            </div>
        </div>
    </section>

    <footer>
        <div class="footer-container">
            <div class="footer-grid">
                <div class="footer-brand"><h3>Australian Living Guideline for Inflammatory Arthritis</h3><p>Evidence-based recommendations for the pharmacological management of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.</p></div>
                <div class="footer-column"><h4>Guideline</h4><a href="#">All Recommendations</a><a href="#">Rheumatoid Arthritis</a><a href="#">Psoriatic Arthritis</a><a href="#">Axial Spondyloarthritis</a></div>
                <div class="footer-column"><h4>Resources</h4><a href="#">How to Use</a><a href="#">Glossary</a><a href="#">Abbreviations</a><a href="#">External Links</a></div>
                <div class="footer-column"><h4>About</h4><a href="#">Who We Are</a><a href="#">Methodology</a><a href="#">Funding</a><a href="#">Contact</a><a href="mailto:sam@whittle.au?subject=Feedback%20on%20Living%20Guidelines">Provide Feedback</a></div>
            </div>
            <div class="footer-bottom">
                <div class="footer-copyright">© 2024 ANZMUSC Clinical Trials Network. All rights reserved.</div>
                <div class="footer-links"><a href="#">Privacy Policy</a><a href="#">Disclaimer</a><a href="#">Accessibility</a></div>
            </div>
        </div>
    </footer>

    <!-- MODAL: Initial DMARD Therapy (rec-0) -->
    <div class="modal-overlay" id="modal-rec-0">
        <div class="modal-content">
            <div class="modal-header">
                <div><div class="modal-category">Initial DMARD Therapy</div><h2 class="modal-title">Initial DMARD therapy for people with rheumatoid arthritis</h2></div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-0', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-0', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-0', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-0', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-0', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-0', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-0-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>Consider using methotrexate in combination with other DMARDs as initial therapy in people with rheumatoid arthritis.</p></div>
                    <div class="remark-box"><p>For most people this implies triple therapy (methotrexate + sulfasalazine + hydroxychloroquine).</p><p>While the combination of methotrexate and most b/tsDMARDs is also effective, this is currently not a feasible option for most people.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For this recommendation, the panel only considered the choice of methotrexate (MTX) monotherapy versus MTX combination therapy as the initial choice of treatment in people with RA who have not previously received any DMARDs. The panel did not consider the choice of DMARD in people with RA who have used MTX and had an inadequate response or have been unable to tolerate it; this will form a separate future recommendation.</p>
                        <p>The panel was satisfied that MTX remains the anchor drug for RA and should remain part of the initial treatment regimen for most people with RA. As such, a network meta-analysis that compared MTX monotherapy to MTX-based combination therapies was used as the primary evidence source for this recommendation.</p>
                        <p>The panel based the recommendation on moderate certainty evidence from the NMA that triple therapy is superior to MTX monotherapy for the primary efficacy outcome (ACR50) and has similar tolerability and safety compared with MTX monotherapy.</p>
                        <p>The panel noted that triple therapy was the only csDMARD combination that was found to have superior efficacy compared with MTX monotherapy.</p>
                        <p>The panel also emphasised that the recommendation is conditional and that there is likely to be a considerable difference in preferences between individuals.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-0-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit</span></div><div class="etd-domain-text"><p>Compared to MTX oral monotherapy, several treatment combinations resulted in a better ACR50 response rate (56-67% vs 41% for methotrexate alone).</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Moderate</span></div><div class="etd-domain-text"><p>Evidence was moderate certainty for csDMARD triple therapy versus methotrexate monotherapy.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability expected</span></div><div class="etd-domain-text"><p>People with RA consider treatment benefits more important than adverse events, but there is considerable variation in preferences between individuals.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues</span></div><div class="etd-domain-text"><p>Cost implications of MTX monotherapy versus combination therapy with csDMARDs are likely to be small.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues</span></div><div class="etd-domain-text"><p>People who are less able to access immediate specialist care may be less likely to receive combination therapy.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues</span></div><div class="etd-domain-text"><p>There is variation in the use of csDMARDs in combination versus monotherapy as initial therapy for RA.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues</span></div><div class="etd-domain-text"><p>Initial treatment with methotrexate alone or in combination with other csDMARDs is consistent with current practice in Australia.</p></div></div>
                </div>
                <div class="tab-content" id="rec-0-practical">
                    <div class="content-section">
                        <p><strong>A treat-to-target approach is recommended for all patients with RA, irrespective of the choice of initial treatment regimen.</strong></p>
                        <ul>
                            <li>Any decision regarding the choice of disease-modifying therapy should be made within a shared decision-making framework</li>
                            <li>The probability of achieving an ACR50 response with MTX monotherapy is about 41%; this increases to 56-67% with initial combination therapy</li>
                        </ul>
                        <p><strong>Other factors that may be important in the choice of initial DMARD therapy include:</strong></p>
                        <ul>
                            <li>The patient's individual preferences and treatment goals</li>
                            <li>Disease activity and prognosis</li>
                            <li>Comorbidity/ies</li>
                            <li>Concurrent medications</li>
                            <li>Impact of RA on daily activities</li>
                            <li>Impact of RA on work and other life roles</li>
                        </ul>
                        <p><strong>Patient Information Resources:</strong></p>
                        <p>The Australian Rheumatology Association provides patient information sheets for those commencing DMARDs.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-0-data"><div class="data-placeholder"><p>📊 Links to GRADE evidence tables will be added here.</p></div></div>
                <div class="tab-content" id="rec-0-consumer"><div class="data-placeholder"><p>👥 A plain-language version for patients will be added here.</p></div></div>
                <div class="tab-content" id="rec-0-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member chair">Panel Chair</span>
                            <span class="panel-member">Panel Member 1</span>
                            <span class="panel-member">Panel Member 2</span>
                            <span class="panel-member">Consumer Representative</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">December 2024</div>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.5 2A1.5 1.5 0 003 3.5v13A1.5 1.5 0 004.5 18h11a1.5 1.5 0 001.5-1.5V7.621a1.5 1.5 0 00-.44-1.06l-4.12-4.122A1.5 1.5 0 0011.378 2H4.5zm2.25 8.5a.75.75 0 000 1.5h6.5a.75.75 0 000-1.5h-6.5zm0 3a.75.75 0 000 1.5h6.5a.75.75 0 000-1.5h-6.5z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">PICO Question</div>
                            <div class="info-value">In people with rheumatoid arthritis who are DMARD-naïve, what is the effectiveness of initial combination DMARD therapy compared to methotrexate monotherapy?</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Initial%20DMARD%20therapy%20for%20people%20with%20rheumatoid%20arthritis" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Subcutaneous/intramuscular methotrexate versus ora -->
    <div class="modal-overlay" id="modal-rec-1">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">DMARD Therapy</div>
                    <h2 class="modal-title">Subcutaneous/intramuscular methotrexate versus oral methotrexate for people with rheumatoid arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-1', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-1', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-1', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-1', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-1', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-1', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-1-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>We conditionally recommend oral administration for people with rheumatoid arthritis who are commencing treatment with methotrexate.</p>
                        <p>In people who have had an inadequate response or who have been intolerant of oral methotrexate, consider a trial of subcutaneous methotrexate.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For this recommendation, the panel considered evidence from three randomised controlled trials (RCTs) that compared oral methotrexate with methotrexate injections (via either the subcutaneous or intramuscular route) in people with RA. The rationale for considering parenteral (injected) methotrexate in preference to oral administration is that methotrexate may not be fully absorbed when taken orally (particularly at doses greater than 15mg [189]), and therefore injection offers a higher effective dose, which may improve efficacy. Furthermore, it has been postulated that by avoiding the gastrointestinal tract, injectable methotrexate may avoid or reduce some of the gastrointestinal adverse effects that are commonly experienced by methotrexate users. Both intramuscular and subcutaneous routes of administration offer the same potential benefits in terms of bioavailability, however subcutaneous injections are less painful and easier to self-administer. Although evidence regarding both forms of parenteral administration were considered together, in practice almost all people with RA who choose to use an injectable form of methotrexate would elect to use the subcutaneous route.</p>
                        <p>Given the uncertainty regarding the overall efficacy and safety of parenteral versus oral methotrexate, data from all existing RCTs were combined. In total, there was at best low certainty evidence that suggested that parenteral methotrexate may result in slightly greater efficacy than oral methotrexate at the same dose, with little difference in safety or tolerability. Since the panel meeting, additional RCT data have been added to the living evidence summary. However the evidence remains low certainty at best and, while parenteral methotrexate may slightly increase the number of people with RA who achieve an ACR50 response compared with oral methotrexate, there may or may not be a difference in mean disease activity. In the largest RCT [176], which randomised 384 methotrexate-naïve individuals with early RA to subcutaneous or oral methotrexate at a dose of 15mg/week, there was no difference between oral and subcutaneous methotrexate in terms of our primary efficacy outcome measure of ACR50, however there were marginal differences in ACR20 and ACR70 responses favouring subcutaneous methotrexate. Although there was no difference in the rate of both serious and total adverse events, participants who received subcutaneous methotrexate were more than twice as likely to withdraw from the study due to adverse events than those who received oral methotrexate.</p>
                        <p>The panel noted that there may be several different clinical questions regarding the role of parenteral methotrexate in the treatment of RA. For example, there are several populations of patients with RA in whom parenteral methotrexate may be considered, including methotrexate-naïve individuals, those who have not reached their treatment goal with oral methotrexate, and those who have experienced adverse effects related to methotrexate. While one of the included RCTs [Islam 2013] included participants who had active RA despite oral methotrexate at a dose of 15mg per week, no trials have yet compared a switch from oral to parenteral methotrexate with other treatment strategies (such as step-up combination csDMARD therapy or a switch to b/tsDMARDs) in people who have had an inadequate response to oral methotrexate at the highest tolerated dose. This remains an important question for future research.</p>
                        <p>As a result, the panel initially considered whether parenteral methotrexate ought to be conditionally recommended over oral methotrexate for all patients receiving methotrexate for RA. Given that there is only low certainty evidence for a marginal advantage in efficacy, and that the evidence does not currently suggest better safety or tolerability, in addition to the potential resource, acceptability and feasibility implications of the widespread use of parenteral methotrexate (particularly in methotrexate-naïve individuals), the panel was not in favour of a broad conditional recommendation in favour of parenteral methotrexate.</p>
                        <p>However, methotrexate remains a key component of contemporary RA treatment strategies due to its relative efficacy and long-term safety, both alone and in combination with other DMARDs, as well as its potential additional beneficial effects on cardiovascular health [190] and overall mortality [191][192] in people with RA. In light of this, the panel considered that the evidence for a potential difference in efficacy favouring parenteral methotrexate may be sufficient to warrant consideration of a switch to the subcutaneous route in those who have not achieved their treatment goals with oral methotrexate in preference to abandoning methotrexate altogether.</p>
                        <p>The evidence regarding the potential benefits of switching from oral to parenteral methotrexate in those who have experienced intolerable adverse effects with oral administration is less convincing, and may reflect the fact that most methotrexate adverse effects are likely to be related to the level of the active intracellular metabolites of methotrexate (polyglutamates), and may therefore be related to higher bioavailability rather than a direct effect on the gastrointestinal tract. While for most patients the primary motivation for switching from oral to subcutaneous methotrexate is likely to be pursuit of greater efficacy, there may be individuals for whom a switch to an alternative route may improve tolerability or favourably alter the balance of benefits and harms. Therefore, in the absence of reliable predictors of methotrexate efficacy and tolerability at the individual patient level, a trial of switching to the subcutaneous route may also warrant consideration in this population.</p>
                        <p>Finally, the panel noted that this recommendation is conditional, and therefore there may be circumstances in which patients commencing methotrexate may prefer to use a subcutaneous route of administration, and there may be patients who have not achieved treatment success with oral methotrexate who prefer an alternative treatment strategy to a trial of injectable methotrexate. A decision regarding the place of subcutaneous methotrexate in an individual patient’s treatment plan should take place within a shared decision-making framework and take into account a variety of individual factors including the current clinical circumstances, prior experience with methotrexate, values and preferences, comorbidities and concomitant medications, and the ability to self-administer or access assistance with injections. Furthermore, given the low certainty of the existing evidence, this living recommendation will continue to be updated as soon as relevant new information becomes available.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-1-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>Compared with oral methotrexate, subcutaneous or intramuscular methotrexate may very slightly increase the number of people achieving ACR50 and may improve pain. However, compared with oral methotrexate, subcutaneous or intramuscular methotrexate may or may not improve disease activity or function. No studies compared the effect of subcutaneous or intramuscular methotrexate with oral methotrexate on quality of life. We are uncertain whether subcutaneous or intramuscular methotrexate results in fewer withdrawals due to adverse events or fewer serious adverse events as the certainty of the evidence is very low. Subcutaneous or intramuscular methotrexate may have little or no effect on the number of adverse events compared with oral methotrexate.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>There is LOW certainty evidence that subcutaneous or intramuscular methotrexate may improve pain and may slightly increase the number of people achieving ACR50 compared to oral methotrexate, and may or may not improve disease activity or function.</p>
                        <p>There is LOW certainty evidence that subcutaneous or intramuscular methotrexate may have little or no effect on the number of adverse events, and VERY LOW certainty evidence regarding withdrawals due to adverse events or serious adverse events compared to oral methotrexate.</p>
                        <p>No studies reported data on quality of life.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>A systematic review of patient preferences for DMARD treatment in RA was identified that included 36 studies published between 1990 and 2018. The included studies generally involved participants who had already commenced DMARDs [84]. The review found that, in general, people with RA consider treatment benefits (particularly improvement in symptoms and function) to be more important than both serious and non-serious adverse events (AEs). However some studies found evidence of important risk aversion (particularly regarding serious AEs), which suggests that there is considerable variation in preferences between individuals. Dosing and administration considerations, including route and frequency of medications, were generally found to be less important than treatment benefits but more important than AEs, although this also varied between and within studies.</p>
                        <p>Evidence also exists that patients&#x27; perception of competing risks of benefits and harms is affected by prior experience with DMARDs, including prior DMARD-related adverse effects [183].</p>
                        <p>The anticipated variability in preferences and values between patients underscores the importance of shared decision-making between clinician and patient regarding treatments for RA.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>In general, methotrexate is an inexpensive medication. Injectable preparations of methotrexate, particularly pre-filled syringes, are more expensive than oral methotrexate. While the absolute cost difference to the individual patient is relatively low, the impact is likely to vary. Optimisation of the efficacy and tolerability of methotrexate might plausibly reduce the proportion of people with RA who progress to b/tsDMARDs, which are considerably more expensive medications.</p>
                        <p>We did not identify any data regarding the differential impact of oral versus injectable methotrexate on the environment. It is plausible that injectable methotrexate (especially pre-filled syringe formulations that are administered via single-use plastic devices) may have a larger negative impact on the environment due to manufacturing, packaging and transport, however the magnitude of such an impact (if present) or other indirect effects is currently unknown.</p>
                        <p>The panel debated the extent to which resource considerations might be important for this recommendation. Overall, despite the relatively low absolute cost of methotrexate, the potential for even relatively minor cost differences to have a large impact on some consumers and the potential additional environmental impact of injectable methotrexate were judged by the panel to be important considerations.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>There are a number of factors that may influence health opportunities and outcomes in individual patients. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may have an impact on equitable access to the use of injectable methotrexate.</p>
                        <p>The panel considered the degree to which equity factors may influence the recommendation regarding the route of administration of methotrexate, and whether this was sufficient to represent ‘important issues’ for this recommendation. Overall the panel agreed that equity considerations are relevant to this recommendation, particularly in regard to people with limited access to healthcare and those for whom self-administration of an injectable medication is likely to be difficult or unachievable due to hand arthritis or other disability.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>It is likely that subcutaneous administration of methotrexate would be acceptable to most stakeholders, including many people with RA, although there may be variation between individuals based on their particular circumstances, prior treatment experience, and preferences. There is some evidence that people with RA often prefer medications administered orally, although this preference varies according to age, duration of disease, and other factors [182]. In general, people with RA are more likely to accept changes to their treatment regimen when they perceive that the change may result in an important improvement in their current symptoms and future prognosis [183].</p>
                        <p>The panel agreed that acceptability of methotrexate injections may vary between individuals. While this is unlikely to be a major consideration, the panel preferred a judgment of &#x27;important issues, or potential issues not investigated&#x27; to &#x27;no important issues&#x27;.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Both oral and injectable methotrexate are generally widely available and affordable in Australia.</p>
                        <p>Injectable methotrexate is currently available either in vials (50mg/2mL) or pre-filled syringes. Use of the vial requires the user to access needles and syringes (typically an insulin syringe) and draw up the correct dose of methotrexate before administration. This requires manual dexterity and sufficient numeracy and visual acuity, which may be a barrier for some patients, particularly those without ready access to a carer or healthcare provider at the time of each weekly dose.</p>
                        <p>The pre-filled syringe may afford fewer barriers to use, although it also requires confidence in self-administration of an injection or access to a carer or healthcare provider. Currently the pre-filled syringe (brand name Trexject) is only available on the Australian Pharmaceutical Benefits Scheme via a Streamlined Authority prescription for people with &quot;severe active rheumatoid arthritis&quot; who &quot;must be unsuitable for administration of an oral form of methotrexate for this condition&quot;. This is also likely to represent a barrier to the use of injectable methotrexate for the treatment of RA, particularly among people with early RA or those who are methotrexate-naïve.</p>
                        <p>The panel felt that while the potential feasibility barriers described were minor, they may still be a factor in some cases, particularly for people with RA who live with a physical or cognitive disability, and therefore may impact on this recommendation.</p></div></div>
                </div>
                <div class="tab-content" id="rec-1-practical">
                    <div class="content-section"><p>A treat-to-target approach is recommended for all patients with RA, irrespective of the choice of treatment regimen</p>
                        <p>Any decision regarding the choice of disease-modifying therapy should be made within a shared decision-making framework between clinician and patient, following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances</p>
                        <p><strong>Consider the following factors when making a decision about using subcutaneous rather than oral methotrexate in an individual with RA:</strong></p>
                        <ul>
                            <li>The patient’s individual preferences and treatment goals</li>
                            <li>Prior experience with oral methotrexate, including the balance of benefits and adverse effects</li>
                            <li>Current disease activity, prognosis, and impact</li>
                            <li>Comorbidities (e.g., malabsorption)</li>
                            <li>Concurrent medications (e.g. other injected medications)</li>
                            <li>The presence of any physical or cognitive limitations that may impact on the ability to self-administer or access weekly injections</li>
                            <li>Access to health care provider or support person for administration of weekly injections if unable to self-administer</li>
                        </ul>
                        <p><strong>The Australian Rheumatology Association website has a number of resources designed to assist people who are planning to self-administer subcutaneous methotrexate, including:</strong></p>
                        <ul>
                            <li>An information sheet on self-injection of methotrexate</li>
                            <li>A video guide to self-injection of methotrexate</li>
                            <li>Guidance on the safe disposal of medical sharps</li>
                        </ul>
                        <p>Consider prescribing supplemental folic acid (e.g. 5mg once weekly on the day after the methotrexate dose) to all patients receiving methotrexate in order to reduce the risk of adverse gastrointestinal effects and liver function test abnormalities and to improve treatment retention (see Cochrane Review)</p></div>
                </div>
                <div class="tab-content" id="rec-1-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-1-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-1-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Choice%20of%20DMARD%20in%20people%20with%20rheumatoid%20arthriti" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Choice of DMARD in people with rheumatoid arthriti-->
    <div class="modal-overlay" id="modal-rec-2">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">bDMARD-IR</div>
                    <h2 class="modal-title">Choice of DMARD in people with rheumatoid arthritis who have not responded to TNFi</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-2', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-2', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-2', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-2', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-2', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-2', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-2-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In people with RA who have had an inadequate response to one TNFi, consider switching therapy to an alternative b/tsDMARD. Consider either a different TNFi or a b/tsDMARD with a different mechanism of action.</p></div>
                    <div class="remark-box"><p>The choice of b/tsDMARD should be a shared decision between clinician and patient based on individual values, preferences, clinical status, and an assessment of risk. In particular, JAK inhibitors may not be preferred in those at a higher risk of cardiovascular disease or cancer.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For this recommendation, the panel considered evidence from a living network meta-analysis (NMA) of DMARDs in people with rheumatoid arthritis (RA) who have had an inadequate response or intolerance to a TNF inhibitor (TNFi). The NMA included 17 RCTs and 14 interventions, with a study duration ranging from 12 to 52 weeks. The NMA is maintained in living mode, and will be continuously updated as relevant new RCT data become available. The network estimates suggest that switching b/tsDMARDs (either to another TNFi or to a b/tsDMARD with an alternative mechanism of action) is superior to placebo and to continuation of the ineffective TNFi, but there is little difference in overall efficacy between the various b/tsDMARDs that are currently available in Australia.</p>
                        <p>The panel agreed that this recommendation assumes that the vast majority of people with active RA despite treatment with a TNFi will choose to try another therapy rather than persist with an ineffective therapy or abandon DMARDs, and therefore the recommendation favours switching to a different intervention. The panel was clear that all of the alternative interventions are associated with a substantial net benefit compared with placebo but, given that there is little difference in net benefit between the effective interventions, the panel favoured a conditional recommendation regarding the choice between interventions that emphasises the importance of an individualised shared decision between clinician and patient.</p>
                        <p>The panel emphasised that there are important benefits associated with all of the included b/tsDMARDs and that the absolute risk of harm is relatively low. The trade-off between potential benefit and harm may particularly favour switching in this population of people with active RA despite treatment with a TNFi, who are at risk of progressive structural damage and other consequences of poorly-controlled systemic inflammation (including vascular disease), and for whom a prior decision to introduce b/tsDMARD therapy has already been made. There are further potential benefits of attempting to achieve better control of inflammation, including less exposure to other, potentially harmful, interventions including glucocorticoids and opioids. The consumer panellists noted that avoidance of additional exposure to glucocorticoids is likely to be of particular importance to many people with RA, especially those who have had previous experience with glucocorticoids.</p>
                        <p>The panel considered that in light of the similarity between interventions in terms of efficacy, an assessment of the risk profile of the different treatment options is likely to be an important determinant of the choice of intervention. The panel discussed the evidence from the ORAL Surveillance trial [184] regarding the risk of cardiovascular events, cancers, and serious infections associated with the use of tofacitinib versus TNFi (see ‘Benefits and Harms’) and considered whether to favour a switch to bDMARDs over tsDMARDs. Discussion regarding the implications of ORAL Surveillance included uncertainty about the extent to which the results of this trial can be applied to other JAKi (such as baricitinib and upadacitinib), which have different molecular interactions with the JAK signalling pathways, and other populations (including younger patients or those without risk factors for cardiovascular disease). Further, there is also uncertainty regarding the extent to which some risks may be amenable to mitigation (particularly cardiovascular risk, via modification of risk factors) or may accrue with long-term use (particularly the development of cancer). Some panellists also pointed out that existing observational data from large cohorts of people treated with JAKi have not demonstrated a significant differential risk between JAKi (e.g., [185][186]) and that data comparing JAKi with other classes of bDMARDs are lacking.</p>
                        <p>The panel also noted that there may be specific risks associated with other b/tsDMARDs (particularly an increased risk of adverse COVID-19 outcomes in people treated with rituximab) that may also influence the relative balance of benefits and harms, and ultimately voted in favour of a conditional recommendation for switching to any of the available b/tsDMARDs. However, use of JAKi may not be preferred in those at a high risk of vascular disease, cancer, thromboembolic disease, or severe infection (particularly herpes zoster). The magnitude of the absolute risk associated with this choice, and its acceptability, is likely to vary between individuals.</p>
                        <p>Most importantly, the choice of treatment ought to be based on a shared decision-making process that incorporates an assessment of risks based on the individual clinical circumstances, and takes into account the individual patient’s values, preferences, prior experiences, functional status, work and other life roles, goals, and risk tolerance.</p>
                        <p>The panel also highlighted that the definition of an “inadequate response” to treatment may vary between individuals, but may broadly be interpreted as persistent disease activity (i.e., falling short of the agreed treatment target) despite an adequate trial of therapy, or the development of adverse effects that warrant discontinuation of the bDMARD. For most TNFi, an adequate duration of therapy may be 3 to 6 months, although this is also likely to vary depending on the drug and the individual clinical circumstances, including disease severity and impact.</p>
                        <p>We anticipate that data relevant to this recommendation will continue to emerge. The living NMA will be continuously updated as new data emerge and this living recommendation will continue to be updated as soon as relevant new information becomes available.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-2-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>The panel considered a set of outcomes from a living network meta-analysis (NMA) comparing the benefits and harms of different DMARDs in adults with RA who have failed to respond to a TNF inhibitor (TNFi).</p>
                        <p>A summary of the initial key findings of the NMA is as follows:</p>
                        <p>1. Compared with placebo, at 6 months follow-up:</p>
                        <p>Continuation or switch in route of administration of the failed TNFi did not result in an improvement in disease activity as measured by ACR50 response or DAS28 Several biologic or targeted synthetic DMARDs (b/tsDMARDs) resulted in a better ACR50 response rate: a TNFi not previously tried, tocilizumab (4mg/kg IV Q4W or 8mg/kg IV Q4W), abatacept (10mg/kg IV Q4W with or without IV loading dose), rituximab (1000mg IV), tofacitinib (5mg po BD), baricitinib (4mg po OD), upadacitinib (15mg po OD), sarilumab (200mg sc) Abatacept (125mg sc Q1W), baricitinib (2mg po OD) and upadacitinib (6mg BD) were not superior to placebo in terms of ACR50 response rate A different TNFi not tried previously, abatacept (125mg sc weekly) and rituximab (1000mg IV) improved mean disease activity. DAS28 data were not available in the network meta-analysis for tocilizumab or the JAK inhibitors (tofacitinib, baricitinib, upadacitinib) Upadacitinib (15mg po OD and 6mg BD) improved mean pain but baricitinib (2mg and 4mg po OD) did not; the network did not contain pain data for any other intervention None of the biologics assessed in the network meta-analysis improved mean function None of the biologics resulted in more withdrawals due to adverse events, or more serious adverse events; the network did not contain data on withdrawal due to adverse events for upadacitinib 15mg</p>
                        <p>2. None of the effective interventions were found to differ from any other in any of the efficacy or safety outcomes measured in the network meta-analysis</p>
                        <p>The panel considered the evidence from the NMA at length. There was general agreement that the NMA data demonstrated that in people with RA who have had an inadequate response to a TNFi, switching to a different therapy (either another TNFi or a b/tsDMARD with a different mechanism of action) was superior to continuation of the current therapy, or discontinuation of b/tsDMARD therapy altogether. The panel also agreed that there is likely to be little difference in efficacy between the various b/tsDMARD options, including TNFi, abatacept, IL-6 inhibitors, rituximab and the JAK inhibitors (JAKi). As a result, the panel considered that the balance of potential benefits and harms clearly favoured a switch in therapy but that the choice of b/tsDMARD would be determined by individual factors, including values, preferences and clinical circumstances, and also by an evaluation of potential harms.</p>
                        <p>The panel noted that the NMA did not demonstrate any difference in safety or tolerability between the various treatment options. However, RCTs designed to evaluate efficacy are typically not powered to estimate differences in adverse events and may not have long enough follow-up periods to detect important long-term harms. The panel also discussed the results of the ORAL Surveillance trial [184]. ORAL Surveillance was an RCT designed to assess the risk of important adverse events (major adverse cardiovascular events (MACE) and cancers) in people with RA who were 50 years of age or older and had at least one cardiovascular risk factor. Participants were randomised to treatment with either the JAKi tofacitinib or a TNFi (etanercept or adalimumab). In brief, the trial did not demonstrate non-inferiority of tofacitinib 5mg bd (the approved dose in Australia) versus TNFi for MACE (cardiovascular death, non-fatal myocardial infarction or stroke) or cancers (excluding non-melanoma skin cancers). The estimated number needed to treat for harm (NNH) with tofacitinib compared with a TNFi over a 5-year period for one additional MACE was 113. The 5-year NNH for cancers was 55. The incidence of serious infections (particularly herpes zoster) was also higher in those taking tofacitinib, and venous thromboembolism was more common in those allocated to the higher dose of tofacitinib compared with a TNFi. As a result of this trial, the European Medicines Agency (EMA) has recommended that JAKi be used in people at increased risk of cardiovascular disease or cancer only if no suitable treatment alternatives are available. Similarly, the US FDA has mandated that manufacturers provide warnings about an increased risk of MACE, malignancy, thrombosis, and mortality with the JAKi and has suggested that these medications be reserved for patients who have had an inadequate response or intolerance to one or more TNFi. The panel noted that the current recommendation applies to this population of people with RA who have already failed to respond to at least one TNFi.</p>
                        <p>The panel decided to vote separately on the balance of benefits and harms for bDMARDs and tsDMARDs. There was consensus that for both bDMARDs and tsDMARDs, there was a net benefit compared with no treatment (or continuation of the ineffective treatment) but that there was uncertainty regarding the comparative net benefit between bDMARDs and tsDMARDs.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Moderate</span></div><div class="etd-domain-text"><p>Placebo was chosen as the primary comparator. The network estimates for the comparisons between the interventions and placebo were mostly of moderate to high certainty. Some comparisons were downgraded from high to moderate certainty for imprecision. For some interventions, primarily continuation or switch in route of the failed TNFi, the certainty of evidence was lower due to both imprecision and risk of bias in the included trials.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>A systematic review of patient preferences for DMARD treatment in RA was identified that included 36 studies published between 1990 and 2018. The included studies generally involved participants who had already commenced DMARDs, including bDMARDs [84]. The review found that, in general, people with RA consider treatment benefits (particularly improvement in symptoms and function) to be more important than both serious and non-serious adverse events. However some studies found evidence of important risk aversion (particularly regarding serious adverse events), which suggests that there is considerable variation in preferences between individuals. Dosing and administration considerations, including route and frequency of medications, were generally found to be less important than treatment benefits but more important than AEs, although this also varied between and within studies.</p>
                        <p>It is plausible that individuals with RA who have not responded to a TNF inhibitor may place more weight on improvement in disease activity, although there is still likely to be important variation between individuals. A recent systematic review of patient-based benefit-risk assessment in people with a range of chronic diseases indicates that variation in individual risk tolerance is common, and may be higher in those with greater disease severity and longer treatment experience [181]. Patients&#x27; perception of competing risks of benefits and harms are also affected by prior experience with DMARDs, including prior DMARD-related adverse effects [183].</p>
                        <p>The anticipated variability in preferences and values between patients underscores the importance of shared decision-making between clinician and patient regarding treatments for RA.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>We have not systematically reviewed the relative cost-effectiveness of the various interventions included in the current network meta-analysis. There are few existing data on the comparative cost-effectiveness of different sequences of b/tsDMARDs in RA [180]. However, in patients for whom a decision to institute b/tsDMARD therapy has already been taken, resource implications are unlikely to be a major determinant of the choice of subsequent DMARDs unless there is a clear difference in cost-effectiveness between the available alternative interventions.</p>
                        <p>Although there are no publicly available data regarding the actual comparative costs of different bDMARDs to the payer (i.e. the Federal Government) in Australia, b/tsDMARDs are expensive therapies and represent an important fraction of total pharmaceutical expenditure. While there are likely to be some cost differences between b/tsDMARDs, these differences may vary over time due to various factors including statutory requirements and market forces (including the advent of biosimilar drugs), and represent a relatively small proportion of the total cost. Therefore the cost implications of the choice between individual b/tsDMARDs are currently unlikely to be an important consideration at the societal level and for funders, particularly if there are marginal differences in efficacy, although this may vary over time.</p>
                        <p>At the individual patient level the direct cost implications are less profound for those who meet Government funding criteria. Currently, almost all Australian patients with RA who have had an inadequate response to a TNFi are eligible for subsidised treatment with an alternative b/tsDMARD. There may be some differences between medications with respect to prescription dispensing fees, particularly for bDMARDs for which co-prescription of methotrexate is required, although the absolute cost difference and its impact is likely to vary between individual patients.</p>
                        <p>We did not identify any data regarding the differential impact of the included interventions on the environment. It is plausible that some b/tsDMARDs (e.g. those that are administered via single-use plastic devices) may have a larger negative impact on the environment due to manufacturing, packaging and transport, however the magnitude of such an impact (if present) or other indirect effects is currently unknown.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>There are a number of factors that may influence health opportunities and outcomes in individual patients. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may be important factors in the choice of subsequent DMARD therapy, particularly DMARD regimens that involve complex dosing, regular dose adjustments, or close specialist supervision, and may have a particular impact on equity if the opportunity to access specialist care varies between groups.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>It is likely that a switch to an alternative DMARD would be acceptable to most people with active RA who have not responded to a TNF inhibitor, although this may not apply equally to all treatment options and there may be variation between individuals based on their particular circumstances, prior treatment experience, and preferences. There is some evidence that people with RA often prefer medications administered orally, although this preference varies according to age, duration of disease, and other factors [182]. In general, people with RA are more likely to accept changes to their treatment regimen when they perceive that the change may result in an important improvement in their current symptoms and future prognosis [183].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>In people with RA, switching from an ineffective or poorly-tolerated TNFi to an alternative b/tsDMARD (including a switch to a different TNFi) is consistent with current rheumatology practice in Australia. All of the interventions included in the network meta-analysis that informs this recommendation (aside from sarilumab) are currently subsidised under the Pharmaceutical Benefits Scheme for the treatment of active RA in people who have had an inadequate response to a TNF inhibitor. For this reason, there are unlikely to be important feasibility implications.</p></div></div>
                </div>
                <div class="tab-content" id="rec-2-practical">
                    <div class="content-section"><div class="data-placeholder"><p>Practical information will be added here.</p></div></div>
                </div>
                <div class="tab-content" id="rec-2-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-2-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-2-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Rheumatoid%20arthritis%3A%20Dose%20reduction%20or%20discontinu" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Rheumatoid arthritis: Dose reduction or discontinu-->
    <div class="modal-overlay" id="modal-rec-3">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Rheumatoid arthritis: Dose reduction or discontinuation of conventional synthetic DMARDs</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-3', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-3', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-3', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-3', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-3', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-3', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-3-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In people with RA who have been in sustained low disease activity or remission for at least 6 months, consider a trial of reduction in the dose of csDMARD.</p>
                        <p>Abrupt discontinuation of csDMARDs is not recommended.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel reviewed evidence from randomised controlled trials (RCTs) of dose reduction or discontinuation of conventional synthetic DMARDs (csDMARDs) in people with rheumatoid arthritis (RA) who had achieved a treatment target (either remission or low disease activity (LDA)). Seven RCTs provided data on dose reduction and 12 RCTs provided data on discontinuation. Only three of the included RCTs evaluated stepwise dose reduction to discontinuation. In most trials, participants had been in a stable low disease activity state for 6 months (range 4-12 months), and participants were followed for a period of 24 to 52 weeks.</p>
                        <p>Data on dose reduction and discontinuation were considered separately. For each intervention, the pooled data included participants who were either taking csDMARDs alone or were taking csDMARDs in combination with biologic or targeted synthetic DMARDs (b/tsDMARDs). The panel was provided with a detailed evidence summary for each outcome of interest, including forest plots that stratified the outcomes by trials in which participants (1) were treated with csDMARDs alone, (2) reduced or discontinued csDMARDs while continuing background b/tsDMARDs at the same dose, or (3) reduced or discontinued both csDMARDs and b/tsDMARDs simultaneously. For both dose reduction and discontinuation, there was little heterogeneity between these three groups of participants.</p>
                        <p>Most trials included treatment regimens and dose reduction interventions that are consistent with current practice. The majority of included trials used remission rather than LDA as the entry criterion, although most used the DAS28 to measure remission. The panel noted that the ACR/EULAR remission criteria (which incorporate either Boolean or SDAI remission) are more stringent and therefore some participants in DAS28 remission may have been in LDA rather than remission if other measures had been used. The treat-to-target approach to RA management recognises that while remission is the preferred state, the treatment target varies between individual patients, and for some patients LDA is a more appropriate target. Given that the trials included patients with both LDA and remission, and recognising the variation in treatment targets between patients, the panel felt that this recommendation should apply to patients in either LDA or remission, although it was noted that patients in a &#x27;deep&#x27; remission (such as Boolean remission) may be more likely to maintain adequate disease control.</p>
                        <p>Given that there was moderate to high certainty evidence that abrupt discontinuation of csDMARDs is associated with loss of disease control, worsening of functional status, and an increased risk of radiographic progression, the panel recommended against discontinuation of csDMARDs in people with RA, irrespective of the continued use of b/tsDMARDs.</p>
                        <p>The majority of the panel discussion addressed the question of reduction in the dose of csDMARDs, and two rounds of voting were undertaken. The panel agreed that the relative benefits and harms were more finely balanced, and that any decision on dose reduction of csDMARDs was likely to be dependent on the individual patient’s goals, preferences, values and context.</p>
                        <p>There was discussion regarding whether the putative benefits of csDMARD dose reduction warranted the potential small risk of disease flare. The panel also noted the apparent incongruity in the finding that dose reduction may increase the number of people experiencing a disease flare but probably has little or no effect on the number of people maintaining remission. It was considered that there may be some people who experience a transient flare that does not result in a change in disease trajectory (i.e., loss of remission or low disease activity state), however the consumer panelists also noted that the individual experience of fluctuation or change in disease activity is not binary and may still have an impact even if criteria for loss of remission are not met.</p>
                        <p>The panel noted that a high proportion (70-100%) of participants in the included trials whose disease flared were able to recapture their previous low disease activity state with resumption of their prior dose of csDMARDs. However it was also noted that the duration and impact of a transient increase in disease activity on work, participation and quality of life is likely to vary between individuals, and therefore this would likely be an important consideration in the shared decision-making process.</p>
                        <p>The panel agreed that while csDMARDs have a good safety profile in the short and long-term, they often have a negative impact on quality of life, including unpleasant adverse effects (including nausea, headache and fatigue), the requirement for regular monitoring (including blood tests), pill burden, and the threat of rare but serious adverse events. For many people, the potential benefits of reducing exposure to these medications may warrant the small risk of disease flare.</p>
                        <p>It was also noted that there are some additional considerations for which the evidence is less certain. In contrast to the evidence regarding dose reduction of b/tsDMARDs, there were scant data regarding stepwise discontinuation of csDMARDs. While it is likely that some patients who have successfully reduced the dose of a csDMARD may choose to continue stepping down the dose until the drug is discontinued, the additional risk of disease flare with this strategy is difficult to estimate. Continuation of a DMARD at a lower dose may be less appealing than the eventual complete discontinuation of the drug, but this is also likely to vary considerably depending on the individual’s context and preferences. Further, while the use of csDMARDs (particularly methotrexate) is associated with a lower risk of cardiovascular disease in people with RA, it is unclear whether this risk modification varies with dose or whether there is sufficient potential incremental reduction in cardiovascular risk in people using csDMARDs and bDMARDs in combination to warrant the use of methotrexate for this reason alone [268][269].</p>
                        <p>Given that a decision regarding csDMARD dose reduction is highly dependent on individual circumstances and preferences, the panel unanimously agreed on a conditional recommendation. There was a general consensus that a conditional recommendation in favour of dose reduction may be more likely to encourage a discussion about treatment preferences and lead to an informed shared decision, while acknowledging that many of those who have achieved their treatment target with csDMARDs (alone or in combination with b/tsDMARDs), may prefer not to adjust their treatment regimen.</p>
                        <p>This recommendation does not address the question of whether csDMARDs or b/tsDMARDs should be tapered first in patients who have achieved their treatment goal with combination csDMARD and b/tsDMARD therapy and who wish to reduce their medication burden. This is addressed in a separate living recommendation (here).</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-3-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Important harms</span></div><div class="etd-domain-text"><p>Dose reduction and discontinuation of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) were considered separately and each compared to continuation of csDMARDs. For each comparison, the analysis pooled three groups of participants:</p>
                        <p>In people using csDMARDs alone, dose reduction or discontinuation of csDMARDs versus continuation of csDMARDs  In people using background b/tsDMARDs, dose reduction or discontinuation of csDMARDs (with continued background treatment of b/tsDMARD) versus continuation of csDMARDs (and continued dose of b/tsDMARD) In people using background b/tsDMARDs, dose reduction or discontinuation of both csDMARDs and b/tsDMARDs versus continuation of csDMARDs (with or without continued b/tsDMARD use)</p>
                        <p>Compared to continuation of treatment at the standard dose, dose reduction of csDMARDs (methotrexate monotherapy without background b/tsDMARDs in the majority) in participants with RA in remission or with low disease activity for at least 6 months:</p>
                        <p>may increase the number of people experiencing a flare is probably comparable in terms of the number of people maintaining remission, disease activity and function may be comparable in terms of the number of people with progression of joint damage may be comparable in terms of the number of people experiencing a serious adverse event and the number of people withdrawing due to adverse events.</p>
                        <p>Compared to continuation of treatment at the standard dose, discontinuation of csDMARDs (methotrexate combined with continued use of bDMARDs or a tsDMARD in the majority) in participants with RA in remission or with low disease activity for at least 6 months:</p>
                        <p>slightly reduces the number of people maintaining remission and slightly worsens disease activity and function probably increases the number of people experiencing a flare and slightly increases the number of people with progression of joint damage is probably comparable in terms of the number of people experiencing a serious adverse event and the number of withdrawals due to adverse events.</p>
                        <p>The characteristics of the participants recruited to the trials seem to largely reflect those in practice who may be considering discontinuation of their DMARD treatment; participants were in remission or low disease activity for 6 to 12 months in the majority of trials, apart from a single trial that included participants with low disease activity for only 4 months.</p>
                        <p>The panel debated the relative benefits and harms of both dose reduction and discontinuation of csDMARDs, and noted that the balance between the potential benefits and harms of dose modification was likely to be different for dose reduction compared to discontinuation. While the panel was initially split on whether the risk of increased disease activity with csDMARD dose modification represented a net “important harm”, there was consensus that the risk of disease flare in those who abruptly discontinue DMARDs was likely to be harmful whereas the risk of flare was much lower in those who reduce their DMARD dose, in which case the potential benefits may outweigh the potential harms for a proportion of patients. The consumer panelists both described the significant impact of disease flare or loss of remission, and noted that the experience and impact of a change in RA disease activity or medication adverse effects may vary between individuals and within the same individual over time.</p>
                        <p>Given the potential for a significant negative impact on RA disease control with discontinuation of csDMARDs, the panel voted for an overall judgment of “important harms” but noted that the risk of important harm is likely to be minimal in those who reduce the csDMARD dose rather than discontinue csDMARDs completely.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Moderate</span></div><div class="etd-domain-text"><p>Dose reduction</p>
                        <p>There was MODERATE certainty evidence that dose reduction of csDMARDs probably has little to no effect on the number of people maintaining remission, on disease activity or physical function.</p>
                        <p>There was LOW certainty evidence that dose reduction of csDMARDs may increase the number of people experiencing a flare, and may have little to no effect on the number of people with progression of joint damage, on the number of people experiencing a serious adverse event or withdrawing due to adverse events.</p>
                        <p>Discontinuation</p>
                        <p>There was HIGH certainty evidence that discontinuation of csDMARDs slightly reduces the number of people maintaining remission, and slightly worsens disease activity and physical function.</p>
                        <p>There was MODERATE certainty evidence that discontinuation of csDMARDs probably increases the number of people experiencing a flare, probably slightly increases the number of people with progression of joint damage, and probably has little or no effect on the number of serious adverse events or the number of withdrawals due to adverse events.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>A systematic review of patient preferences regarding DMARD treatment found that, in general, people with RA consider treatment benefits (particularly improvement in symptoms and function) to be more important than both serious and non-serious adverse events (AEs) [84]. However some studies found evidence of important risk aversion (particularly regarding serious AEs), which suggests that there is considerable variation in preferences between individuals. A scoping review of patient preferences for treatment modification in people with RA also identified variability in preferences between individuals [183]. While a common theme was a desire to return to a &quot;normal life&quot;, the effect of this desire on treatment choices was dependent on the impacts of the disease and its treatments in the individual&#x27;s unique life circumstances.</p>
                        <p>A qualitative study of patients with well-controlled RA indicated a general preference for reduction of medication burden, particularly in regard to concerns about the cumulative toxicity of DMARDs, but this was tempered by concern about the impact of a possible disease flare [1].</p>
                        <p>The variation between individuals in their assessment of competing risks between disease and treatment, suggests that an individualised shared decision-making framework is of particular importance when considering treatment modification, including dose reduction or discontinuation of DMARDs.</p>
                        <p>The panel unanimously agreed that there is likely to be substantial variability in preferences between individuals based on their unique circumstances, goals, disease course and impact, comorbidity, and experience with previous and current medications.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>In contrast to b/tsDMARDs, csDMARDs are relatively inexpensive medications. Therefore, the direct cost impact of dose reduction or discontinuation at both the individual and system level is likely to be relatively minor. The importance of any out-of-pocket cost difference may vary between individual patients. There is evidence that out-of-pocket healthcare costs may act as a barrier to accessing treatment for some people - as many as 25% of Australians living with arthritis (of any type) report skipping healthcare treatment due to cost [243]. The proportion of Australians who delayed or did not fill a medication prescription due to cost increased to 7.6% in 2022-23, from 5.6% in 2021-22 [247].</p>
                        <p>Most data on the cost-effectiveness of DMARD tapering strategies in people with RA are focused on b/tsDMARDs. A cost-effectiveness analysis of the TARA trial, which compared csDMARD tapering with TNF inhibitor tapering in participants with RA who had achieved low disease activity with combination therapy, found that both strategies were cost-effective [245].</p>
                        <p>While there are no data that specifically estimate the effect of csDMARD dose reduction or discontinuation on the environment, it is plausible that reduced prescription drug use may lower any negative impact on the environment attributable to manufacturing, packaging and transport. The magnitude of such an impact (if present) or other indirect effects is currently unknown.</p>
                        <p>The panel noted that at the time of this panel meeting, the relative cost of living in Australia is very high, and therefore even relatively small changes in out-of-pocket costs may have a large impact for some people. It was also noted that the cost implications of csDMARD dose reduction may be unpredictable and any putative cost savings attributable to lower medication use may potentially be offset by increased direct healthcare costs related to more frequent disease monitoring or management of flares, and indirect costs (e.g. an impact on work status) in the event of an increase in disease activity.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Many factors influence individual patient&#x27;s health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect csDMARD dose reduction, including an impact on access to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p>
                        <p>The panel noted that any adjustment of treatment regimen, and the potential impact on disease activity, may present a number of challenges for individuals living with RA and that this may affect some individuals disproportionately.</p>
                        <p>The panel also highlighted that the current severe shortage of rheumatologists in Australia may increase the risk that access to urgent specialist care may be limited, and that this risk may be greater for disadvantaged groups or those living in rural or remote areas.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The acceptability of csDMARD dose reduction or discontinuation is likely to vary between patients. In addition, the perspective of people living with RA on the acceptability of DMARD tapering differs from the perspective of clinicians [246][244], highlighting the importance of shared decision-making tailored to the individual patient&#x27;s preferences and context.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered that while csDMARD dose reduction was likely to be feasible for many individuals, there was the potential for barriers to implementation in some settings, particularly where access to care and support may be limited during the period of dose modification.</p></div></div>
                </div>
                <div class="tab-content" id="rec-3-practical">
                    <div class="content-section"><p>A treat-to-target approach is recommended for all patients with RA, including during dose reduction.</p>
                        <p>All decisions regarding the DMARD regimen in people with rheumatoid arthritis should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual&#x27;s circumstances.</p>
                        <p>While this recommendation is based on data from trials in which patients had been in either LDA or remission for 6-12 months, and there are few reliable predictors of successful DMARD dose reduction, a &#x27;deep remission&#x27; (eg Boolean remission) or maintenance of the treatment target for at least 12 months may represent optimal preconditions for a trial of dose reduction.</p>
                        <p>Following dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure (e.g., DAS28, SDAI, CDAI). Maintenance of an agreed treatment target state (either remission or low disease activity) should be ensured before considering further adjustment of the treatment regimen.</p>
                        <p>Patients should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a mechanism for patients to contact their prescriber between visits if necessary.</p>
                        <p>In the event of loss of disease control (e.g., persistent increase in composite disease activity measure or new symptoms that are unacceptable to the patient), we recommend reintroduction of the previous effective dose of csDMARDs.</p>
                        <p>Reduction or cessation of glucocorticoids is also an important goal and ought to be considered before an attempt at csDMARD dose reduction.</p>
                        <p>In people using a combination of methotrexate and a bDMARD who are considering stepwise dose reduction, note that maintenance of a low dose of methotrexate (e.g., 7.5 - 10mg per week) may be required due to prescribing restrictions for some bDMARDs, and should be considered if there are concerns regarding the development of anti-drug antibodies (e.g., people who have previously experienced secondary failure of a monoclonal antibody)</p></div>
                </div>
                <div class="tab-content" id="rec-3-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-3-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-3-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: March 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Psoriatic%20Arthritis%3A%20Dose%20reduction%20or%20discontinua" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Psoriatic Arthritis: Dose reduction or discontinua-->
    <div class="modal-overlay" id="modal-rec-4">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Psoriatic Arthritis: Dose reduction or discontinuation of conventional synthetic DMARDs</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-4', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-4', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-4', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-4', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-4', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-4', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-4-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In people with psoriatic arthritis who have been in sustained low disease activity or remission for at least 6 months (including adequate control of skin disease), consider a trial of reduction in the dose of csDMARD.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel reviewed evidence from randomised controlled trials (RCTs) of dose reduction or discontinuation of conventional synthetic DMARDs (csDMARDs) in people with psoriatic arthritis (PsA). Only two RCTs were available. In light of the paucity of data, the panel debated whether it was possible to make a recommendation at all. Three rounds of voting were undertaken. Ultimately the panel concluded that it was likely to be more useful for clinicians and consumers if a conditional recommendation were made, but highlighted that the evidence base is extremely limited and that further evidence is likely to change the existing effect estimates and may alter this living recommendation. Given its highly conditional nature, any decision regarding dose reduction of csDMARDs in people with psoriatic arthritis will be highly contingent on the individual patient’s circumstances, disease manifestations, treatment history, comorbidity, preferences, values and treatment goals.</p>
                        <p>In each voting round there was incomplete agreement on the direction of the recommendation, but in every round more panelists voted for a conditional recommendation in favour of csDMARD dose reduction than a conditional recommendation against. The panel noted that, regardless of the direction of the recommendation, any decision regarding csDMARD dose modification in people with psoriatic arthritis should be based on a careful consideration of the individual circumstances and treatment goals. The panel felt that a conditional recommendation in favour of dose reduction might be more likely to encourage such a conversation about treatment preferences and lead to an informed shared decision, while acknowledging that many of those who have achieved their treatment target with csDMARDs (alone or in combination with b/tsDMARDs), may prefer not to adjust their treatment regimen.</p>
                        <p>The panel considered the evidence from the two relevant RCTs. The first included participants who had achieved Minimal Disease Activity (MDA) with csDMARDs or bDMARDs, either alone or in combination, and compared stepwise dose reduction of each drug versus continuation of treatment [173]. Only 17 participants were included, of whom seven were eligible for reduction of the bDMARD first. Among the 10 participants using csDMARDs alone, there were two disease flares, both of which occurred in participants who had been randomised to dose reduction.</p>
                        <p>The second included participants who had been on a stable combination of methotrexate and tofacitinib but who were not necessarily in a low disease activity state [270]. Participants were randomised to either continue methotrexate or abruptly discontinue it while maintaining the same dose of tofacitinib.</p>
                        <p>The panel discussed the scarcity of data at length. In particular, the panel noted that the data from Moverley 2015 provided very low certainty evidence regarding csDMARD dose reduction, given that only 10 participants were receiving csDMARDs (alone or in combination), and only two disease flares were reported among these participants during the 12 week follow-up period. Further, the panel noted that there are no data regarding dose reduction or discontinuation of csDMARDs in participants who have achieved good disease control with the combination of a csDMARD with a b/tsDMARD other than tofacitinib, despite this being a relatively common clinical scenario.</p>
                        <p>The panel then debated whether the conditional recommendation should apply broadly to all individuals using csDMARDs for the treatment of psoriatic arthritis, or whether the recommendation might differ depending on the concomitant use of b/tsDMARDs. Due to the very limited evidence base, the panel concluded that a broad conditional recommendation was most appropriate, that highlighted the importance of the individual context and shared decision-making.</p>
                        <p>The panel noted that while csDMARDs generally have a good safety profile in the short and long-term, they often have a negative impact on quality of life, including unpleasant adverse effects (including nausea, headache and fatigue), the requirement for regular monitoring (including blood tests), pill burden, and the threat of rare but serious adverse events. For some people, the potential benefits of reducing exposure to these medications may warrant an increased risk of disease flare.</p>
                        <p>There was insufficient evidence to recommend a dose reduction strategy (for example, a single dose reduction versus stepwise dose reduction or discontinuation), however it is likely that the risk of flare is higher with abrupt discontinuation compared to dose reduction, although this risk may be modified by the concomitant use of other DMARDs. There are no data on predictors of flare in the individual patient.</p>
                        <p>The consumer panelists highlighted the importance of the extra-articular manifestations of psoriatic arthritis, particularly skin disease. One panelist reported that the impact of a flare in cutaneous psoriasis may have an even greater negative impact than a flare of arthritis and that, as a result, the risks associated with DMARD dose reduction in psoriatic arthritis may be greater, and less predictable, than in other forms of inflammatory arthritis.</p>
                        <p>The panel indicated that data regarding the risk of disease flare following dose reduction in people treated with csDMARDs for cutaneous psoriasis might be of additional value in formulating this recommendation. A brief literature search was performed subsequent to the panel meeting but before finalisation of the recommendation. Current major dermatology guidelines (including the American Academy of Dermatology and NICE) do not directly address this question. Only one RCT was found that evaluated the effect of methotrexate dose reduction in people who had achieved good control of psoriasis, however this trial compared three dose reduction strategies (sudden discontinuation, half dose, double dosing interval) without a continuation arm for comparison [288]. The two dose reduction strategies were associated with a lower rate of skin flare compared with the sudden discontinuation strategy.</p>
                        <p>The panel also noted that there are no data regarding the trade-offs in potential long-term consequences of continuing csDMARDs (such as hepatotoxicity) versus reducing exposure to csDMARDs (such as joint or other tissue damage, or impact on cardiovascular risk).</p>
                        <p>We anticipate that data relevant to this recommendation will continue to emerge. This living recommendation will continue to be updated as soon as relevant new information becomes available.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-4-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>Dose reduction</p>
                        <p>Compared to continuation of treatment at the standard dose, dose reduction of methotrexate (MTX) alone, or sequential reduction of MTX and concomitant conventional synthetic DMARDs (csDMARDs) or biological DMARDs (bDMARDs), in participants with psoriatic arthritis in remission or with low disease activity for at least 6 months:</p>
                        <p>may increase the number of people experiencing a flare  may increase mean disease activity slightly may be comparable in terms of the number of people maintaining remission, the number of people maintaining low/minimal disease activity and the number of people experiencing an adverse event We are uncertain whether dose reduction of csDMARDs results in fewer withdrawals due to adverse events or fewer serious adverse events, as no events were reported and the certainty of the evidence is very low.</p>
                        <p>No studies were found that measured or reported the number of people with radiographic progression of joint damage. Function was measured but not reported by one study.</p>
                        <p>The panel noted that the single randomised controlled trial (RCT) that provided data on dose reduction [173] included 17 patients, of whom only ten were eligible for tapering of csDMARDs, and that therefore any estimates of the effect of csDMARD dose reduction based on this trial alone were unlikely to be reliable.</p>
                        <p>Discontinuation</p>
                        <p>Compared to continuation of oral MTX plus tofacitinib, abrupt discontinuation of oral MTX and continuation of tofacitinib in participants with psoriatic arthritis:</p>
                        <p>may be comparable in terms of the number of people experiencing a flare, the number of people maintaining low/minimal disease activity, the number of withdrawals due to adverse events, the number of people experiencing a serious adverse event or any adverse events, mean disease activity and function</p>
                        <p>No studies were found that measured or reported the number of people maintaining remission or progression of joint damage.</p>
                        <p>Only one RCT was found that evaluated the effect of csDMARD dose reduction or discontinuation in people who had achieved good control of cutaneous psoriasis [288]. This trial compared three strategies for dose reduction or discontinuation of treatment in people who achieved a PASI75 response with MTX (sudden discontinuation, halving of the MTX dose, doubling of the MTX dosing interval), however it did not include a comparator arm in which MTX was continued at the same dose. The two dose reduction strategies were associated with a lower rate of skin flare compared with sudden discontinuation.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very Low</span></div><div class="etd-domain-text"><p>Dose reduction</p>
                        <p>There was LOW certainty evidence that dose reduction of csDMARDs may increase the number of people experiencing a flare and increase disease activity but may have little or no effect on the number of people maintaining remission or low/minimal disease activity or on the number of people experiencing a serious adverse event.</p>
                        <p>There was VERY LOW certainty evidence for the effects of dose reduction of csDMARDs on serious adverse events or withdrawals due to adverse events as no events were reported for these.</p>
                        <p>No trials of csDMARD dose reduction measured or reported radiographic progression, and no trials reported function.</p>
                        <p>Upon review of the evidence from the one RCT that addressed this question, the panel agreed that they had VERY LOW confidence in the effect estimates for all outcomes.</p>
                        <p>Discontinuation</p>
                        <p>There was LOW certainty evidence that discontinuation of csDMARDs may have little to no effect on the number of people experiencing a flare, the number of people maintaining low/minimal disease activity, the number of withdrawals due to adverse events, the number of people experiencing a serious adverse event or any adverse events, mean disease activity and function.</p>
                        <p>No trials of csDMARD discontinuation measured or reported the number of people maintaining remission or progression of joint damage.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>While there is considerable variability between individuals in the clinical manifestations and impacts of psoriatic arthritis, musculoskeletal symptoms (particularly pain) have been reported to be the most burdensome to people living with psoriatic arthritis [285]. Among Australian patients with inflammatory arthritis (including psoriatic arthritis), the most important attributes of treatments include both clinical efficacy and the risk of mild-to-moderate adverse effects [286]. The relative importance of these attributes, and preferences for treatments, may vary between individuals.</p>
                        <p>A study performed among British people with psoriatic arthritis investigated the relative importance of characteristics associated with both the disease (including function, participation, costs, pain and fatigue) and treatment (including gastrointestinal distress, headache, infections, hair loss, blood testing, and impact on pregnancy) [287]. A discrete choice experiment was used to estimate the trade-off between the benefits of medication and risk of relapse for patients in a low disease activity state who might be considering tapering therapy. The majority of participants were taking methotrexate either alone or in combination with other csDMARDs or a TNF inhibitor. Participants attached the highest importance to eliminating severe nausea and were willing to accept an increase in the risk of relapse of more than 30% in exchange for improvements in this adverse effect.</p>
                        <p>The variation between individuals in their assessment of competing risks between disease and treatment, suggests that an individualised shared decision-making framework is of particular importance when considering treatment modification, including dose reduction or discontinuation of DMARDs.</p>
                        <p>The panel noted the importance of the full range of clinical manifestations of psoriatic arthritis, particularly cutaneous psoriasis, and that the variation between individuals (and within individuals over time) in the clinical features and their relative importance requires a thoughtful shared approach to treatment adjustment that takes all of these factors into account.</p>
                        <p>The panel unanimously agreed that there is likely to be substantial variability in preferences between individuals based on their unique circumstances, goals, disease course and impact, comorbidity, and experience with previous and current medications.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>We did not identify any data regarding the cost-effectiveness of dose reduction or discontinuation of csDMARDs in people with psoriatic arthritis. In contrast to b/tsDMARDs, csDMARDs are relatively inexpensive medications. Therefore, the direct cost impact of dose reduction or discontinuation at both the individual and system level is likely to be relatively minor. The importance of any out-of-pocket cost difference may vary between individual patients. There is evidence that out-of-pocket healthcare costs may act as a barrier to accessing treatment for some people - as many as 25% of Australians living with arthritis (of any type) report skipping healthcare treatment due to cost [243]. The proportion of Australians who delayed or did not fill a medication prescription due to cost increased to 7.6% in 2022-23, from 5.6% in 2021-22 [247].</p>
                        <p>While there are no data that specifically estimate the effect of csDMARD dose reduction or discontinuation on the environment, it is plausible that reduced prescription drug use may lower any negative impact on the environment attributable to manufacturing, packaging and transport. The magnitude of such an impact (if present) or other indirect effects is currently unknown.</p>
                        <p>While some panelists considered the resource implications of this recommendation to be relatively minor, the panel noted that at the time of this panel meeting, the relative cost of living in Australia is very high, and therefore even relatively small changes in out-of-pocket costs may have a large impact for some people. It was also noted that the cost implications of csDMARD dose reduction may be unpredictable and any putative cost savings attributable to lower medication use may potentially be offset by increased direct healthcare costs related to more frequent disease monitoring or management of flares, and indirect costs (e.g. an impact on work status) in the event of an increase in disease activity.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Many factors influence individual patient&#x27;s health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect csDMARD dose reduction, including an impact on access to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p>
                        <p>The current severe shortage of rheumatologists in Australia may increase the risk that access to urgent specialist care may be limited, and that this risk may be greater for disadvantaged groups or those living in rural or remote areas.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The acceptability of csDMARD dose reduction or discontinuation is likely to vary between patients. Although there is scant direct evidence in psoriatic arthritis, among people living with rheumatoid arthritis there is evidence that the perspective of patients regarding the acceptability of DMARD tapering differs from the perspective of clinicians [244][246], highlighting the importance of shared decision-making tailored to the individual patient&#x27;s preferences and context.</p>
                        <p>csDMARD tapering is likely to be broadly acceptable to other stakeholders.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>While csDMARD dose reduction is likely to be feasible for many individuals, there is the potential for barriers to implementation in some settings, particularly where access to care and support may be limited during the period of dose modification.</p></div></div>
                </div>
                <div class="tab-content" id="rec-4-practical">
                    <div class="content-section"><p>A treat-to-target approach is recommended for all patients with psoriatic arthritis, including during dose reduction.</p>
                        <p>All decisions regarding the DMARD regimen in people with psoriatic arthritis should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual&#x27;s circumstances.</p>
                        <p>Any discussion regarding dose reduction should also consider the potential impact on extra-articular manifestations of psoriatic arthritis, particularly psoriasis.</p>
                        <p>While this recommendation is based on very limited data, a stable low disease activity state for at least 6 months is likely to be the minimum time frame for consideration of csDMARD dose reduction, and a &#x27;deep remission&#x27; (eg Very Low Disease Activity) or maintenance of the treatment target for at least 12 months may represent optimal preconditions for a trial of dose reduction.</p>
                        <p>Following dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure (e.g., PASDAS). Maintenance of an agreed treatment target state should be ensured before considering further adjustment of the treatment regimen.</p>
                        <p>Clinical review after dose reduction should also include surveillance for the emergence of  extra-articular clinical features (e.g., psoriasis, nail dystrophy).</p>
                        <p>Patients should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a mechanism for patients to contact their prescriber between visits if necessary.</p>
                        <p>In the event of loss of disease control (e.g., persistent increase in composite disease activity measure or new symptoms that are unacceptable to the patient), we recommend reintroduction of the previous effective dose of csDMARDs.</p></div>
                </div>
                <div class="tab-content" id="rec-4-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-4-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-4-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: August 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Rheumatoid%20Arthritis%3A%20Dose%20reduction%20or%20discontinu" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Rheumatoid Arthritis: Dose reduction or discontinu-->
    <div class="modal-overlay" id="modal-rec-5">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Rheumatoid Arthritis: Dose reduction or discontinuation of biologic or targeted synthetic DMARDs</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-5', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-5', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-5', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-5', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-5', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-5', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-5-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In people with RA who have been in sustained low disease activity or remission for at least 6 months, consider stepwise reduction in the dose of b/tsDMARD. Continue dose reduction until cessation is achieved or the lowest effective b/tsDMARD dose is identified, as long as the treatment target is maintained.</p>
                        <p>Abrupt cessation of b/tsDMARDs without prior dose reduction is not recommended.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel considered evidence from trials that included patients treated with b/tsDMARDs who had achieved a state of sustained low-disease activity (LDA) or remission. The majority of participants had experienced stable low disease activity for at least 6 months, although the duration varied from 3 to 12 months in the included trials. The expert panel expressed the view that many patients and clinicians may choose to wait for a longer period before a trial of dose reduction. Importantly, there are currently no reliable clinical or laboratory predictors of which patients are most likely to achieve successful dose reduction or cessation.</p>
                        <p>Data for dose reduction included different approaches to reducing b/tsDMARDs, including both a single reduction in dose or multiple (stepwise) dose reductions, and either a reduction in the regular dose or an increase in the dosing interval. The panel was satisfied that there was sufficient consistency in the data and applicability to clinical practice to warrant combination of the data in this way. It was noted that the data were primarily in patients using TNF inhibitors (especially adalimumab and etanercept) although results for dose reduction appear to be consistent for b/tsDMARDs with other mechanisms of action. There are currently no data on drug cessation for b/tsDMARDs other than TNF inhibitors.</p>
                        <p>The panel considered data on dose reduction separately from data on complete cessation of b/tsDMARDs but concluded that a single recommendation that incorporated both reduction and cessation was preferable to two separate overlapping recommendations.</p>
                        <p>While some trials included only patients in remission, many included patients who were in LDA but not remission. Most included trials used the DAS28 to measure remission and LDA. The panel noted that the ACR/EULAR remission criteria (which incorporate either Boolean or SDAI remission) are more stringent and therefore some participants in DAS28 remission may have been in LDA rather than remission if other measures had been used. The treat-to-target approach to RA management recognises that while remission is the preferred state, the treatment target varies between individual patients, and for some patients LDA is a more appropriate target. Given that the trials included patients with both LDA and remission, and recognising the variation in treatment targets between patients, the panel felt that this recommendation should apply to patients in either LDA or remission, although it was noted that patients in a &#x27;deep&#x27; remission (such as Boolean remission) may be more likely to maintain adequate disease control.</p>
                        <p>The panel noted that the ability to quickly recapture disease control with resumption of a higher dose is high for b/tsDMARDs, although not universal, and that this may be an important consideration in the shared decision-making process for individuals.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-5-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>In adults with rheumatoid arthritis and low disease activity, reducing the dose of a bDMARD or tsDMARD probably has little effect on control of disease activity, including mean DAS and the proportion who remain in remission (or a low disease activity state). There may be a small negative effect on radiographic progression and function. Based on clinical trials there appears to be little difference in safety or tolerability but adverse event rates in trials are low and therefore data are limited.</p>
                        <p>Discontinuing a bDMARD or tsDMARD without prior dose reduction probably reduces the proportion of participants with persistent remission, probably slightly worsens disease activity, probably increases the proportion of people who experience a flare, may slightly increase the proportion of people with minimal radiographic progression, may lead to a slight deterioration in function and may slightly worsen quality of life. Due to the small number of events reported, we are uncertain whether discontinuation results in fewer serious adverse events or whether adverse events differ between groups.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>There are some limitations to the certainty of the evidence for dose reduction. First, most of the data are for TNF inhibitors (particularly adalimumab and etanercept), and therefore may not be directly applicable to other b/tsDMARDs. Second, for some outcomes there may not be sufficient precision in the data to demonstrate that dose reduction is an equivalent strategy to b/tsDMARD continuation. Third, the relatively short follow-up period in trials limits the number of important adverse events detected and may reduce the likelihood of detecting radiographic progression, thereby reducing our confidence in the estimates of these outcomes.</p>
                        <p>There is less certainty in the evidence regarding abrupt b/tsDMARD cessation. Data on drug abrupt cessation were available for TNF inhibitors only, and therefore may not be applicable to other b/tsDMARDs. Most of the evidence for cessation was considered to be low certainty, although there was moderate certainty for mean disease activity score. We have very low confidence in the evidence regarding adverse events due to low event rates.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>We have no systematically collected information regarding patients’ preferences and values. It is likely that individual patient preferences for reduced exposure to medication versus the risk of flare will vary.</p>
                        <p>A qualitative study of patients with well-controlled RA [1] indicated a general preference for reduction of medication burden, particularly in regard to concerns about the cumulative toxicity of DMARDs, but this was tempered by concern about the impact of a possible disease flare. Tolerance for the risk of flare was mediated by social circumstances, including the impact of a disease flare on employment and burden to family. There was variation between individuals in the assessment of competing risks between disease and treatment, suggesting that an individualised shared decision-making framework is of particular importance in this context.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>b/tsDMARDs are generally considered to be expensive therapies and therefore strategies to reduce the total cumulative dose are likely to reduce costs for payers (governments and insurers) and may reduce out-of-pocket costs for patients. In the Australian context, the direct cost impact for individual patients is relatively small but this may differ in other contexts. The importance of direct out-of-pocket cost implications of dose reduction versus continuation is likely to vary between individual patients. There are no publicly-available data regarding the actual comparative costs of different bDMARDs to the payer (i.e. the Federal Government) in Australia.</p>
                        <p>Most trials that have assessed b/tsDMARD dose reduction have not assessed costs or cost-effectiveness. Compared with anti-TNF continuation, two trials found that anti-TNF activity-guided dose reduction significantly reduced costs and resulted in decremental cost-effectiveness ratios but the estimates were very broad [3].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered that many factors influence individual patient’s health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect b/tsDMARD dose reduction, including an impact on access to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>From a recent survey of ARAD participants (unpublished data):</p>
                        <p>The medication you have taken is known as a biologic or targeted DMARD: Evidence shows that some people with well-controlled disease can safely reduce the dose of their biologic or targeted DMARD or how frequently they take it, without any worsening of their condition. If your treating specialist suggested it, would you be willing to try taking your biologic or targeted DMARD less frequently, or at a reduced dose?</p>
                        <p>Responses as follows: Yes: 216 (53%) No: 66 (16%) Maybe: 127 (31%)</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Implementation of the recommendation may be influenced in some cases by local prescribing rules or reimbursement conditions, and by the accessibility of care in the case of a disease flare. Current Australian prescribing and reimbursement rules for b/tsDMARDs are complex. For example, some reimbursement rules are predicated on stable disease control with full-dose medication. In this situation, some patients or prescribers may be concerned about the risk that, in the event of a disease flare with dose reduction, the resumption of a higher dose of the current b/tsDMARD may be prohibited.</p></div></div>
                </div>
                <div class="tab-content" id="rec-5-practical">
                    <div class="content-section"><p>A treat-to-target approach is recommended for all patients with RA, including during dose reduction.</p>
                        <p>While this recommendation is based on data from trials in which patients had been in either LDA or remission for 6-12 months, the panel felt that either a &#x27;deep remission&#x27; (eg Boolean remission) or persistent LDA for at least 12 months were more likely to represent optimal preconditions for a trial of dose reduction.</p>
                        <p>&#x27;Stepwise dose reduction&#x27; includes any method that reduces the b/tsDMARD dose in an incremental manner. This may include a reduction in the regular dose (eg a 50% reduction in etanercept dose from 50mg weekly to 25mg weekly) or an increase in the dosing interval (eg from adalimumab 40mg every two weeks to 40mg every three weeks). Further incremental reductions may be possible depending on the particular medication (eg adalimumab 40mg every four weeks). A combination of dose reduction and an increase in dosing interval could also be considered (eg etanercept 25mg every two weeks).</p>
                        <p>Following dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure (e.g., DAS28, SDAI, CDAI). Maintenance of an agreed treatment target state (either remission or low disease activity) should be ensured before considering further dose reduction.</p>
                        <p>Patients should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a mechanism for patients to contact their prescriber between visits if necessary.</p>
                        <p>In the event of loss of disease control (e.g., persistent increase in composite disease activity measure or new symptoms that are unacceptable to the patient), we recommend reintroduction of the previous effective dose of b/tsDMARD.</p>
                        <p>During b/tsDMARD dose reduction, concurrent csDMARDs should be continued at a stable dose.</p>
                        <p>Reduction or cessation of glucocorticoids is also an important goal and ought to be considered before an attempt at b/tsDMARD dose reduction.</p>
                        <p><strong>NPS MedicineWise have produced the following resources to support the implementation of this recommendation:</strong></p>
                        <ul>
                            <li>RA Dose Reduction Patient Decision Aid</li>
                            <li>RA Dose Reduction Fact Sheet</li>
                            <li>RA Dose Reduction Algorithm</li>
                        </ul></div>
                </div>
                <div class="tab-content" id="rec-5-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-5-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-5-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Axial%20Spondyloarthritis%3A%20Dose%20reduction%20or%20discont" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Axial Spondyloarthritis: Dose reduction or discont-->
    <div class="modal-overlay" id="modal-rec-6">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Axial Spondyloarthritis: Dose reduction or discontinuation of biologic DMARDs</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-6', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-6', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-6', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-6', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-6', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-6', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-6-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In people with axial spondyloarthritis who have been in sustained low disease activity or remission for at least 6 months, consider reduction in the dose of bDMARD. Continue at the lower dose as long as the treatment target is maintained. Abrupt cessation of bDMARDs is not recommended.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel considered data on dose reduction separately from data on complete discontinuation of bDMARDs but concluded that a single recommendation that incorporated both reduction and discontinuation was preferable to two separate overlapping recommendations. Data for dose reduction included different approaches to reducing bDMARDs, including a reduction in the regular dose or an increase in the dosing interval. There were no trials that tested the effect of further dose adjustments based on the response to an initial dose reduction (i.e., ‘stepwise’ dose reduction) or dose reduction prior to discontinuation.</p>
                        <p>The panel acknowledged that the evidence regarding adverse drug effects following dose reduction or cessation was of very low certainty. Furthermore, the long-term effects of bDMARD dose reduction on either the disease (including structural damage) or the risk of adverse drug effects remain unknown. Ideally, all patients using a b/tsDMARD should be offered the opportunity to participate in a registry in order to provide long-term data.</p>
                        <p>The panel felt that the potential for a flare in disease activity following a reduction in bDMARD dose might be balanced by the potential benefits of a lower burden of immunosuppressant medication, but that the decision to reduce the dose would be influenced by individual circumstances, preferences and values, and that a continuous, open and informed shared decision-making process should underpin any such decision. The data regarding bDMARD discontinuation suggested a higher likelihood of loss of disease control and the panel believed that the balance of benefits and harms would be unlikely to favour discontinuation for most patients, however it was noted that some trial participants were able to achieve a drug-free remission.</p>
                        <p>The panel noted that the ability to quickly recapture disease control with resumption of the normal dose of TNFi is high but not universal, and that this may be an important consideration in the shared decision-making process for individuals.</p>
                        <p>Another consideration in shared decision-making for the individual patient with axial spondyloarthritis may be the presence of extraskeletal manifestations such as psoriasis, uveitis and inflammatory bowel disease. The balance of risks and benefits may be different in patients for whom bDMARDs have also been an effective therapy for these disease manifestations.</p>
                        <p>At the time of the initial panel meeting, all of the data were from patients treated with TNF inhibitors (TNFi). Subsequently, a trial of discontinuation of an IL-17 inhibitor (ixekizumab) was published but this did not change the overall estimate of benefits and harms and no change was made to the recommendation. It remains unclear to what extent the current data may be extrapolated to dose reduction for bDMARDs other than TNF inhibitors or discontinuation for bDMARDs that do not target either TNF or IL-17. Similarly, there are currently no data regarding dose reduction or discontinuation of targeted synthetic DMARDs in axial spondyloarthritis.</p>
                        <p>The panel considered evidence from trials that included patients treated with bDMARDs who had achieved a state of sustained low-disease activity, inactive disease or remission. Different definitions of this disease state were used but all used composite measures that included patient-reported pain and inflammatory symptoms and in most cases included blood markers of inflammation. All were considered to be appropriate targets within a treat-to-target framework. All participants had received bDMARDs in full dose for at least six months, although the duration varied between trials. The expert panel expressed the view that many patients and clinicians may choose to wait for longer than six months before a trial of dose reduction. While there are currently no reliable clinical or laboratory predictors of which patients are most likely to achieve successful dose reduction or cessation, the panel considered that a prolonged period of inactive disease may represent the optimum circumstances under which to develop a plan for dose reduction.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-6-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>In adults with axial spondyloarthritis and sustained low disease activity, reducing the dose of bDMARD probably results in fewer patients with persistent remission and may slightly increase the proportion of patients with a disease flare, but probably has little or no effect on disease activity as measured by BASDAI and may have little or no effect on the number of patients in ASAS partial remission. Dose reduction probably has little or no effect on function.</p>
                        <p>Abrupt cessation of bDMARD may result in fewer people with persistent remission or ASAS partial remission, probably worsens disease activity, may increase the number of people who experience a flare, and probably worsens function.</p>
                        <p>The effect of either dose reduction or discontinuation on the safety or tolerability of bDMARDs is difficult to estimate due to low rates of adverse events in the included clinical trials.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>There are some limitations to our confidence in the evidence. There was moderate certainty for most of the evidence for the effect of dose reduction on disease activity, although certainty in the evidence was low for the number of patients with a disease flare and the proportion with ASAS partial remission. Confidence in the evidence for the effect of bDMARD discontinuation was moderate for disease activity (measured by BASDAI) and function, but was otherwise low. We have very low confidence in the evidence regarding adverse events following either dose reduction or discontinuation due to low event rates.</p>
                        <p>At the time of the initial panel meeting, all of the data were from trials of TNF inhibitors. Subsequently, a trial of discontinuation of an IL-17 inhibitor (ixekizumab) was published but this did not change the overall estimate of benefits and harms and no change was made to the recommendation. It remains unclear to what extent the current data may be extrapolated to dose reduction for bDMARDs other than TNF inhibitors or discontinuation for bDMARDs that do not target either TNF or IL-17.</p>
                        <p>We combined data from trials that included patients with either ankylosing spondylitis, non-radiographic axial spondyloarthritis or both, on the assumption that these represent aspects of the same disease spectrum, although we recognise that not all patients with non-radiographic axial spondyloarthritis will progress to radiographic disease (i.e., ankylosing spondylitis).</p>
                        <p>There were some differences between the trials in the definition of low disease activity or remission, the amount of time participants were in a low disease activity state before dose reduction, and the method used for dose reduction (such as increased dosing interval versus a lower dose of drug at the same interval). There are no data regarding the effect of further dose adjustments based on the response to an initial dose reduction (i.e., ‘stepwise’ dose reduction). All patients in the trials of bDMARD discontinuation stopped the drug without a prior dose taper.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>We have no systematically collected information regarding patients’ preferences and values. It is likely that individual patient preferences for reduced exposure to medication versus the risk of flare will vary.</p>
                        <p>There are no data on the effect of dose reduction on important non-musculoskeletal features of spondyloarthritis (including inflammatory disorders of the eye, intestinal tract and skin). The presence of these clinical features may also influence individual patients&#x27; preferences regarding DMARD dose reduction.</p>
                        <p>A qualitative study [6] of British patients with inflammatory arthritis - including ankylosing spondylitis - found that patients who were using bDMARDs were interested in reducing their dose when the disease was under control in the hope that this would reduce inconvenience and potential toxicity while maintaining disease control, and reduce overall cost to society. However this was balanced by concerns that dose reduction might result in a disease flare and that resumption of the full dose, if required, might be limited due to the high cost of bDMARDs or might not achieve the previous level of disease control. Shared decision-making, including control over flexible dosing, was identified as an important theme.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Most trials that have assessed bDMARD dose reduction have not assessed costs or cost-effectiveness. bDMARDs are generally considered to be expensive therapies and therefore strategies to reduce the total cumulative dose are likely to reduce costs for payers (governments and insurers) and may reduce out-of-pocket costs for patients. In the Australian context, the direct cost impact for individual patients is relatively small but this may differ in other contexts. The importance of direct out-of-pocket cost implications of dose reduction versus continuation is likely to vary between individual patients. There are no publicly-available data regarding the actual comparative costs of different bDMARDs to the payer (i.e., the Federal Government) in Australia.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered that many factors influence individual patients&#x27; health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect bDMARD dose reduction, including an impact on access to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Evidence for acceptability of the intervention to consumers comes from a recent survey of ARAD participants (unpublished data):</p>
                        <p>The medication you have taken is known as a biologic or targeted DMARD: Evidence shows that some people with well-controlled disease can safely reduce the dose of their biologic or targeted DMARD or how frequently they take it, without any worsening of their condition. If your treating specialist suggested it, would you be willing to try taking your biologic or targeted DMARD less frequently, or at a reduced dose?</p>
                        <p>Responses as follows:  Yes: 95 (50%)  No: 45 (23%)  Maybe: 51 (27%)</p>
                        <p>There is little evidence regarding the acceptability of bDMARD dose reduction or discontinuation to clinicians, policymakers or other stakeholders, although the panel felt that consideration of reduction of medication burden in a shared decision-making framework would likely be acceptable to all stakeholders.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Implementation of the recommendation may be influenced in some cases by local prescribing rules or reimbursement conditions, and by the accessibility of care in the case of a disease flare. Current Australian prescribing and reimbursement rules for bDMARDs are complex. For example, some reimbursement rules are predicated on stable disease control with full-dose medication. In this situation, some patients or prescribers may be concerned about the risk that, in the event of a disease flare with dose reduction, the resumption of a higher dose of the current bDMARD may be prohibited.</p></div></div>
                </div>
                <div class="tab-content" id="rec-6-practical">
                    <div class="content-section"><p>A treat-to-target approach within a shared decision-making framework is recommended for all patients with axial spondyloarthritis, including during dose reduction.</p>
                        <p>Although we have included a conditional recommendation against complete discontinuation of bDMARDs due to the substantially higher proportion of disease flares in patients who discontinue bDMARDs compared with those who continue at a full or reduced dose, there is a small proportion of patients with axial spondyloarthritis who are able to achieve disease-free remission (i.e., complete withdrawal from bDMARDs after achieving a clinical remission). Therefore, a discussion of the potential benefits and risks of bDMARD discontinuation after dose reduction may form part of the shared decision-making process.</p>
                        <p>TNFi dose reduction may include a decrease in the regular dose (e.g., a 50% reduction in etanercept dose from 50mg weekly to 25mg weekly) or an increase in the dosing interval (e.g., from adalimumab 40mg every two weeks to 40mg every three weeks).</p>
                        <p>Following dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure that includes patient-reported outcomes (e.g., BASDAI, ASDAS) and escalation to the full dose should be considered if the treatment target has not been maintained.</p>
                        <p>The presence of extraspinal features of axial spondyloarthritis (e.g., enthesitis) and extraskeletal manifestations (including psoriasis, uveitis and inflammatory bowel disease) during the disease course should be considered when contemplating dose reduction and clinical review after dose reduction should include surveillance for the emergence of these clinical features.</p>
                        <p>Patients should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a mechanism for patients to contact their prescriber between visits if necessary.</p></div>
                </div>
                <div class="tab-content" id="rec-6-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-6-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-6-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Psoriatic%20Arthritis%3A%20Dose%20reduction%20or%20discontinua" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Psoriatic Arthritis: Dose reduction or discontinua-->
    <div class="modal-overlay" id="modal-rec-7">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Psoriatic Arthritis: Dose reduction or discontinuation of biologic or targeted synthetic DMARDs</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-7', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-7', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-7', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-7', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-7', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-7', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-7-recommendation">
                    <span class="strength-badge conditional-against">⊖ Conditional Recommendation Against</span>
                    <div class="recommendation-box"><p>Do not routinely reduce the dose of b/tsDMARDs in patients with psoriatic arthritis who are in low disease activity or remission. Abrupt cessation of b/tsDMARDs is not recommended.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>There is very little evidence from clinical trials on which to base a recommendation regarding tapering or discontinuation of b/tsDMARDs in patients with psoriatic arthritis who have achieved their treatment target (i.e., clinical remission or a similar low disease activity state). There are no published trials of tapering in this patient population. Initially, the only data available regarding cessation of b/tsDMARDs were from a pilot RCT of discontinuation versus continuation of DMARDs in patients with psoriatic arthritis who had achieved stable minimal disease activity (MDA). As this trial enrolled only 17 participants on a variety of treatment regimens, the panel considered that this single small trial provided very low certainty evidence. Subsequently, a larger RCT was published that compared discontinuation versus continuation of ixekizumab (an IL-17 inhibitor) in patients who had achieved MDA. While this provided more data regarding some outcomes, the panel agreed that there was still substantial uncertainty regarding the benefits and harms of b/tsDMARD discontinuation in this population.</p>
                        <p>Due to the lack of evidence, there was considerable discussion among the panel regarding the relative merits of a conditional recommendation for or against a trial of b/tsDMARD dose reduction in patients who have been in a stable low disease activity state for at least six months. The panel considered that a cautious trial of dose reduction may be a suitable option for patients who place a high value on reduced exposure to medication (e.g., to reduce overall medication burden, personal or societal cost, or due to concerns about current or potential adverse effects). They considered that this would be reasonable to consider within a shared decision-making framework, but that the lack of data regarding the risks of such an approach precluded a conditional recommendation in favour of dose reduction. In particular, there may be a risk of disease flare with b/tsDMARD dose reduction and a proportion of patients who flare may not regain a low disease activity state with resumption of a higher dose. There is a lack of data regarding the proportion who fail to regain a low disease activity state.</p>
                        <p>It was also noted that psoriatic arthritis is a disease that varies considerably in its clinical manifestations both between patients and also within the same patient over time, and therefore decisions regarding dose modification will depend heavily on the individual context. The panel felt that data regarding the potential benefits and harms of b/tsDMARD dose reduction in other inflammatory arthropathies (rheumatoid arthritis and axial spondyloarthritis) could not be reliably applied to the unique clinical syndrome of psoriatic arthritis.</p>
                        <p>Another consideration in shared decision-making for the individual patient with psoriatic arthritis may be the presence of extraskeletal manifestations, particularly psoriasis. The balance of risks and benefits may be different in patients for whom b/tsDMARDs have also been an effective therapy for skin disease or other symptoms.</p>
                        <p>Abrupt discontinuation of b/tsDMARDs is likely to increase the risk of disease flare compared with gradual dose reduction, and is therefore not recommended.</p>
                        <p>The panel felt that this was likely to be a question of importance to patients with psoriatic arthritis and therefore clinical trials of dose reduction are strongly encouraged. It is noted that two trials are currently registered which may inform future versions of this conditional living recommendation.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-7-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>There are no data on the effect of dose reduction of b/tsDMARDs in patients with psoriatic arthritis.</p>
                        <p>In patients with psoriatic arthritis in sustained minimal disease activity, discontinuation of b/ts DMARDs may reduce the proportion of participants with persistent remission, may increase the proportion of people who experience a flare, may result in little or no difference in function, and may or may not reduce the number of participants with adverse events.</p>
                        <p>We are uncertain about the effect of discontinuation of b/tsDMARDs on disease activity. We are also unable to estimate the risk of serious adverse events or withdrawals due to adverse events as there were too few events. Data on the effect of discontinuation of b/tsDMARDs are limited to patients using TNF inhibitors or the IL-17 inhibitor ixekizumab.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very Low</span></div><div class="etd-domain-text"><p>There are no data on the effect of dose reduction of b/tsDMARDs in patients with psoriatic arthritis.</p>
                        <p>We are uncertain about the effect of discontinuation of b/tsDMARDs in patients with psoriatic arthritis in sustained minimal disease activity. Data are available from two trials. One was a pilot RCT (of 17 patients on various treatment regimens including 10 participants on TNFi alone or in combination with csDMARDs). The other was an RCT of discontinuation versus continuation of the IL-17 inhibitor ixekizumab.</p>
                        <p>While the certainty of the evidence is low for some outcomes (proportion of participants who remain in remission, proportion who flare, function, and proportion who experience adverse events), it remains very low for several other important outcomes (disease activity and the proportion of participants with serious adverse events or withdrawals due to adverse events).</p>
                        <p>There are no trials that measure radiographic progression or switching to another  b/tsDMARD. There are no trials of discontinuation of b/tsDMARDs other than ixekizumab (an IL-17 inhibitor) or TNF inhibitors.</p>
                        <p>Overall, our confidence in the estimates of benefits and harms of discontinuation of treatment in people with psoriatic arthritis who have achieved a low disease activity state with any b/tsDMARD remains very low.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>We have no systematically collected information regarding patients’ preferences and values. It is likely that individual patient preferences for reduced exposure to medication versus the risk of flare will vary. The presence of non-musculoskeletal features of psoriatic arthritis (particularly psoriasis) may also influence individual patients&#x27; preferences regarding DMARD dose reduction.</p>
                        <p>A qualitative study [6] of British patients with inflammatory arthritis - including psoriatic arthritis - found that patients who were using bDMARDs were interested in reducing their dose when the disease was under control in the hope that this would reduce inconvenience and potential toxicity while maintaining disease control, and reduce overall cost to society. However this was balanced by concerns that dose reduction might result in a disease flare and that resumption of the full dose, if required, might be limited due to the high cost of bDMARDs or might not achieve the previous level of disease control. Shared decision-making, including control over flexible dosing, was identified as an important theme.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>There are no data on the cost-effectiveness of b/tsDMARD dose reduction for psoriatic arthritis. b/tsDMARDs are generally considered to be expensive therapies and therefore strategies to reduce the total cumulative dose are likely to reduce costs for payers (governments and insurers) and may reduce out-of-pocket costs for patients. In the Australian context, the direct cost impact for individual patients is relatively small but this may differ in other contexts. The importance of direct out-of-pocket cost implications of dose reduction versus continuation is likely to vary between individual patients. There are no publicly-available data regarding the actual comparative costs of different b/tsDMARDs to the payer (i.e., the Federal Government) in Australia.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered that many factors influence individual patients&#x27; health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect bDMARD dose reduction, including an impact on access to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Evidence for acceptability of the intervention to consumers comes from a recent survey of ARAD participants (unpublished data):</p>
                        <p>&quot;The medication you have taken is known as a biologic or targeted DMARD: Evidence shows that some people with well-controlled disease can safely reduce the dose of their biologic or targeted DMARD or how frequently they take it, without any worsening of their condition. If your treating specialist suggested it, would you be willing to try taking your biologic or targeted DMARD less frequently, or at a reduced dose?&quot;</p>
                        <p>Responses as follows: Yes: 74 (46%) No: 31 (19%) Maybe: 55 (34%)</p>
                        <p>There is little evidence regarding the acceptability of b/tsDMARD dose reduction or discontinuation to clinicians, policymakers or other stakeholders, although the panel felt that consideration of reduction of medication burden in a shared decision-making framework would likely be acceptable to all stakeholders.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Implementation of the recommendation may be influenced in some cases by local prescribing rules or reimbursement conditions, and by the accessibility of care in the case of a disease flare. Current Australian prescribing and reimbursement rules for b/tsDMARDs are complex. For example, some reimbursement rules are predicated on stable disease control with full-dose medication. In this situation, some patients or prescribers may be concerned about the risk that, in the event of a disease flare with dose reduction, the resumption of a higher dose of the current bDMARD may be prohibited.</p></div></div>
                </div>
                <div class="tab-content" id="rec-7-practical">
                    <div class="content-section"><p>A treat-to-target approach within a shared decision-making framework is recommended for all patients with psoriatic arthritis, including consideration of dose reduction.</p>
                        <p>Although we have conditionally recommended against reducing the dose of b/tsDMARDs in patients with psoriatic arthritis who are in a stable low-disease activity state, there may be some patients for whom the potential benefits of using a lower dose may outweigh the potential risk of a disease flare. The potential for flare, the risk of failure to regain remission with resumption of a higher dose, and the current lack of evidence to help estimate these risks should all be discussed.</p>
                        <p>In patients who choose to attempt dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure that includes patient-reported outcomes (e.g., PASDAS) and escalation to the full dose should be considered if the treatment target has not been maintained.</p>
                        <p>The presence of extra-articular features of psoriatic arthritis (e.g., psoriasis, nail dystrophy) should also be considered when contemplating dose reduction and clinical review after dose reduction should include surveillance for the emergence of these clinical features.</p>
                        <p>Patients should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a mechanism for patients to contact their prescriber between visits if necessary.</p></div>
                </div>
                <div class="tab-content" id="rec-7-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-7-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-7-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Dose%20reduction%20or%20discontinuation%20of%20b/tsDMARDs%20ve" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Dose reduction or discontinuation of b/tsDMARDs ve-->
    <div class="modal-overlay" id="modal-rec-8">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Dose reduction or discontinuation of b/tsDMARDs versus dose reduction or discontinuation of csDMARDs in people with rheumatoid arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-8', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-8', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-8', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-8', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-8', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-8', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-8-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In people with rheumatoid arthritis who have achieved sustained low disease activity or remission with a combination of csDMARDs and b/tsDMARDs and who wish to reduce their medication burden, consider a trial of reduction of the dose of the csDMARD.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel reviewed evidence from randomised controlled trials (RCTs) that compared dose reduction or discontinuation of conventional synthetic DMARDs (csDMARDs) versus biological or targeted synthetic DMARDs (b/tsDMARDs) in people with rheumatoid arthritis (RA) who have achieved low disease activity (LDA) or remission with a combination of csDMARDs and b/tsDMARDs. Four RCTs were available, one of which compared dose reduction of csDMARDs versus b/tsDMARDs [240], two that compared abrupt discontinuation of csDMARDs versus b/tsDMARDs [226][234], and one which compared dose reduction of a bDMARD (abatacept) with discontinuation of a csDMARD (methotrexate) [291].</p>
                        <p>This living guideline contains other recommendations regarding dose reduction and discontinuation of csDMARDs and b/tsDMARDs in people with RA who have achieved LDA or remission; the current recommendation focuses on which DMARD to adjust first in people who are using a combination of csDMARDs and b/tsDMARDs. Given that the prior recommendations conditionally favour dose reduction but recommend against abrupt discontinuation, the panel elected to focus primarily on the choice of first DMARD to undergo dose reduction.</p>
                        <p>The panel voted in favour of a conditional recommendation for dose reduction of csDMARDs rather than b/tsDMARDs. In formulating this recommendation, the panel considered a number of issues, including the following:</p>
                        <p>Data from the TARA trial, the only RCT to have directly compared dose reduction of csDMARDs and b/tsDMARDs [240]. Although this trial did not demonstrate a statistically-significant difference between the two tapering strategies, difficulties with recruitment meant that it only had 70% power to detect an absolute difference of 20% in flare rates between groups, and therefore may have been underpowered to detect a true difference between the two interventions. The cumulative flare rate at 12 months was 33% in those who reduced csDMARDs versus 43% in those who reduced the dose of bDMARDs.</p>
                        <p>Cost-effectiveness. A study that used 2-year data from the TARA trial found similar costs for both strategies [245]. Lower medication costs in the bDMARD tapering group were offset by higher productivity costs due to higher absenteeism in this group related to the frequency and impact of disease flares.</p>
                        <p>Consideration of the potential individual impact of disease flares. While the rates of “recapture” of the prior low disease activity state with restoration of the previous treatment regimen were high across all the included trials (typically &gt;80%), flares often persisted for three months or longer [226][240]. An impact analysis of participants in TARA found that flares negatively affected function, fatigue, quality of life, and general health for at least 3 months [292]. Therefore, even a small difference in flare rates between dose reduction strategies may have a large impact at the level of the individual patient.</p>
                        <p>The relative paucity of RCT data. While the TARA trial directly addressed the topic of this recommendation, it did not include participants using b/tsDMARDs other than TNFi. While one of the two discontinuation trials included participants using tofacitinib in combination with methotrexate, it is unclear to what extent these data can be used to inform dose reduction strategies, and the relative impact of dose modification strategies in people using other combinations of b/tsDMARDs and csDMARDs remains unknown.</p>
                        <p>The potential impact of reduction in pill burden versus a reduction in injection frequency for subcutaneously-administered bDMARDs. The consumer panellists expressed the view that this was likely to be highly dependent on the preferences and prior experience of the individual patient.</p>
                        <p>The theoretical role of csDMARDs (particularly methotrexate) in reducing the formation of anti-drug antibodies when used in combination with monoclonal antibody bDMARDs. The panel discussed the paucity of evidence regarding this effect of methotrexate in the setting of LDA and planned dose reduction, but also noted that co-prescription of methotrexate remains part of the prescribing restrictions for some bDMARDs in Australia (namely abatacept, golimumab and infliximab), and therefore that continued stepwise dose reduction of methotrexate towards discontinuation may not be preferred in many cases.</p>
                        <p>The effect of different dose reduction strategies on long-term outcomes (including adverse effects, radiographic progression, and cardiovascular events) remains unknown.</p>
                        <p>For a large proportion of patients, the state of LDA or remission may have been achieved by adding a b/tsDMARD to one or more csDMARDs that had been insufficient to achieve the treatment goal alone. In such cases, a dose reduction strategy that favours restoration of the previously ineffective treatment regimen rather than maintenance of the most recently-added medication (i.e., the b/tsDMARD) may be an unattractive option for patients and prescribers in the absence of clear evidence that this strategy is not inferior to the alternative.</p>
                        <p>Importantly, the panel noted that this recommendation is conditional and is likely to be highly dependent on individual factors, including disease history, previous experience with medications, the presence of adverse effects, comorbidity, current and previous disease impact, and the individual’s life circumstances, preferences, values and treatment goals.</p>
                        <p>We anticipate that data relevant to this recommendation will continue to emerge. This living recommendation will continue to be updated as soon as relevant new information becomes available.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-8-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>Dose reduction</p>
                        <p>Compared with dose reduction of csDMARDs (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide), dose reduction of b/tsDMARDs (etanercept, adalimumab, certolizumab or golimumab) in participants with RA in remission or with low disease activity at 12 months follow-up:</p>
                        <p>May be comparable in terms of the number of people maintaining remission, the number of people experiencing flare, disease activity, function and quality of life, and in the number of people experiencing an adverse event. The effect on the number of people with radiographic joint progression or on the number of people experiencing serious adverse events is uncertain.</p>
                        <p>The number of people who withdrew due to adverse events was not reported.</p>
                        <p>Discontinuation</p>
                        <p>Compared with discontinuation of csDMARDs (methotrexate), discontinuation of b/tsDMARDs (etanercept, abatacept, tofacitinib) in participants with RA in remission or with low disease activity at 12 months follow-up:</p>
                        <p>May reduce the number of people maintaining remission  May increase the number of people experiencing a flare May be comparable in terms of disease activity, function, quality of life, and the number of people experiencing an adverse event The effect on the number of people experiencing a serious adverse events or the number of withdrawals due to adverse events is uncertain</p>
                        <p>Radiographic progression was not measured.</p>
                        <p>The panel considered that the balance of benefits and harms differed for DMARD dose reduction strategies versus discontinuation strategies. While a discontinuation strategy may favour stopping csDMARDs rather than b/tsDMARDs, the panel noted that this guideline’s existing recommendations regarding dose modification of both csDMARDs and b/tsDMARDs conditionally favour dose reduction but recommend against abrupt discontinuation of DMARDs. Therefore the panel elected to focus on the data regarding dose reduction and unanimously agreed on a rating of “small net benefit, or little difference between alternatives”.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>Dose reduction</p>
                        <p>Compared with dose reduction of csDMARDs, there was LOW certainty evidence that dose reduction of b/tsDMARDs may have little or no effect on the number of people maintaining remission, the number of people experiencing a flare, disease activity, function and quality of life.</p>
                        <p>Compared with dose reduction of csDMARDs, there was VERY LOW certainty evidence for the effects of b/ts dose reduction on radiographic progression and serious adverse events.</p>
                        <p>The number of people withdrawing due to adverse events was not reported.</p>
                        <p>Discontinuation</p>
                        <p>Compared to discontinuation of csDMARDs there was LOW certainty evidence that discontinuation of b/tsDMARDs may reduce the number of people maintaining remission, may increase the number of people experiencing a flare and may be comparable in terms of disease activity, function, quality of life, and the number of people experiencing an adverse event.</p>
                        <p>Compared to discontinuation of csDMARDs there was VERY LOW certainty evidence for the effects of discontinuation of b/tsDMARDs number of people experiencing serious adverse events or the number of withdrawals due to adverse events.</p>
                        <p>Radiographic progression was not reported.</p>
                        <p>The panel considered that the evidence regarding dose reduction strategies, derived from a single trial that was relatively underpowered, was low certainty at best.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>While there are few data regarding patient preferences in the specific context of choosing between tapering csDMARDs and b/tsDMARDs, existing evidence regarding DMARD tapering in RA more broadly suggests that variation between individuals is likely.</p>
                        <p>A systematic review of patient preferences regarding DMARD treatment found that, in general, people with RA consider treatment benefits (particularly improvement in symptoms and function) to be more important than both serious and non-serious adverse events (AEs) [35]. However some studies found evidence of important risk aversion (particularly regarding serious AEs), which suggests that there is considerable variation in preferences between individuals.</p>
                        <p>A qualitative study of patients with well-controlled RA indicated a general preference for reduction of medication burden, particularly in regard to concerns about the cumulative toxicity of DMARDs, but this was tempered by concern about the impact of a possible disease flare [1].</p>
                        <p>A scoping review of patient preferences for treatment modification (including DMARD tapering) in people with RA also identified variability in preferences between individuals [183]. The individual&#x27;s satisfaction with the current treatment or health state, past treatment experiences, and perception of the consequences of change in the context of their unique life circumstances, were found to be important determinants of preferences regarding treatment change.</p>
                        <p>The variation between individuals in their assessment of competing risks between disease and treatment, suggests that an individualised shared decision-making framework is of particular importance when considering treatment modification, including dose reduction or discontinuation in those taking DMARDs in combination.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>b/tsDMARDs are generally considered to be expensive therapies and therefore strategies that preference reduction in the total cumulative dose of these medications are likely to reduce costs for payers (governments and insurers) and may reduce out-of-pocket costs for patients. There are no publicly-available data regarding the actual comparative costs of different bDMARDs to the payer (i.e. the Federal Government) in Australia. In contrast, csDMARDs are relatively inexpensive medications. Therefore, dose reduction or discontinuation of csDMARDs in preference to b/tsDMARDs is likely to have less impact on direct cost reduction at the system level.</p>
                        <p>In the Australian context, the direct cost impact for individual patients is relatively small but this may differ in other contexts. The importance of any out-of-pocket cost difference may vary between individual patients. There is evidence that out-of-pocket healthcare costs may act as a barrier to accessing treatment for some people - as many as 25% of Australians living with arthritis (of any type) report skipping healthcare treatment due to cost [243]. The proportion of Australians who delayed or did not fill a medication prescription due to cost increased to 7.6% in 2022-23, from 5.6% in 2021-22 [247].</p>
                        <p>A cost-effectiveness analysis of two-year data from the TARA trial [245], which compared csDMARD tapering with TNF inhibitor tapering in participants with RA who had achieved low disease activity with combination therapy, found that both strategies were cost-effective (in a Dutch healthcare setting). Total costs were similar regardless of which DMARD was tapered first; medication costs were lower in those who tapered TNFi first, but indirect costs were higher due to increased productivity loss.</p>
                        <p>While there are no data that specifically estimate the relative impact of csDMARD versus b/tsDMARD dose reduction or discontinuation on the environment, it is plausible that there may be differences attributable to differential manufacturing, packaging and transport. The magnitude of such an impact (if present) or other indirect effects is currently unknown.</p>
                        <p>The panel discussed the cost-effectiveness data, and the potential impact of disease flares at the individual level, including evidence from the included trials that flares may last for three months or longer. The panel considered the difficulty in weighing the relatively similar cost-impact of the two tapering strategies at the group or societal level against the potential impact of small differences in flare rates at the level of the individual experiencing a flare. The panel voted for a rating of “important issues”, noting that despite the difference in cost between csDMARDs and b/tsDMARDs, the potentially substantial impact on individual outcomes if there is a difference in the frequency or depth of flares following dose modification is likely to be an important factor in decision-making in the clinic.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Many factors influence individual patient&#x27;s health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect preferences for DMARD regimen modification, including the potential impact of access to medications or to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p>
                        <p>The panel considered that there were likely to be relatively few differential health equity consequences of the different dose reduction strategies, however there remained potential for such differences to exist.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The acceptability of csDMARD dose reduction or discontinuation is likely to vary between individual patients and other stakeholders. A qualitative study of patients and rheumatologists regarding tapering DMARDs in RA found that both groups were concerned about the risk of disease flare with dose reduction, particularly the risk of failure to recapture the previous low disease activity state, but that there was considerable variation in the degree of concern [246]. Rheumatologists often favoured tapering of csDMARDs based on a perceived beneficial trade-off between risk of flare and potential reduction in drug-related harms.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Modification of the DMARD regimen is likely to be broadly feasible but may be influenced in some cases by local prescribing rules or reimbursement conditions, and by the accessibility of care in the case of a disease flare. Current Australian prescribing and reimbursement rules for b/tsDMARDs are complex. For example, some b/tsDMARD reimbursement rules are predicated on stable disease control with full-dose medication. In this situation, some patients or prescribers may be concerned about the risk that, in the event of a disease flare with dose reduction, the resumption of a higher dose of the current b/tsDMARD may be prohibited or delayed.</p>
                        <p>The panel also noted that some b/tsDMARDs currently require co-prescription of methotrexate under Australian prescribing restrictions, and that this may also impact the feasibility of some strategies for dose reduction or discontinuation.</p></div></div>
                </div>
                <div class="tab-content" id="rec-8-practical">
                    <div class="content-section"><p>A treat-to-target approach is recommended for all patients with rheumatoid arthritis, including during dose reduction.</p>
                        <p>A dose-reduction strategy is preferred - abrupt discontinuation of any DMARD in people with rheumatoid arthritis who have achieved their treatment goal is not currently recommended. See living recommendations for:</p>
                        <p>Dose reduction or discontinuation of conventional synthetic DMARDs</p>
                        <p>Dose reduction or discontinuation of biologic or targeted synthetic DMARDs</p>
                        <p>In people on a combination of b/tsDMARDs and more than one csDMARD, start by reducing the dose of one of the csDMARDs. The choice of which csDMARD to taper first should be tailored to the individual, including consideration of their treatment history, adverse effects, comorbidity, concomitant medications, and individual preferences.</p>
                        <p>Stepwise reduction of csDMARDs to complete discontinuation may be considered if the treatment goal is maintained</p>
                        <p>Maintenance of a low dose of methotrexate (e.g., 7.5 - 10mg per week) may be required due to prescribing restrictions for some bDMARDs, and should be considered if there are concerns regarding the development of anti-drug antibodies (e.g., people who have previously experienced secondary failure of a monoclonal antibody)</p>
                        <p>All decisions regarding the DMARD regimen in people with rheumatoid arthritis should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual&#x27;s circumstances.</p>
                        <p>While this recommendation is based on limited data, a stable low disease activity state for at least 6 months is likely to be the minimum time frame for consideration of csDMARD dose reduction, and a &#x27;deep remission&#x27; or maintenance of the treatment target for at least 12 months may represent optimal preconditions for a trial of dose reduction.</p>
                        <p>Following dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure (e.g., SDAI). Maintenance of an agreed treatment target state should be ensured before considering further adjustment of the treatment regimen.</p>
                        <p>Patients should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a mechanism for patients to contact their prescriber between visits if necessary.</p>
                        <p>In the event of loss of disease control (e.g., persistent increase in composite disease activity measure or new symptoms that are unacceptable to the patient), we recommend reintroduction of the previous effective DMARD regimen.</p></div>
                </div>
                <div class="tab-content" id="rec-8-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-8-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-8-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: August 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Perioperative%20adjustment%20of%20DMARDs%20in%20people%20with" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Perioperative adjustment of DMARDs in people with-->
    <div class="modal-overlay" id="modal-rec-9">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Perioperative</div>
                    <h2 class="modal-title">Perioperative adjustment of DMARDs in people with inflammatory arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-9', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-9', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-9', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-9', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-9', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-9', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-9-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>Do not routinely discontinue csDMARDs in the perioperative period.</p>
                        <p>Do not routinely discontinue bDMARDs in the perioperative period; consider temporary discontinuation in individuals with a high risk of infection or where the impact of infection would be severe.</p>
                        <p>Consider temporary discontinuation of tsDMARDs in the perioperative period.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>This recommendation applies to all DMARDs used for inflammatory forms of arthritis including RA, PsA and SpA. While RCT evidence exists regarding perioperative discontinuation of csDMARDs, there is only observational evidence for bDMARDs and a paucity of evidence regarding tsDMARDs. Given the potential differences between these groups of medications in terms of the risk of infection, disease flare and other perioperative complications, the panel elected to consider the three medication groups separately in the recommendation. The panel acknowledged that there are also likely to be differences between drugs within these broad groups, particularly those with different molecular targets and dosing schedules. Therefore, the panel also emphasised that this is a conditional recommendation and that an individual assessment of the potential risks and benefits of modification of the DMARD schedule should be made. Glucocorticoids were not included in this recommendation, although the potential impact of concomitant glucocorticoid use in the perioperative period in people with inflammatory arthritis was noted.</p>
                        <p>The panel intended the current recommendations to apply broadly to all types of elective surgery, but noted that the majority of the evidence relates to elective orthopaedic surgery and that individual decision-making may vary in the setting of some other forms of surgery (particularly urgent surgery or interventions that involve incision into the respiratory, alimentary or genitourinary tracts).</p>
                        <p>In general, the primary consideration for most people with IA on DMARDs who are planning surgery is the trade off between a theoretical increased risk of infection and an increased risk of disease flare. Broadly, the sum of existing observational and RCT data does not suggest an important increase in the risk of postoperative infection in those who continue csDMARDs or bDMARDs through the perioperative period, but disease flares may be more common with interruption of DMARD therapy.</p>
                        <p>The panel was satisfied that the evidence regarding csDMARDs was sufficient to warrant a conditional recommendation in favour of continuing these drugs without interruption in most individuals undergoing elective surgery, although some patients may elect to hold treatment based on an individual assessment of risks and benefits. Current trial data exists only for patients using methotrexate and leflunomide and the panel expects that these would be the csDMARDs most likely to be considered for transient interruption prior to surgery in patients considered to be at very high risk, although the long duration of action of both drugs (particularly leflunomide) is noted. It is unlikely that clinicians or patients would choose to hold other csDMARDs, including sulfasalazine or hydroxychloroquine.</p>
                        <p>There was a spectrum of opinions regarding the best approach to bDMARDs. It was noted that bDMARDs are potent immunomodulators that are associated with an increased risk of infection in general, and therefore the lowest-risk approach may be to temporarily discontinue these drugs in the perioperative period. However it was also noted that the current body of observational evidence does not suggest that continuation of therapy is associated with an important risk of infection, and it remains unknown whether interruption of treatment for an arbitrary period either reduces the risk of infection or has a net beneficial effect versus the risk of disease flare. Disease flare in the perioperative period is unlikely to be benign, particularly if there is an impact on rehabilitation from surgery or if it results in rescue therapy with glucocorticoids. The panel debated whether to make a conditional recommendation in favour of temporary discontinuation for most patients, except those at low risk of infection or where treatment interruption may unnecessarily delay surgery, or to favour continuation of bDMARDs except in those at higher risk of infection or its consequences. Ultimately the panel came to a consensus in favour of a conditional recommendation to continue bDMARDs during the perioperative period.</p>
                        <p>The panel was also divided on the best approach to tsDMARDs. Given the current lack of evidence regarding this class of medications, the potential impact on the risk of infection and other perioperative complications (including the possibility of blunting of the acute phase response in the setting of infection and a theoretical increase in the risk of thrombosis), the panel agreed on a conditional recommendation to temporarily discontinue tsDMARDs perioperatively. The panel acknowledged that the optimal timing is unknown but noted that holding tsDMARDs from approximately one week before surgery is likely to be a reasonable approach to balancing the risk of infection versus disease flare, and is in line with similar recommendations from other international societies [109].</p>
                        <p>Given the uncertainties regarding all types of DMARDs, particularly b/tsDMARDs, the panel recommended that an individualised approach should take into account the following interacting factors:</p>
                        <p>The type of surgery    Surgery that involves implantation of foreign materials (including arthroplasty) is likely to be associated with higher risk of infection     Minor or superficial surgery is likely to have a lower risk of infection than complex surgery or clean-contaminated surgery that involves breaching the respiratory, alimentary or genitourinary tracts    The impact of infection or disease flare   For example, infection related to minor surgery may have a trivial impact but infection in people with prostheses may have a more severe or prolonged impact    The consequences of disease flare may be more important in those with severe or unstable inflammatory arthritis    The urgency of surgery    While reduction in the intensity of disease-modifying therapy may be considered in settings in which surgery is elective and minimisation of any excess risk of infection is preferred, in more urgent settings (e.g., cancer surgery), surgery should not be delayed in order to discontinue b/tsDMARDs     Other risk factors for infection   Any potential impact of DMARDs on the risk of post-surgical infection may be more pronounced in people with other risk factors for infection, including advanced age, comorbidity (e.g., diabetes mellitus), glucocorticoid use, and prior history of serious infection   The patient’s preferences and goals</p>
                        <p>The panel also discussed the optimal timing of reinstitution of DMARDs in patients who have elected to hold therapy perioperatively. In the absence of evidence to inform this decision, the panel considered it reasonable to recommence therapy when surgical sutures have been removed, adequate wound healing has occurred and there are no other symptoms or signs of infection. For most people this is likely to be one or two weeks following surgery.</p>
                        <p>The panel noted that some DMARDs, particularly those that target the IL-6 pathway (e.g., tocilizumab), and possibly JAK inhibitors, may dampen the acute phase response and therefore clinicians should remain vigilant to the possibility of infection even in the presence of normal inflammatory markers.</p>
                        <p>The panel emphasised the need for further research on this topic, particularly in regard to the use of b/tsDMARDs in the perioperative period.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-9-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>For the purpose of this recommendation we considered inflammatory arthritis to include rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). We identified three RCTs, all comparing perioperative discontinuation versus perioperative continuation of csDMARDs (methotrexate and leflunomide) in adults with RA undergoing elective orthopaedic surgery. The three RCTs provided outcome data on the occurrence of flare, post-operative infections, prosthetic joint infection, adverse events (including but not limited to wound dehiscence) and serious adverse events (including but not limited to need for revision surgery). None of the studies reported on mean disease activity, length of hospital stay, post-operative opioid use, function and quality of life.</p>
                        <p>Based on the RCT data, perioperative discontinuation of DMARDs, compared to perioperative continuation of DMARDs:</p>
                        <p>may increase the risk of flare may have little or no effect on the number of people with post-operative infections, the number of people reporting adverse events and the number of people reporting serious adverse events</p>
                        <p>To supplement the evidence base, we included data from observational studies comparing perioperative discontinuation versus continuation of any DMARDs in adults with inflammatory diseases undergoing any type of elective surgery. There were eight eligible observational studies. Most of the participants had undergone elective orthopaedic surgery or various joint arthroplasties, with one study specifically looking at participants who had undergone spinal surgery. Four studies specifically investigated perioperative discontinuation versus continuation of bDMARDs, including TNF inhibitors [113][115][117] and abatacept [118], two studies investigated MTX [111][116] and two studies assessed combination DMARD therapy [112] or all DMARDs [114].</p>
                        <p>Evidence from observational cohort studies largely concurs with the findings from RCTs, indicating there may be an increased risk of flare if DMARDs are discontinued, with no apparent reduction in risk of postoperative infection. While we could not estimate the risk of prosthetic joint infections from trials, observational data suggests there may be no reduction in risk with discontinuation of DMARDs perioperatively.</p>
                        <p>The panel voted that there was “small net benefit or little difference” for all DMARDs combined but noted that the existing RCT evidence applies only to csDMARDs (methotrexate and leflunomide) and that there is an absence of evidence regarding tsDMARDs in the perioperative period. The panel also noted that flares may vary in severity, duration and impact, and that there may be various factors that impact on the risk of perioperative flare, including the preoperative disease activity, history of flares, use of combination DMARDs, use of glucocorticoids, and the duration of DMARD discontinuation. There are few data to permit accurate estimation of the absolute risk of a perioperative disease flare in the individual patient. The panel also noted that disease flares may be particularly important if they impair successful recovery or rehabilitation from surgery, or if they require additional use of glucocorticoids.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>There was low certainty evidence for the following outcomes:</p>
                        <p>risk of flare number of people with post-operative infections number of people reporting adverse events number of people reporting serious adverse events</p>
                        <p>No studies were found that looked at mean disease activity, length of hospital stay, post-operative opioid use, function and quality of life.</p>
                        <p>Evidence from the three RCTs is limited to patients with RA, discontinuation of csDMARDs (methotrexate and leflunomide) and elective orthopaedic surgery. The two RCTs that investigated methotrexate discontinuation included participants who were using slightly lower doses of methotrexate (average 10mg/week) than are used in most patients in the current era.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>We did not identify any studies that directly investigated values and preferences of patients with RA on DMARDs undergoing surgical procedures. It is likely that the primary trade-off is between a potential increase in the risk of post-operative infection (particularly infection of a prosthesis) associated with the use of DMARDs in the perioperative period and the risk of a flare of the underlying inflammatory arthritis associated with interruption of disease-modifying therapy.</p>
                        <p>It is likely that individuals may vary in the relative importance afforded to these outcomes. Such variation is likely to have multiple contributors including the individual disease status and trajectory, treatment goals, history of disease flares and infections, current medications, the nature of the surgery, demographic factors (such as age) and individual risk tolerance. The American College of Rheumatology (ACR) panel that developed the current (2017) ACR guideline on the use of DMARDs in patients undergoing elective arthroplasty reported that the consumer panel considered the risk of infection to be &quot;much more important&quot; than the risk of flare, and estimated the relative importance of infection compared to flares as &quot;greater than 10:1&quot; [109]. This was noted to be a strong driver of that guideline&#x27;s cautious approach to the use of b/tsDMARDs in the perioperative period. In contrast, a study performed in the UK that included patients, rheumatologists and orthopaedic surgeons in focus groups reported that patients prioritised avoidance of disease flare and &quot;would be willing to accept a risk of post-operative infection as high as 3-7% to prevent a flare of their disease&quot;  [119].</p>
                        <p>The panel agreed unanimously that individual patients are likely to vary in their weighting of outcomes in this setting. The consumer member of the panel noted that infection is likely to be a greater concern for many people with inflammatory arthritis, particularly infections that may have severe or irreversible consequences (including those affecting prosthetic joints), but that this would be likely to vary according to the type of surgery, the individual’s prior experience (including infections and disease flares), and the potential individual impact of a surgical site infection or other hospital-acquired infection.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>While b/tsDMARDs are expensive medications, temporary interruption of therapy is unlikely to have an important impact on overall costs. Major adverse outcomes of surgery in this population, including infection or disease flare, may carry an additional resource burden to the individual patient and to the healthcare system, however there are no available cost-effectiveness data regarding the decision to continue or withhold DMARDs in the perioperative period.</p>
                        <p>We do not anticipate any environmental impact of temporary discontinuation of DMARDs in the perioperative period.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered that this recommendation is unlikely to have a major impact on health equity. Some of the risks associated with this recommendation, including infection and disease flare, may have a disproportionately high impact in populations or geographic areas with limited access to specialist care (particularly rheumatologists) in the post-operative period.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Adjustment of DMARD regimens in the perioperative period with the goal of optimising the balance between the risk of flare and the risk of perioperative complications, particularly infection, is likely to be acceptable to all stakeholders including consumers, surgeons, rheumatologists, hospital administrators, and funders. The panel considered that there may be some variation in acceptability between different stakeholders.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>In general, adjustment of DMARD regimens in the perioperative period for people with RA is likely to be feasible to implement. However, some evidence suggests the existence of variation in practice in other settings in which society guideline recommendations on this topic currently exist. For example, a national survey of rheumatologists and orthopaedic surgeons in the UK found that 79% of rheumatologists follow BSR guidelines whereas only 39% of surgeons follow BSR or local guidelines, and there was frequently disagreement about which specialty was responsible for perioperative dose adjustment [119]. It is therefore plausible that a similar variation in implementation of recommendations on this topic may also occur in an Australian context.</p>
                        <p>There may be some other barriers to implementation depending on the particular healthcare setting. For example, implementation may be complex in hospital settings in which junior medical staff may be responsible for adjusting treatment arrangements in the perioperative period, particularly in situations where there is a high turnover of staff. In addition, implementation may be more challenging for some bDMARDs with infrequent dosing schedules, particularly in settings where surgery may be commonly delayed or rescheduled, or in the case of urgent surgery.</p></div></div>
                </div>
                <div class="tab-content" id="rec-9-practical">
                    <div class="content-section"><p>All decisions regarding the perioperative DMARD regimen in people with inflammatory arthritis should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances</p>
                        <p><strong>Consider the potential risks and benefits of temporary discontinuation of DMARDs in the perioperative period based on the following factors:</strong></p>
                        <ul>
                            <li>Type and urgency of surgery</li>
                            <li>Risk factors for infection</li>
                            <li>Potential impact of infection or flare</li>
                        </ul>
                        <p><strong>For patients planning to withhold DMARDs perioperatively, consider the following schedule as a guide:</strong></p>
                        <ul>
                            <li>For most bDMARDs, withhold for one dosing cycle prior to surgery</li>
                            <li>i.e., plan surgery at approximately the time of the subsequent dose (e.g., for a monthly injection, aim for surgery in the 5th week after the last injection)</li>
                            <li>For rituximab, aim for surgery at least 3 months after the most recent dose</li>
                            <li>For JAK inhibitors, stop treatment approximately 7 days before surgery</li>
                            <li>For methotrexate, withhold for one dosing cycle prior to surgery (i.e. plan surgery 1-2 weeks after the most recent dose)</li>
                            <li>For leflunomide, stop treatment approximately 7 days before surgery</li>
                        </ul>
                        <p>Aim to recommence DMARDs when surgical sutures have been removed, adequate wound healing has occurred and there are no other symptoms or signs of infection</p>
                        <p>Be aware that some b/tsDMARDs (e.g., tocilizumab and JAK inhibitors) may diminish or eliminate the acute phase response, particularly if the drug is discontinued or recommenced close to the time of surgery, and therefore the practitioner should be vigilant for the possibility of infection even in those with normal inflammatory markers.</p></div>
                </div>
                <div class="tab-content" id="rec-9-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-9-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-9-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Laboratory%20safety%20monitoring%20in%20people%20with%20inflam" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Laboratory safety monitoring in people with inflam-->
    <div class="modal-overlay" id="modal-rec-10">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Monitoring</div>
                    <h2 class="modal-title">Laboratory safety monitoring in people with inflammatory arthritis using conventional synthetic DMARDs</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-10', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-10', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-10', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-10', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-10', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-10', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-10-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In people with inflammatory arthritis who are taking conventional synthetic DMARDs (methotrexate, leflunomide, sulfasalazine), we recommend a stratified approach to laboratory safety monitoring:</p>
                        <p>Perform blood tests within a month of initiation or dose increase of a csDMARD, acute intercurrent illness, or addition of relevant concomitant medications   
Continue monitoring every 1-3 months in those at higher risk of csDMARD adverse effects (including renal impairment, liver disease, diabetes, metabolic syndrome, advanced age, polypharmacy, or clinical indicators of toxicity)   
In people on a stable dose of csDMARDs without other risk factors, monitoring may be reduced to 6-monthly or less, based on individual preferences in a shared decision-making framework</p></div>
                    <div class="remark-box"><p>Safety monitoring typically includes full blood count, liver function tests and serum creatinine.</p>
                        <p>Methotrexate should generally be withheld during periods of acute intercurrent illness.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>Background</p>
                        <p>While regular blood monitoring for adverse effects of csDMARDs is universally accepted as an important component of the safe use of medications in people with inflammatory arthritis, there is little consensus on the optimal monitoring strategy and this remains a high-priority topic for guidance among Australian rheumatologists [307]. Some international guidelines, including those published by the American College of Rheumatology [309] and the British Society for Rheumatology [217] recommend frequent testing (as often as fortnightly) upon initiation of csDMARDs, particularly methotrexate, followed by a gradual reduction in frequency (typically to 3-month intervals) in the long term. Other guidelines, including those produced by EULAR and APLAR, are less prescriptive.</p>
                        <p>There are currently no Australian guidelines on this topic. The Australian Rheumatology Association produces information sheets on DMARDs for people diagnosed with inflammatory arthritis. While previous versions of the methotrexate information sheet have indicated that blood tests (full blood count and liver function tests) are needed “every 2 to 4 weeks for the first few months of treatment and then every 1 to 3 months after that”, the current version simply states that “full blood count and liver function tests will be individualised by your doctor according to your risk”.</p>
                        <p>The panel sought to create a recommendation that is evidence-based, and provides sufficient detail to assist practitioners and patients to co-design a monitoring strategy, while acknowledging the considerable variation in individual determinants of, and preferences for, an ideal monitoring schedule.</p>
                        <p>There was general agreement that some form of routine blood monitoring is necessary, and that this ought to typically include a full blood count, liver function tests, and a measure of renal function. It was also noted that people living with inflammatory arthritis often have blood tests to monitor disease activity, to manage or investigate comorbid conditions, or to satisfy prescribing requirements for some medications, particularly biologic or targeted synthetic DMARDs. In light of this, csDMARD safety monitoring ought to integrate with other tests where possible, in order to reduce the testing burden on patients, and requires clear communication between all members of the treating team to prevent inadvertent over-testing and to identify a clear plan for review and follow-up of test results.</p>
                        <p>Evidence</p>
                        <p>In the absence of relevant evidence from randomised controlled trials, the panel reviewed evidence from two observational studies that compared different laboratory safety monitoring schedules [304][306]. While these did not demonstrate a difference in safety outcomes between testing regimens, the certainty of this evidence was very low. Therefore, the panel considered some additional evidence.</p>
                        <p>Data from three large administrative cohorts (two in the US [298][299], and one in the UK [302]) were reviewed. These indicated that abnormal routine laboratory monitoring results in people taking csDMARDs (primarily methotrexate) are relatively uncommon (approximately 1 - 7%), and do not necessarily lead to changes in therapy, although none of these studies assessed the rate of adverse clinical outcomes associated with abnormal test results. Notably, in the UK primary care cohort [302], 53% of those taking methotrexate for rheumatoid arthritis had normal blood results on every testing occasion. These individuals with ‘persistently normal’ tests tended to be younger and have fewer comorbidities. Similarly, in a Dutch cohort of people taking DMARDs for rheumatoid arthritis, only 3.3% of markedly abnormal blood results occurred in those in whom there was no increased pre-test probability of abnormality (such as a known previous abnormality, recent DMARD dose change, or a clinical indication for blood testing) [304].</p>
                        <p>In a primary care cohort of people with inflammatory rheumatic diseases in the UK, where DMARD monitoring in those on stable doses of csDMARDs is usually performed in general practice, the risk of methotrexate discontinuation due to abnormal blood tests was 1 in 24 in the first year of treatment, and 1 in 45 per year thereafter [310]. A prognostic model developed on the same dataset that included several potential predictors of methotrexate discontinuation (including age, sex, body mass index, comorbidity, alcohol consumption and concomitant medications) showed promising discrimination between those at higher and lower risk of methotrexate toxicity but has not been externally validated [308].</p>
                        <p>A further single-centre study that compared methotrexate monitoring strategies employed by rheumatologists and dermatologists found that the less frequent testing schedule used by rheumatologists compared with dermatologists was associated with greater drug survival but no increase in serious adverse events [303].</p>
                        <p>While concerns regarding the potential hepatotoxicity of methotrexate remain a driver of monitoring practice, an audit of all liver transplants performed in the US between 1987 and 2011 found that only 0.07% of transplants were performed for methotrexate-induced end-stage liver disease [301]. The panel noted that this suggests that the total burden of serious liver disease attributable to methotrexate is likely to be low, although it may also indicate the success of current monitoring strategies in preventing end-stage liver disease. A more recent study using non-invasive measures of liver fibrosis in a UK cohort of people using methotrexate for rheumatoid arthritis or psoriasis for at least 6 months found that the cumulative methotrexate dose was not associated with liver stiffness (an indicator of liver fibrosis) [305]. The primary risk factors for liver fibrosis were diabetes, age, and obesity.</p>
                        <p>The panel also reviewed data from a survey of primarily Australian and US rheumatologists regarding usual monitoring practices, that demonstrated considerable variation in the frequency of blood monitoring and the actions taken in response to abnormal results [297]. Most rheumatologists in the study reported stratifying the frequency of testing according to the duration of treatment, with more frequent testing in the first months after introduction of the DMARD. The highest proportion (44%) reported a “two-stage” approach, most commonly commencing with monthly tests before stepping down to 3-monthly tests, although a third of respondents employed a “three-stage” approach, commonly commencing with fortnightly tests before stepping down to monthly and then 3-monthly intervals. More than a third of survey respondents considered that current guidelines regarding safety monitoring recommend testing schedules that are too frequent.</p>
                        <p>Strategy</p>
                        <p>The panel noted that a stratified approach to testing frequency had face validity and was broadly consistent with the evidence regarding current practice norms. However, rather than simply basing the testing frequency on the duration of therapy, the panel considered that the preferred approach may be to stratify testing based on the estimated absolute risk of DMARD-related harm. While data are limited, acute changes (such as introduction of the drug, change in dose, addition or change in concomitant medications with potential interactions, or acute intercurrent illness), or chronic risk factors (such as renal impairment, advanced age, extant liver disease, relevant comorbidity, and diabetes), are likely to represent higher risk categories that warrant more frequent testing. Outside of these circumstances, the absolute risk of abnormal tests is likely to be low, and a more relaxed testing frequency may be appropriate.</p>
                        <p>The panel recognised that data to inform a specific testing frequency within these strata do not exist, and that many factors, including individual preferences, values, treatment goals, risk tolerance and life circumstances, remain relevant to the optimal testing frequency in the individual patient.</p>
                        <p>The panel also recognised that regular blood testing constitutes a burden for patients, not just the inconvenience and opportunity cost of providing a blood sample, but also the potential anxiety and additional consequences of receiving and acting upon abnormal results. The panel noted the concept of “minimally disruptive medicine” (MDM) that recognises that for people with chronic diseases, particularly those with complex multimorbidity, there is a complex balance between the burden of healthcare itself and the individual patient’s capacity to manage this additional workload [300]. An MDM approach aims to support individuals to achieve their health goals while minimising the burden of treatment. Such an approach is likely to be highly relevant to DMARD safety monitoring and reinforces the importance of co-design of a monitoring strategy that aligns with the individual patient’s clinical needs, preferences, and capacity.</p>
                        <p>Such an individualised approach also aligns with quality statement 3 in the Australian Rheumatology Association Rheumatoid Arthritis Clinical Care Standard: “In people with rheumatoid arthritis, pre-treatment screening and ongoing safety monitoring for DMARDs follow evidence-based guidelines and consider each person’s circumstances over time&quot;.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-10-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>We did not identify any randomised controlled trials that addressed this question directly.</p>
                        <p>We included data from two observational studies that assessed reduced periodic monitoring of liver enzymes, renal function and full blood count compared with routine monitoring.</p>
                        <p>Evidence from a small single centre retrospective cohort study of temporarily relaxed blood test monitoring from 3-monthly tests to 6-monthly tests for people with stable disease taking methotrexate during COVID restrictions in the UK, indicates that a small proportion of people having blood tests at 6-monthly intervals had abnormal test results (6/67, 9%), but this did not lead to any harms [306].</p>
                        <p>Evidence from a large long-term cohort study (published as an abstract) indicated that the incidence of highly abnormal test results over a 12-year period in a large number of people with rheumatoid arthritis taking disease modifying anti-rheumatic drugs (DMARDs) and undergoing recommended 3- to 6- monthly routine testing (the Netherlands) (4911 people) was very low, and did not differ between those taking DMARDs for which regular blood monitoring is recommended versus those using other DMARDs [304].</p>
                        <p>The panel noted that the evidence base to inform the optimal monitoring strategy is extremely limited, and that other factors, including historical practice conventions, mechanistic considerations, and individual risk tolerance, have contributed to current practice, which is known to vary between practitioners [297]. For this reason, the panel unanimously agreed on a rating of “small net benefit, or little difference between alternatives”.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very Low</span></div><div class="etd-domain-text"><p>There is no evidence from randomised controlled trials. The evidence from observational studies regarding the effect of different safety monitoring methods is very low certainty.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>We did not identify any studies that directly investigated the values and preferences of people living with inflammatory arthritis (IA) regarding safety monitoring for csDMARDs. Specifically, we did not find any data regarding the relative weight that patients afford to the potential risks of more frequent blood monitoring (such as inconvenience, cost, anxiety, opportunity cost, and the risk of subsequent additional investigations) versus the putative benefits of earlier detection and potential prevention of serious adverse effects of disease-modifying therapy.</p>
                        <p>Data from the Australian Rheumatology Association Database (ARAD; manuscript in preparation) investigating the experiences and preferences of 451 Australians using DMARDs for the treatment of rheumatoid or psoriatic arthritis indicates variation in the frequency of routine blood monitoring, although 12 weeks was the most common interval (in 30% of respondents). Most respondents were adherent to the monitoring schedule recommended by their prescriber, and reported perceiving more benefits than harms or costs associated with regular blood testing, although 10% reported opportunity costs related to employment and 45% travelled for more than 30 minutes to have their blood tests. The perceived benefits related primarily to detection of hepatotoxicity and measurement of disease activity rather than detection of myelosuppression.</p>
                        <p>In general, there is evidence that people with IA consider the risk of adverse events to be less important than treatment benefits, but there is considerable variation in preferences and risk aversion between individuals [84]. Similarly, the impact of safety monitoring requirements on patients&#x27; preferences regarding the choice of DMARD ranks lower than other factors such as route of administration, dosing frequency, efficacy, and out-of-pocket cost [295]. In a British study of methotrexate monitoring in primary care, more than half of people with RA were undertaking blood monitoring more frequently than BSR recommendations, due to either risk aversion or inaccurate information on monitoring frequency [296].</p>
                        <p>There is likely to be variation between individual patients in their preferences, influenced by a variety of factors including social circumstances, concomitant medications, alcohol consumption, prior adverse events, comorbidity, and individual risk tolerance.</p>
                        <p>The panel discussed the likelihood of variation in preferences, and the multiple potential contributors to this variation. One of the consumer panellists noted that many patients are concerned about the long-term risks associated with csDMARDs, particularly methotrexate, and that, for many, participation in regular blood testing may allow a better sense of control over mitigation of this perceived risk.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>We did not find any evidence regarding the cost-effectiveness of current csDMARD laboratory safety monitoring practices.</p>
                        <p>The frequency of blood monitoring is likely to have cost implications at both the societal and individual level. While the cost of routine blood monitoring for Australians taking csDMARDs is typically covered by Medicare, there may be other associated costs including travel and parking, and opportunity costs associated with the time spent attending for blood tests. There may also be indirect or additional costs, including additional testing if abnormalities are detected on routine monitoring.</p>
                        <p>The panel noted that the total cost to the healthcare system of regular blood testing in this population is likely to be substantial, but the degree to which this is offset by prevention of major harmful outcomes is unknown. Similarly, the potential cost implications of unwarranted discontinuation of effective and inexpensive medications in those with minor abnormalities on blood testing, including progression to expensive b/tsDMARDs, remains unknown.</p>
                        <p>The importance of any out-of-pocket cost difference may vary between individual patients. There is evidence that out-of-pocket healthcare costs may act as a barrier to accessing treatment for some people - as many as 25% of Australians living with arthritis (of any type) report skipping healthcare treatment due to cost [243].</p>
                        <p>While there are no data that specifically estimate the relative impact of the frequency of blood  monitoring on the environment, it is plausible that there may be differences attributable to the increased volume of healthcare activity and associated factors, including travel. It is also plausible that this may be offset to some extent if serious adverse events are prevented by monitoring. The magnitude of such an impact (if present) or other indirect effects is currently unknown.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Many factors influence individual patient&#x27;s health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect preferences and capability regarding csDMARD safety monitoring.</p>
                        <p>The panel noted that monitoring regimens are often complex and place a burden on patients. The extent and consequences of this burden is likely to vary between individuals. Further, the imposition of a long-term monitoring regimen may offer a sense of reassurance and control for some, while for others it may reinforce a misperception that DMARDs are inherently toxic, particularly in those with lower health literacy. Seeking opportunities to provide additional information and education for patients is also crucial and may help to prevent some health inequity.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The acceptability of different csDMARD safety monitoring schedules is likely to vary between individual patients and among other stakeholders. In the absence of clear evidence regarding the most effective method for safety monitoring, acceptability is likely to be highly preference-dependent.</p>
                        <p>The panel discussed at some length the potential for acceptability of any recommendation that may vary from current practice norms given the paucity of data to inform best practice, and the likelihood of aversion to rare but major risks (particularly organ failure) rather than more common but less tangible competing risks. Further, the panel noted that while there is variation in monitoring practice, individual approaches to monitoring are often entrenched and may be unlikely to change in the absence of evidence to support an alternative approach.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Routine blood monitoring is an established practice for people taking csDMARDs for the treatment of inflammatory arthritis. The specific method (including frequency of testing) varies considerably between practitioners [297]. It is plausible that this variation in practice is relatively entrenched and, in the absence of clear evidence to support a particular monitoring method, change in practice at the level of the individual may be difficult to achieve.</p></div></div>
                </div>
                <div class="tab-content" id="rec-10-practical">
                    <div class="content-section"><p><strong>All decisions regarding the DMARD regimen in people with rheumatoid arthritis, including safety monitoring, should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual&#x27;s circumstances</strong></p>
                        <ul>
                            <li>There are likely to be several risk factors for csDMARD adverse effects that may influence the preferred frequency of testing. These may include:</li>
                            <li>Comorbidity (particularly renal impairment, liver disease, diabetes mellitus, metabolic syndrome)</li>
                            <li>Polypharmacy, including:</li>
                            <li>combinations of csDMARDs</li>
                            <li>concomitant medications that have pharmacokinetic interactions with csDMARDs</li>
                            <li>concomitant medications that are also associated with a risk of marrow suppression or hepatotoxicity</li>
                            <li>DMARD dose</li>
                            <li>Advanced age (e.g. &gt;75 years)</li>
                            <li>Acute illness</li>
                            <li>Prior episodes of abnormal blood tests (particularly cytopenia)</li>
                            <li>Alcohol intake</li>
                            <li>While this recommendation broadly applies to methotrexate, leflunomide and sulfasalazine, it is unclear whether blood monitoring frequency should differ between these medications. Many practitioners perform routine monitoring in people established on sulfasalazine less frequently than in those established on methotrexate or leflunomide</li>
                            <li>More frequent monitoring may be considered in people using csDMARDs in combination, particularly the combination of methotrexate and leflunomide</li>
                            <li>Folic acid supplements should be prescribed routinely to people using methotrexate for inflammatory arthritis</li>
                            <li>People taking methotrexate should be advised to hold the drug during episodes of acute illness, unless instructed otherwise</li>
                            <li>Clear communication between all members of the treating team (particularly the GP and the rheumatologist) should be established, including prompt notification of medication or dose changes, the preferred monitoring strategy, and a process for managing abnormal test results</li>
                            <li>The Australian Rheumatology Association provides patient information sheets for those commencing DMARDs, including the following:</li>
                            <li>Sulfasalazine</li>
                            <li>Leflunomide</li>
                            <li>Methotrexate</li>
                        </ul></div>
                </div>
                <div class="tab-content" id="rec-10-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-10-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-10-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Perioperative%20adjustment%20of%20glucocorticoids%20in%20peo" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Perioperative adjustment of glucocorticoids in peo-->
    <div class="modal-overlay" id="modal-rec-11">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Perioperative</div>
                    <h2 class="modal-title">Perioperative adjustment of glucocorticoids in people with inflammatory arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-11', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-11', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-11', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-11', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-11', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-11', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-11-recommendation">
                    <span class="strength-badge conditional-against">⊖ Conditional Recommendation Against</span>
                    <div class="recommendation-box"><p>Do not routinely use additional ‘stress dose’ glucocorticoids in people taking regular glucocorticoids for inflammatory arthritis who are undergoing elective surgery. Continue the usual oral glucocorticoid dose during the perioperative period, including on the day of surgery.</p></div>
                    <div class="remark-box"><p>Consider a stress dose in people at high risk of adrenal insufficiency or for whom any relative adrenal insufficiency would be poorly tolerated.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel noted the paucity of evidence available to inform this recommendation. Given the uncertainty regarding the relative benefits and harms of administering a stress dose of glucocorticoids to people with inflammatory arthritis (IA) who have been taking regular glucocorticoids, the panel agreed on a conditional recommendation. Many outcomes that may be important to people with IA who are undergoing surgery, such as disease activity, function, and length of hospital stay, have not been measured in clinical trials of glucocorticoid stress dosing.</p>
                        <p>The panel considered that there is potential for current practice to vary based on factors other than evidence from trials, including established practice norms within clinical environments or specialties, estimation of relative risks and harms based on mechanistic or physiological considerations, and individual clinical circumstances. In light of the possible variation in standard practice between different members of the perioperative care team, the panel considered it important to make a conditional recommendation despite the lack of evidence.</p>
                        <p>Given that the evidence from the single RCT that included participants with inflammatory arthritis is of very low certainty, the panel took into account other sources of evidence, including observational studies. A single, non-randomised study [205] in patients with RA undergoing orthopaedic surgery also provided low certainty evidence but did not demonstrate a difference in haemodynamic stability or other outcomes between those who received stress doses of glucocorticoids and those who were maintained on their usual glucocorticoid dose. In addition, the panel noted that existing systematic reviews of perioperative glucocorticoid stress dosing that included other populations treated with glucocorticoids (such as organ transplant recipients), also reported that the evidence base is of low certainty but has not demonstrated a difference in outcomes in participants receiving stress dosing compared with continuation of the usual daily glucocorticoid dose [212][213][214].</p>
                        <p>There was a variety of views among panellists on the preferred direction of the conditional recommendation, and two voting rounds were undertaken. Panellists considered that the use of a single stress dose during anaesthesia might be a reasonable consideration, given that this may abrogate a potentially-avoidable complication of elective surgery and may be unlikely to have any long term adverse effects. However it was also noted that it is unknown whether this would be a sufficient dose to offset any theoretical increased risk of clinically-relevant adrenal insufficiency in patients who had received their usual oral glucocorticoid dose on the morning of surgery, or whether a dose sufficient to prevent adrenal insufficiency may be associated with adverse events in the perioperative period. The panel also discussed whether maintenance of a sufficient degree of clinical vigilance in patients at risk of glucocorticoid-induced adrenal suppression, with prompt administration of supplemental intravenous glucocorticoids in those with clinical signs consistent with adrenal insufficiency, might be sufficient to mitigate the risk in the majority of patients taking glucocorticoids, while avoiding exposure of the majority of patients who do not develop relative adrenal insufficiency to the potential perioperative risks of additional glucocorticoids.</p>
                        <p>Given the uncertainty about the competing risks associated with the routine use of an increased dose of glucocorticoid, the panel decided against a recommendation in favour of this intervention. The panel reiterated that the recommendation is conditional, and that there may be many clinical settings in which the treating team may elect to use stress dosing, including patients at high risk of adrenal insufficiency (e.g., those who have had a prior episode, or who have experienced prolonged glucocorticoid dependence), patients for whom any haemodynamic compromise would be poorly tolerated (e.g., advanced ischaemic heart disease), in the setting of highly-complex or prolonged surgery or additional physiological stress, or where the individual patient&#x27;s values and preferences favour the use of additional glucocorticoids.</p>
                        <p>The panel noted that existing recommendations on this topic also exhibit some differences due to the lack of evidence. Recent guidelines produced by the American College of Rheumatology [216], the British Society for Rheumatology [217], and the German Society for Rheumatology [215], all contain conditional recommendations against stress dosing in keeping with our Australian recommendation, whereas British guidelines jointly produced by the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK [211] recommend additional intra- and postoperative glucocorticoids in adults who had taken prednisolone ≥5mg daily for four weeks or longer. The British guideline recommendation is based on a theoretical greater harm from clinical adrenal insufficiency than the potential adverse consequences of a transient increase in glucocorticoid dose, but is also conditional on a number of factors including the underlying disease, the nature of the surgery and the likelihood of adrenal suppression.</p>
                        <p>Finally, the panel emphasised the evidence gap regarding this common clinical scenario and the need for further randomised controlled trials to determine the optimal management of glucocorticoids in the perioperative period in patients with inflammatory arthritis (and others) taking regular glucocorticoids. This living recommendation will be updated if relevant new evidence emerges.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-11-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>For the purpose of this recommendation we considered inflammatory arthritis to include rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). We identified one randomised controlled trial (RCT), one non-randomised controlled study and four observational studies that addressed our primary question of whether people with inflammatory arthritis treated with glucocorticoids who are undergoing elective surgery should continue their glucocorticoids at their current dose or receive a higher (stress) dose during the perioperative period. The RCT included participants with secondary adrenal insufficiency due to the use of glucocorticoids at a dose of at least 7.5mg prednisone per day for several months for a variety of diseases, including eight participants with RA.</p>
                        <p>Based on the RCT data, we remain uncertain about the benefits and harms of additional or increased doses of glucocorticoids compared to continuation of the usual dose of glucocorticoids, because the certainty of the evidence is very low. Clinical adrenal insufficiency, post-operative infections and other adverse events were rare and only reported in one of the treatment groups of the trial, and therefore we could not estimate the risks of these events with additional doses of GCs. The RCT did not report on several outcomes of interest, including arthritis flare, prosthetic joint infection, mean disease activity or function.</p>
                        <p>Evidence from one non-randomised controlled study [205] and one observational study [208] of adults with RA undergoing elective orthopaedic surgery did not suggest that the risk of perioperative adrenal insufficiency varies according to the dose of glucocorticoids used perioperatively, although this evidence is very low certainty.</p>
                        <p>Evidence from a further three observational studies [206][207][209] suggests higher perioperative glucocorticoid exposure may be associated with an increased risk of postoperative infection (reported in one study) and prosthetic joint infection (consistent across the three larger cohort studies), and possibly long term mortality (reported in one large cohort). However evidence from these studies is also very low certainty and did not directly assess the effect of glucocorticoid stress dosing versus continuation of the usual glucocorticoid dose.</p>
                        <p>The panel agreed that there was insufficient evidence to reliably estimate the relative benefits and harms of continuing the usual glucocorticoid dose versus the use of an additional dose or doses of glucocorticoids in the perioperative period.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very Low</span></div><div class="etd-domain-text"><p>Evidence was from a single small randomised controlled trial and was very low certainty due to potential selection, detection and reporting biases, imprecision from very small event rates, and indirectness as the study included people with various conditions; only four participants per group had inflammatory arthritis (specifically, RA).</p>
                        <p>Evidence from the observational studies was also very low certainty overall. Three of the four studies were large population-based cohorts from administrative datasets but the generalisability was limited as it is unclear if participants in these studies received additional (&quot;stress&quot;) glucocorticoid doses perioperatively and all cohorts included RA participants (but no participants with other forms of IA).</p>
                        <p>The applicability of the evidence is limited. The RCT included people with various conditions and only four participants per group (8 of 18 total participants) had IA. The evidence from the observational studies was largely limited to participants with RA undergoing elective joint replacements, and while the studies assessed prior glucocorticoid exposure, it is unclear if participants received stress glucocorticoid doses perioperatively in three of the four studies.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>We did not identify any studies that directly investigated values and preferences of patients with IA on glucocorticoids undergoing surgical procedures. It is likely that the primary trade-off is between a potential risk of clinically-relevant intra- or post-operative adrenal insufficiency (including serious hypotension) and the potential risk of surgical complications related to a transient increase in the glucocorticoid dose, including infection and poor wound healing.</p>
                        <p>The panel considered that there is likely to be variability between individual patients in their preferences, influenced by a variety of factors including the duration and dose of glucocorticoids, the nature and complexity of the surgery, concomitant medications (particularly b/tsDMARDs or other immunomodulatory drugs), the risk and potential consequences of infection or altered wound healing, comorbidity, history of adrenal insufficiency, and individual risk tolerance.</p>
                        <p>The panel also noted that the existing evidence base is insufficient to permit a reliable estimate of competing risks, but that this should not discourage discussion of perioperative glucocorticoid management with patients who are planning elective surgery. Indeed, the panel considered it important that decisions regarding perioperative glucocorticoid management ought to form part of the routine pre-operative counselling and consent process.The conditional nature of this recommendation and the lack of certainty in the evidence base implies that the choice of intervention is dependent on the individual clinical circumstances and patient preferences, and heightens the importance of clear communication between members of the clinical team (including surgeon, anaesthetist, perioperative physician, pharmacist, and GP) and the patient prior to surgery.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Glucocorticoids are a low-cost intervention and short-term adjustment of dosing is unlikely to have any direct cost implications. Major adverse outcomes of surgery in this population, including infection, altered wound healing or intra- or post-operative haemodynamic compromise, may carry an additional resource burden to the individual patient and to the healthcare system, however there are no available cost-effectiveness data regarding the decision to adjust glucocorticoid dosing in the perioperative period.</p>
                        <p>We do not anticipate any environmental impact of glucocorticoid stress dosing in the perioperative period.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Individuals with limited access to specialists might face challenges in making informed decisions about their perioperative glucocorticoid management. Variation in access to care might lead to inappropriate use of glucocorticoids, either underuse or overuse, and result in possible health inequities. However, this specific recommendation — whether to continue glucocorticoids at the usual dose or provide an increased &quot;stress&quot; dose — is not expected to have substantial health equity implications.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Adjustment of glucocorticoid dosing in the perioperative period with the goal of optimising the balance between the risk of adrenal insufficiency and the risk of adverse effects related to glucocorticoids, is likely to be acceptable to all stakeholders including consumers, surgeons, rheumatologists, hospital administrators, and funders.</p>
                        <p>The panel noted there are a number of clinicians who may be involved in perioperative care, including anaesthetists, surgeons, pharmacists, and perioperative physicians, in addition to the patient’s usual care team (including the GP and rheumatologist), and that the acceptability of the recommendation may vary between team members. It was also noted that the panel for this recommendation did not include a surgeon or anaesthetist but did include one member with expertise and experience in perioperative management, and two pharmacists.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>In general, any adjustment of glucocorticoid dosing in the perioperative period for people with IA is likely to be feasible to implement. However it is plausible that there may be uncertainty regarding the specialist with the primary responsibility for advising the patient and making clinical decisions in the perioperative setting (e.g., rheumatologist, anaesthetist, surgeon, perioperative physician, general practitioner), and that the approach to the use of stress dosing and the use of clinical guidelines on this topic may vary between specialties, which might lead to variation in implementation of this recommendation.</p>
                        <p>While the majority of panellists considered that there were important or potential feasibility issues, some considered there were no major issues while others felt that the recommendation might be difficult to implement. After discussion, there was consensus that there were some potential feasibility issues. One such potential barrier to implementation of this recommendation may be the number of clinicians involved in perioperative and intra-operative clinical decision-making, particularly if recommendations on this topic developed by different specialty groups do not align. The panel highlighted that this again underscores the importance of clear communication between clinicians and with the patient, and a deliberate and clearly-documented approach to the conditional nature of this recommendation, including the individual clinical context and the patient’s values and preferences.</p></div></div>
                </div>
                <div class="tab-content" id="rec-11-practical">
                    <div class="content-section"><p>All decisions regarding the perioperative management of glucocorticoids in people with inflammatory arthritis should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual&#x27;s circumstances.</p>
                        <p>It is important that there is clear communication about adjustment of glucocorticoid dosing in the perioperative team between all members of the clinical team, including the rheumatologist, surgeon, anaesthetist, perioperative physician, GP, pharmacist, nursing staff, and the patient.</p>
                        <p><strong>Consider the potential risks and benefits of additional (stress) doses of glucocorticoids in the perioperative period based on the following factors:</strong></p>
                        <ul>
                            <li>Dose and duration of prior glucocorticoid exposure</li>
                            <li>Nature of the surgical procedure  (e.g. highly complex or prolonged surgery)</li>
                            <li>Potential consequences of adrenal insufficiency (e.g. hypotension in a patient with severe ischaemic heart disease)</li>
                            <li>Risk factors for infection, poor wound healing, thrombosis or other potential consequences of additional glucocorticoid use, including comorbidity and concomitant immunomodulatory drugs</li>
                            <li>Prior episodes of adrenal insufficiency</li>
                        </ul>
                        <p>In patients with inflammatory arthritis who are using glucocorticoids, aim for the lowest achievable daily dose in the lead-up to elective surgery.</p>
                        <p>Physiological tests of adrenal function (e.g., short synacthen test) are not routinely required in decision-making regarding the perioperative use of stress doses of glucocorticoids.</p>
                        <p>Clinicians should have a low threshold for the administration of an additional dose of parenteral glucocorticoids in the intra- or post-operative period in patients who exhibit clinical features consistent with adrenal insufficiency, such as hypotension or tachycardia that is out of proportion to blood loss or unexplained hyponatremia.</p></div>
                </div>
                <div class="tab-content" id="rec-11-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-11-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-11-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: August 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Opioids%20for%20pain%20in%20rheumatoid%20arthritis" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Opioids for pain in rheumatoid arthritis-->
    <div class="modal-overlay" id="modal-rec-12">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Pain Management</div>
                    <h2 class="modal-title">Opioids for pain in rheumatoid arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-12', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-12', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-12', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-12', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-12', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-12', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-12-recommendation">
                    <span class="strength-badge conditional-against">⊖ Conditional Recommendation Against</span>
                    <div class="recommendation-box"><p>Do not routinely use opioids for the treatment of pain in rheumatoid arthritis.
A brief course of a short-acting opioid may be considered for severe pain when other analgesic options have failed.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel noted the lack of high quality evidence regarding the use of opioids for RA pain. On balance, there may be some short-term improvement in pain but for many patients this may be at the cost of unpleasant adverse effects. Importantly, there are no data on the benefits of long-term use of opioids, but there is a large body of literature that highlights the potential long-term harms of opioid use for chronic non-cancer pain in general. Therefore, any decision to use opioids in RA should take place within a clear shared decision-making framework that acknowledges the relative lack of specific data on short-term risks and benefits and the large body of literature regarding the potential risks of long-term opioid use.</p>
                        <p>While the panel was of the view that, on average, the potential benefits of opioids are unlikely to outweigh the potential harms, it was also recognised that some individuals may derive a net benefit from a short course of opioids. Therefore, while there is a general recommendation against the use of opioids in the setting of RA pain, in some situations the patient and doctor may elect to trial a short course of opioids. For example, if there is disabling pain due to untreated inflammation and while waiting for DMARDs to take effect and NSAIDs, glucocorticoids or other analgesic strategies have been ineffective or are contraindicated, a brief course of opioids may be warranted. It is likely that such situations would be uncommon in contemporary rheumatology practice. The panel recognised, however, that opioid use among patients with RA appears to be relatively prevalent which suggests that opioids are being used for longer durations or different indications in many patients. In recent years, the persistence of joint pain in a proportion of people with RA despite effective treatment of inflammation has been increasingly recognised. It is unlikely that this type of pain is suited to opioid therapy due to both its chronicity (which would imply a need for long-term opioid use) and its clinical and mechanistic resemblance to ‘nociplastic’ pain (similar to the centrally-mediated pain in fibromyalgia) for which opioids are considered to be ineffective or harmful.</p>
                        <p>The panel also noted that an important proportion of patients who initiate short-term opioid therapy will go on to become long-term users, therefore caution is required even when a brief course of opioids is intended, and mechanisms to prevent transition to chronic use should be established, particularly in patients with a chronic disease such as RA.</p>
                        <p>The panel was strongly of the view that some attempt should be made to identify the phenotype of the pain in the patient with RA. In general, inflammatory pain is best treated with anti-inflammatory strategies (including DMARDs, glucocorticoids and NSAIDs). Pain due to joint damage may occasionally warrant a trial of opioids, although the risks of long-term use should be carefully considered in this setting. Pain that is thought to be related to activation of central mechanisms (i.e. nociplastic pain) is often associated with other clinical features, including widespread tenderness, allodynia, sleep disturbance and cognitive clouding; in such cases the potential risks of opioids typically outweigh any potential benefits.</p>
                        <p>The panel also noted that there are some populations for whom the risks of opioids more clearly outweigh the potential benefits (e.g. the elderly, individuals with active mental illness, those with multiple comorbidities, and those with a history of substance misuse). The panel more strongly recommends against the use of opioids in such cases.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-12-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>There was considerable debate among the panel about whether the potential benefits and harms of opioids are balanced or whether there is net harm on average. There was a majority (but not unanimous) panel vote for “Small net benefit, or little difference between the alternatives”, based on the data from trials of short-term use of opioids in people with rheumatoid arthritis. Some panellists were of the opinion that, on balance, there were important harms that outweighed the potential benefits.</p>
                        <p>Evidence regarding opioid analgesics in patients with rheumatoid arthritis (RA) comes mostly from short-term trials comparing various opioids with placebo: opioids may improve mean pain and increase the number of people who report treatment success but may have little or no effect on function. Opioids may have a small or no effect on the number of people reporting adverse events in short-term clinical trials (up to 6 weeks). We are uncertain of the effect of opioids on serious adverse events or withdrawals from treatment due to either inefficacy or adverse effects.</p>
                        <p>There is very little evidence regarding the efficacy and safety of opioids compared with other types of analgesic medications in patients with RA.</p>
                        <p>The Cochrane review of opioids for RA pain [7] used a ‘net efficacy adjusted for risk’ (NEAR) analysis to estimate the balance of benefits and harms of opioids in RA. The NEAR calculation combines efficacy and adverse event outcomes into a single estimate of the proportion of participants in each treatment group who achieve the clinically desirable state of both analgesic response and avoidance of important adverse effects. By this measure, there was no evidence of a difference between opioids and placebo: the NEAR relative risk (that is, the chance of achieving beneﬁt without harm for those treated with opioids versus placebo) was 1.20 (95% CI, 0.89–1.61).</p>
                        <p>Although there was relatively little high-quality data specific to RA, the widespread use of opioids for chronic non-cancer pain, including in patients with RA, has been increasingly recognised in recent years and use is increasing. The prevalence of opioid use among Australians with RA has been estimated at 32.9% (95% CI 31.6, 34.2) [15] . The use of high-potency opioids in this group has increased over time and now represents approximately a third of all opioid use. Across all indications, over 1.9 million Australians initiate treatment with opioids each year, the majority for non-cancer pain [13]. 2.6% of people who initiate opioids in Australia for non-cancer pain will go on to become persistent users over a 12-month period [16]. In a US emergency department setting, for every 48 patients given an initial opioid prescription, one will become a long-term opioid user [23]. Rheumatological conditions may be a risk factor for transition from first use to long-term opioid use for non-cancer pain [17].</p>
                        <p>Use of low-potency or low-dose opioids is also associated with a risk of transition to high-dose therapy. Tolerance with long-term use of opioids often leads to a requirement for dose escalation. Almost one percent of Australians who commence weak opioids may escalate to high-dose opioid therapy (equivalent to at least 90mg oral morphine per day) and approximately one in 13 will transition to a strong opioid during a 12-month period [21]. Older people are at increased risk of transition to higher doses or more potent opioids. Higher doses are associated with an increased risk of opioid-related morbidity and mortality.</p>
                        <p>All of the trials included in the evidence summary for this recommendation evaluated short-term use (up to 6 weeks); the effectiveness of opioids for RA pain beyond 6 weeks is unknown. Potential harms from chronic use of opioids are well recognised but are unlikely to be adequately captured in short-term trials. Evidence is available regarding harms in trials of medium-term use of opioids (2 weeks to 13 months) for chronic non-cancer pain [18]: opioid use is associated with an increased risk of any adverse event (RR versus placebo 1.42, 95% CI 1.22, 1.66) and serious adverse events (RR 2.75, 95% CI 2.06, 3.67). Adverse effects that occurred at significantly increased rates in opioid users included nausea and vomiting, constipation, dizziness, drowsiness and fatigue, pruritus, hot flushes and sweating.</p>
                        <p>Evidence for opioid harms in the longer term comes from observational studies. Data from a study of almost 100,000 UK patients treated with opioids for musculoskeletal conditions and followed for a median of 3.4 years indicate that long-term opioid use is associated with a dose-dependent increase in the risk of fractures and other major trauma, overdose, falls, gastrointestinal pathology and addiction [19]. Episodes of major trauma increased by 84 for every 10,000 person-years of use of low-dose opioids (equivalent to &lt;20mg morphine per day) and by 139/10,000 for doses equivalent to at least 50mg morphine per day. While the risk of dependence, addiction and overdose is generally well recognised, the potential for other important harms associated with opioid use, including fractures, endocrine dysfunction, and worsening of chronic pain (opioid-induced hyperalgesia), is frequently underestimated.</p>
                        <p>Opioid prescription is also associated with an increased risk of mortality. Treatment with opioids for chronic non-cancer pain is associated with a 58% increase in the risk of all-cause mortality compared with other analgesic therapies (HR 1.58, 95% CI 1.38 to 1.82), equivalent to 148 excess deaths per 10,000 person-years of treatment [20].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>Evidence from trials regarding benefits and harms of opioids in patients with RA was generally of low certainty. Important outcomes for which there was low certainty evidence included pain, function and the number of participants reporting treatment success. There was very low certainty evidence for serious adverse events and withdrawals due to either adverse events or inadequate analgesia.</p>
                        <p>We included trials of any opioid, including medications with other mechanisms of action in addition to opioid receptor effects (i.e. tramadol) and compound analgesics (e.g. an opioid plus paracetamol). Some of the opioids included in these trials are not currently available in Australia. Importantly, most of the evidence comes from trials that pre-date the modern era of treat-to-target management of RA, and none of the participants in the included trials were using biologic or targeted synthetic DMARDs for the treatment of their RA, so the results may not necessarily generalise to people with RA who have been treated with an intensive disease-modifying strategy. No trials were longer than 6 weeks in duration.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>Patients with rheumatoid arthritis report relief of pain to be their highest priority [9]. A 2018 systematic review of patient values and preferences regarding chronic non-cancer pain [8] included 6 studies involving patients with various forms of chronic non-cancer pain (CNCP). While none of the included studies specifically recruited patients with RA, one included patients with other forms of musculoskeletal pain, including osteoarthritis and fibromyalgia. It is likely that the preferences and values of patients with various forms of CNCP are broadly applicable to people with RA pain.</p>
                        <p>Across the included studies, pain relief was consistently reported as being of high importance to patients. The most important adverse effects were nausea/vomiting and alteration of mental state. Other adverse effects, including risk of addiction, were of lesser importance.</p>
                        <p>Included studies that evaluated the trade-off between benefits and harms indicated that substantial pain relief (at least 2 points on a 10-point numerical scale) would be required for a net benefit in the presence of adverse effects (particularly nausea or vomiting).</p>
                        <p>No studies considered the risk of overdose or death, although these outcomes and deliberate misuse or diversion of prescription opioids are common concerns at a societal level. Similarly, while opioid prescribers also view CNCP as an important problem, they are more likely to report concerns about the risk of opioid misuse or addiction [10].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Direct costs of prescription opioid analgesics to individuals are generally relatively low, although prescribing rules in Australia require frequent visits to healthcare providers for ongoing prescriptions which may result in higher out-of-pocket costs or may have an impact on work.</p>
                        <p>The societal costs of chronic non-cancer pain are significant. Approximately 3 million Australian adults use prescription opioids [13]. The majority of these are people with non-cancer pain, although it is likely that opioid use for rheumatoid arthritis represents only a small fraction of these cases. Potential costs to society of widespread use of opioids for chronic non-cancer pain include direct and indirect costs relating to overdose, misuse, dependence and altered productivity.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Socioeconomic factors are important determinants of chronic pain, opioid use and opioid-related adverse outcomes [11][22]. Variation in access to rheumatologists for people with early inflammatory arthritis may lead to delayed treatment with DMARDs in some settings, which may increase the risk of persistent pain throughout the disease course. Access to comprehensive and multidisciplinary chronic pain management services varies within Australia. In particular, access may be limited for socially-disadvanted people and those in regional and remote areas [12]. This may affect pain management strategies in general and, specifically, may alter the balance of potential benefits and harms of opioid analgesics.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>It is likely that the option of short-term use of opioids guided by an explicit management plan in a shared decision-making framework would be acceptable to both patients and prescribers. Evidence from qualitative studies suggests that while patients strongly value relief of pain, this is balanced by concerns about adverse effects (particularly nausea and vomiting) and that patients feel that opioids should be used with caution [14]. Given the potential net harms of opioids use at the population level, widespread use of opioids for RA pain may be less acceptable to policy-makers.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Opioids are a widely-available and feasible treatment option.</p></div></div>
                </div>
                <div class="tab-content" id="rec-12-practical">
                    <div class="content-section"><p>Any decision regarding the use of opioids should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances (including comorbidities and concomitant medications)</p>
                        <p>In patients who are already using opioids, the lowest effective dose should be sought, and opportunities for reduction in dose or cessation should be considered at each visit</p>
                        <p><strong>In all patients for whom opioids are being considered or currently prescribed:</strong></p>
                        <ul>
                            <li>Consider age, other pharmacotherapy and important comorbidities (e.g., cognitive impairment, falls risk, active mental illness, history of drug or alcohol misuse) and avoid any opioid use in individuals at increased risk of harm from opioids</li>
                            <li>Actively enquire about the individual patient’s prior or current experience with opioid analgesics (including effectiveness, adverse effects, and dose used), and current use of other centrally-acting drugs</li>
                            <li>Consider the pain phenotype: make sure inflammatory pain is adequately treated, and be alert for comorbid fibromyalgia or nociplastic pain (for which opioids are generally not recommended). Ensure that other treatable or reversible pathology (e.g., occult insufficiency fracture) has been adequately considered and investigated</li>
                        </ul>
                        <p><strong>In patients for whom a trial of opioids is being considered:</strong></p>
                        <ul>
                            <li>Ensure that appropriate non-pharmacological therapies (e.g. physiotherapy) and other analgesic strategies have been optimised prior to consideration of opioid prescription</li>
                            <li>Before commencing treatment with opioids, the prescriber and patient should agree on the goals of therapy and the method for measuring outcomes</li>
                        </ul>
                        <p><strong>If a decision is made to proceed with a trial of opioids, the following should be considered:</strong></p>
                        <ul>
                            <li>Commence at a low dose of a short-acting opioid</li>
                            <li>A written treatment plan should be agreed upon by the patient and prescriber, and this should be provided to other relevant parties (e.g., the GP)</li>
                            <li>Discuss the risks of driving a motor vehicle and operating heavy machinery during initiation and dose adjustment of opioids, and develop a plan to mitigate this risk</li>
                            <li>The primary prescriber and the dispensing pharmacy should also be identified in the written plan and all parties should be informed</li>
                            <li>Establish a clear plan for discontinuation of opioids if the treatment goals are not met</li>
                        </ul>
                        <p>Please click HERE for a number of resources produced by NPS MedicineWise about opioids for chronic non-cancer pain.</p></div>
                </div>
                <div class="tab-content" id="rec-12-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-12-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-12-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Opioids%20for%20pain%20in%20axial%20spondyloarthritis" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Opioids for pain in axial spondyloarthritis-->
    <div class="modal-overlay" id="modal-rec-13">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Pain Management</div>
                    <h2 class="modal-title">Opioids for pain in axial spondyloarthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-13', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-13', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-13', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-13', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-13', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-13', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-13-recommendation">
                    <span class="strength-badge conditional-against">⊖ Conditional Recommendation Against</span>
                    <div class="recommendation-box"><p>Do not routinely use opioids for the treatment of pain in axial spondyloarthritis.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel discussed at length the balance between the potential benefits and harms of opioids for axial spondyloarthritis pain. In particular, given that the only evidence regarding efficacy in this population was of very low certainty, the panel carefully considered the extent to which the balance of potential benefits and harms can be inferred from other data, including the large body of literature regarding the risks associated with prescription opioids. On balance, due to the lack of evidence regarding efficacy and the known risk of long-term harm associated with opioid use in the broader population of people with chronic non-cancer pain, the panel formed the consensus view that the known risks are likely to outweigh the potential benefits for axial spondyloarthritis.</p>
                        <p>As a result, the panel recommended against the routine use of opioids for axial spondyloarthritis pain. This recommendation differs slightly from the recommendation for rheumatoid arthritis pain which, while still a conditional recommendation against opioids, also recommends that &quot;a brief course of a short-acting opioid may be considered for severe pain when other analgesic options have failed&quot;. The rheumatoid arthritis recommendation is based on low certainty evidence of short-term efficacy of opioids in a proportion of patients; no such evidence currently exists for patients with axial spondyloarthritis.</p>
                        <p>Importantly, this living recommendation has been made in the setting of very low certainty evidence, and therefore is susceptible to change if new evidence emerges.</p>
                        <p>The lack of evidence regarding benefits does not exclude the possibility that opioids may be beneficial in some patients with axial spondyloarthritis. There was considerable discussion within the panel regarding the relative lack of evidence regarding opioids in this population, and the difficulty of generating a recommendation that appropriately acknowledges the known short- and long-term risks of opioid use while allowing for the possibility that there may be some circumstances in which (short-term) opioid therapy may be an appropriate choice within a shared decision-making framework, even without a precise estimate of the potential benefits and risks.</p>
                        <p>The panel acknowledged that there may be some situations in which the patient and doctor may elect to consider a short course of opioids. For example, if there is disabling pain due to untreated inflammation and while waiting for b/tsDMARDs to take effect and NSAIDs or other analgesic strategies have been ineffective or are contraindicated, consideration of a brief course of opioids may be warranted. It is likely that such situations would be uncommon in contemporary rheumatology practice. Any decision to use opioids in axial spondyloarthritis should take place within a clear shared decision-making framework that acknowledges the lack of specific data on short-term risks and benefits and the large body of literature regarding the potential risks of long-term opioid use.</p>
                        <p>The panel also noted that opioid use among patients with axial spondyloarthritis appears to be relatively prevalent which suggests that opioids are being used for longer durations or in place of other evidence-based therapies in many patients. The panel also noted that an important proportion of patients who initiate short-term opioid therapy for any indication will go on to become long-term users, therefore caution is required even when a brief course of opioids is intended, and mechanisms to prevent transition to chronic use should be established, particularly in patients with a chronic disease such as axial spondyloarthritis. Similarly, consideration should be given to deprescribing opioids in current users. The &quot;Practical Info&quot; section provides some further guidance for patients and practitioners who are considering a trial of opioids or who are currently using opioids.</p>
                        <p>The panel was also of the view that some attempt should be made to identify the phenotype of the pain in patients with inflammatory arthritis and persistent pain. In general, inflammatory pain is best treated with anti-inflammatory strategies (including NSAIDs and DMARDs). Pain due to joint damage or spinal ankylosis may very occasionally warrant a trial of opioids, although the risks of long-term use should be carefully considered in this setting. Pain that is thought to be related to activation of central mechanisms (i.e. nociplastic pain) is often associated with other clinical features including widespread tenderness, allodynia, sleep disturbance and cognitive clouding; in such cases the risks of opioids typically outweigh any potential benefits.</p>
                        <p>The panel also noted that there are some populations for whom the risks of opioids more clearly outweigh the potential benefits (e.g. the elderly, individuals with active mental illness, those with multiple comorbidities, and those with a history of substance misuse). The panel more strongly recommends against the use of opioids in such cases.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-13-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Important harms</span></div><div class="etd-domain-text"><p>Benefits: In adults with axial spondyloarthritis (including ankylosing spondylitis), we are uncertain of the benefits of opioid use compared with other analgesics (i.e. NSAIDs) or in addition to NSAIDs versus NSAIDs alone, with regards to treatment success, pain or function, due to very low certainty evidence.</p>
                        <p>Harms: In adults with axial spondyloarthritis (including ankylosing spondylitis), we are uncertain of the harms of opioid use compared with other analgesics (i.e. NSAIDs) or in addition to NSAIDs versus NSAIDs alone, with regards to the number of adverse events, ineffective analgesia and withdrawals due to either or both of these outcomes. No serious adverse events were reported in two randomised controlled trials.</p>
                        <p>There was considerable debate among the panel regarding the balance of potential benefits and harms of opioid therapy in people with axial spondyloarthritis pain. Only two randomised controlled trials were available, which provided very low certainty evidence regarding efficacy or short-term harms. Given the lack of evidence regarding efficacy and the known risk of long-term harm associated with opioid use in the broader population of people with chronic non-cancer pain, the panel formed the consensus view that the known risks outweigh the potential benefits in this setting.</p>
                        <p>There are few data regarding the prevalence of opioid use among people with axial spondyloarthritis, particularly in the Australian setting. Observational data from the US suggests that opioid use for spondyloarthritis pain is common. Data from a claims database indicated that patients with various forms of inflammatory arthritis are at higher risk of receiving long-term opioid prescriptions, and that the risk was highest for patients with ankylosing spondylitis [28]. In a cohort of US patients with ankylosing spondylitis, 9.5% were taking chronic opioids (defined as taking opioids daily for at least 6 months) and 21.7% were using intermittent or “on demand” opioids [29]. Opioid use was higher among those with multiple comorbidities, polypharmacy (including anxiolytics and hypnotics), higher functional impairment and depression.</p>
                        <p>Across all indications, over 1.9 million Australians initiate treatment with opioids each year, the majority for non-cancer pain [13]. 2.6% of people who initiate opioids in Australia for non-cancer pain will go on to become persistent users over a 12-month period [16]. In a US emergency department setting, for every 48 patients given an initial opioid prescription, one will become a long-term opioid user [23]. Rheumatological conditions may be a risk factor for transition from first use to long-term opioid use for non-cancer pain [17].</p>
                        <p>Use of low-potency or low-dose opioids is also associated with a risk of transition to high-dose therapy. Tolerance with long-term use of opioids often leads to a requirement for dose escalation. Almost one percent of Australians who commence weak opioids may escalate to high-dose opioid therapy (equivalent to at least 90mg oral morphine per day) and approximately one in 13 will transition to a strong opioid during a 12-month period [21]. Older people are at increased risk of transition to higher doses or more potent opioids. Higher doses are associated with an increased risk of opioid-related morbidity and mortality.</p>
                        <p>Although there is little trial evidence regarding harms of opioids that is specific to spondyloarthritis, data are available regarding harms in patients with chronic non-cancer pain from trials of medium-term use of opioids (2 weeks to 13 months) [18]: opioid use is associated with an increased risk of any adverse event (RR versus placebo 1.42, 95% CI 1.22, 1.66) and serious adverse events (RR 2.75, 95% CI 2.06, 3.67). Adverse effects that occurred at significantly increased rates in opioid users included nausea and vomiting, constipation, dizziness, drowsiness and fatigue, pruritus, hot flushes and sweating.</p>
                        <p>Evidence for opioid harms in the longer term comes from observational studies. Data from a study of almost 100,000 UK patients treated with opioids for musculoskeletal conditions and followed for a median of 3.4 years indicate that long-term opioid use is associated with a dose-dependent increase in the risk of fractures and other major trauma, overdose, falls, gastrointestinal pathology and addiction [19]. Episodes of major trauma increased by 84 for every 10,000 person-years of use of low-dose opioids (equivalent to &lt;20mg morphine per day) and by 139/10,000 for doses equivalent to at least 50mg morphine per day. While the risk of dependence, addiction and overdose is generally well recognised, the potential for other important harms associated with opioid use, including fractures, endocrine dysfunction, and worsening of chronic pain (opioid-induced hyperalgesia), is frequently underestimated.</p>
                        <p>Opioid prescription is also associated with an increased risk of mortality. Treatment with opioids for chronic non-cancer pain is associated with a 58% increase in the risk of all-cause mortality compared with other analgesic therapies (HR 1.58, 95% CI 1.38 to 1.82), equivalent to 148 excess deaths per 10,000 person-years of treatment [20].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very Low</span></div><div class="etd-domain-text"><p>There is very low certainty evidence for the effect of opioid use compared with other analgesics (i.e. NSAIDs) or in addition to NSAIDs versus NSAIDs alone, for: participant-reported treatment success total withdrawals due to adverse events or inadequate analgesia withdrawals due to adverse events withdrawals due to inadequate analgesia number of participants reporting adverse events number of serious adverse events mean change in pain from baseline mean change in function from baseline.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>A 2018 systematic review of patient values and preferences regarding chronic non-cancer pain (CNCP) [8] included 6 studies involving patients with various forms of CNCP. While none of the included studies specifically recruited patients with axial spondyloarthritis, one included patients with other forms of musculoskeletal pain, including osteoarthritis and fibromyalgia. It is likely that the preferences and values of patients with various forms of CNCP are broadly applicable to people with spondyloarthritis pain.</p>
                        <p>Across the included studies, pain relief was consistently reported as being of high importance to patients. The most important adverse effects were nausea/vomiting and alteration of mental state. Other adverse effects, including risk of addiction, were of lesser importance.</p>
                        <p>Included studies that evaluated the trade-off between benefits and harms indicated that substantial pain relief (at least 2 points on a 10-point numerical scale) would be required for a net benefit in the presence of adverse effects (particularly nausea or vomiting).</p>
                        <p>No studies considered the risk of overdose or death, although these outcomes and deliberate misuse or diversion of prescription opioids are common concerns at a societal level. Similarly, while opioid prescribers also view CNCP as an important problem, they are more likely to report concerns about the risk of opioid misuse or addiction [10].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Direct costs of prescription opioid analgesics to individuals are generally relatively low, although prescribing rules in Australia require frequent visits to healthcare providers for ongoing prescriptions which may result in higher out-of-pocket costs or may have an impact on work.</p>
                        <p>The societal costs of chronic non-cancer pain are significant. Approximately 3 million Australian adults use prescription opioids [13]. The majority of these are people with non-cancer pain, although it is likely that opioid use for axial spondyloarthritis represents only a small fraction of these cases. Potential costs to society of widespread use of opioids for chronic non-cancer pain include direct and indirect costs relating to overdose, misuse, dependence and altered productivity. There was concern among some panellists that the societal costs of opioid therapy may be disproportionately high compared with other analgesic strategies in axial spondyloarthritis, and that this may therefore represent an important argument against the use of opioids in this setting.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Socioeconomic factors are important determinants of chronic pain, opioid use and opioid-related adverse outcomes [11][22]. Variation in access to rheumatologists for people with inflammatory back pain or other features of axial spondyloarthritis may lead to delayed diagnosis and treatment in some settings, which may increase the risk of persistent pain throughout the disease course.</p>
                        <p>Access to comprehensive and multidisciplinary chronic pain management services varies within Australia. In particular, access may be limited for socially-disadvantaged people and those in regional and remote areas [12]. This may affect pain management strategies in general and, specifically, may alter the balance of potential benefits and harms of opioid analgesics.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>It is likely that the option of short-term use of opioids guided by an explicit management plan in a shared decision-making framework would be acceptable to both patients and prescribers. Evidence from qualitative studies in patients with musculoskeletal disease suggests that while patients strongly value relief of pain, this is balanced by concerns about adverse effects (particularly nausea and vomiting) and that patients feel that opioids should be used with caution [14]. Given the potential net harms of opioids use at the population level, widespread use of opioids for axial spondyloarthritis pain may be less acceptable to policy-makers.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Opioids are generally a widely-available and feasible treatment option. In some settings, alternatives to opioids, particularly for chronic pain, including multidisciplinary and multimodal pain management services, may be difficult to access or implement. This may particularly be the case in rural or remote areas [12], among socially-disadvantaged individuals, or in primary care settings where resources or access to multidisciplinary or specialist services are limited. In such cases the barriers to opioid avoidance or deprescribing may make a recommendation against opioid use difficult to implement without additional resources. The panel strongly supported the development of implementation initiatives that seek to facilitate either avoidance of opioid initiation or deprescribing in those already using opioids.</p></div></div>
                </div>
                <div class="tab-content" id="rec-13-practical">
                    <div class="content-section"><p>Any decision regarding the use of opioids should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances (including comorbidities and concomitant medications)</p>
                        <p>In patients who are already using opioids, the lowest effective dose should be sought, and opportunities for reduction in dose or cessation should be considered at each visit</p>
                        <p><strong>In all patients for whom opioids are being considered or currently prescribed:</strong></p>
                        <ul>
                            <li>Consider age, other pharmacotherapy and important comorbidities (e.g., cognitive impairment, falls risk, active mental illness, history of drug or alcohol misuse) and avoid any opioid use in individuals at increased risk of harm from opioids</li>
                            <li>Actively enquire about the individual patient’s prior or current experience with opioid analgesics (including effectiveness, adverse effects, and dose used), and current use of other centrally-acting drugs</li>
                            <li>Consider the pain phenotype: make sure inflammatory pain is adequately treated, and be alert for comorbid fibromyalgia or nociplastic pain (for which opioids are generally not recommended). Ensure that other treatable or reversible pathology (e.g., occult insufficiency fracture) has been adequately considered and investigated</li>
                        </ul>
                        <p><strong>In patients for whom a trial of opioids is being considered:</strong></p>
                        <ul>
                            <li>Ensure that appropriate non-pharmacological therapies (e.g. physiotherapy) and other analgesic strategies have been optimised prior to consideration of opioid prescription</li>
                            <li>Before commencing treatment with opioids, the prescriber and patient should agree on the goals of therapy and the method for measuring outcomes</li>
                        </ul>
                        <p><strong>If a decision is made to proceed with a trial of opioids, the following should be considered:</strong></p>
                        <ul>
                            <li>Commence at a low dose of a short-acting opioid</li>
                            <li>A written treatment plan should be agreed upon by the patient and prescriber, and this should be provided to other relevant parties (e.g., the GP)</li>
                            <li>Discuss the risks of driving a motor vehicle and operating heavy machinery during initiation and dose adjustment of opioids, and develop a plan to mitigate this risk</li>
                            <li>The primary prescriber and the dispensing pharmacy should also be identified in the written plan and all parties should be informed</li>
                            <li>Establish a clear plan for discontinuation of opioids if the treatment goals are not met</li>
                        </ul></div>
                </div>
                <div class="tab-content" id="rec-13-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-13-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-13-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Opioids%20for%20pain%20in%20psoriatic%20arthritis" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Opioids for pain in psoriatic arthritis-->
    <div class="modal-overlay" id="modal-rec-14">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Pain Management</div>
                    <h2 class="modal-title">Opioids for pain in psoriatic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-14', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-14', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-14', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-14', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-14', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-14', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-14-recommendation">
                    <span class="strength-badge conditional-against">⊖ Conditional Recommendation Against</span>
                    <div class="recommendation-box"><p>Do not routinely use opioids for the treatment of pain in psoriatic arthritis.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel discussed at length the balance between the potential benefits and harms of opioids for psoriatic arthritis pain. In particular, given the absence of randomised controlled trials in this population, the panel carefully considered the extent to which the balance of potential benefits and harms can be inferred from other data, including the large body of literature regarding the risks associated with prescription opioids. On balance, due to the lack of evidence regarding efficacy and the known risk of long-term harm associated with opioid use in the broader population of people with chronic non-cancer pain, the panel formed the consensus view that the known risks are likely to outweigh the potential benefits for psoriatic arthritis.</p>
                        <p>As a result, the panel recommended against the routine use of opioids for psoriatic arthritis pain. This recommendation differs slightly from the recommendation for rheumatoid arthritis pain which, while still a conditional recommendation against opioids, also recommends that &quot;a brief course of a short-acting opioid may be considered for severe pain when other analgesic options have failed&quot;. The rheumatoid arthritis recommendation is based on low certainty evidence of short-term efficacy of opioids in a proportion of patients; no such evidence currently exists for patients with psoriatic arthritis.</p>
                        <p>Importantly, this living recommendation has been made in the absence of evidence from randomised controlled trials in people with psoriatic arthritis, and therefore is susceptible to change if new evidence emerges.</p>
                        <p>The lack of evidence regarding benefits does not exclude the possibility that opioids may be beneficial in some patients with psoriatic arthritis. There was considerable discussion within the panel about the lack of evidence regarding opioids in this population, and the difficulty of generating a recommendation that appropriately acknowledges the known short- and long-term risks of opioid use while allowing for the possibility that there may be some circumstances in which (short-term) opioid therapy may be an appropriate choice within a shared decision-making framework, even without a precise estimate of the potential benefits and risks.</p>
                        <p>The panel acknowledged that there may be some situations in which the patient and doctor may elect to consider a short course of opioids. For example, if there is disabling pain due to untreated inflammation and while waiting for DMARDs to take effect and NSAIDs or other analgesic strategies have been ineffective or are contraindicated, consideration of a brief course of opioids may be warranted. It is likely that such situations would be uncommon in contemporary rheumatology practice. Any decision to use opioids in psoriatic arthritis should take place within a clear shared decision-making framework that acknowledges the lack of specific data on short-term risks and benefits and the large body of literature regarding the potential risks of long-term opioid use.</p>
                        <p>The panel also noted that an important proportion of patients who initiate short-term opioid therapy for any indication will go on to become long-term users, therefore caution is required even when a brief course of opioids is intended, and mechanisms to prevent transition to chronic use should be established, particularly in patients with a chronic disease such as psoriatic arthritis. Similarly, consideration should be given to deprescribing opioids in current users. The &quot;Practical Info&quot; section provides some further guidance for patients and practitioners who are considering a trial of opioids or who are currently using opioids.</p>
                        <p>The panel was also of the view that some attempt should be made to identify the phenotype of the pain in patients with inflammatory arthritis and persistent pain. In general, inflammatory pain is best treated with anti-inflammatory strategies (including NSAIDs and DMARDs). Pain due to joint damage may very occasionally warrant a trial of opioids, although the risks of long-term use should be carefully considered in this setting. Pain that is thought to be related to activation of central mechanisms (i.e. nociplastic pain) is often associated with other clinical features including widespread tenderness, allodynia, sleep disturbance and cognitive clouding; in such cases the risks of opioids typically outweigh any potential benefits.</p>
                        <p>The panel also noted that there are some populations for whom the risks of opioids more clearly outweigh the potential benefits (e.g. the elderly, individuals with active mental illness, those with multiple comorbidities, and those with a history of substance misuse). The panel more strongly recommends against the use of opioids in such cases.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-14-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Important harms</span></div><div class="etd-domain-text"><p>In people with psoriatic arthritis (PsA), we are uncertain whether opioid use is safe or effective as no studies addressing the question were identified.</p>
                        <p>There are few data regarding the prevalence of opioid use among people with psoriatic arthritis, however across all indications over 1.9 million Australians initiate treatment with opioids each year, the majority for non-cancer pain [13]. 2.6% of people who initiate opioids in Australia for non-cancer pain will go on to become persistent users over a 12-month period [16]. In a US emergency department setting, for every 48 patients given an initial opioid prescription, one will become a long-term opioid user [23]. Rheumatological conditions may be a risk factor for transition from first use to long-term opioid use for non-cancer pain [17].</p>
                        <p>Use of low-potency or low-dose opioids is also associated with a risk of transition to high-dose therapy. Tolerance with long-term use of opioids often leads to a requirement for dose escalation. Almost one percent of Australians who commence weak opioids may escalate to high-dose opioid therapy (equivalent to at least 90mg oral morphine per day) and approximately one in 13 will transition to a strong opioid during a 12-month period [21]. Older people are at increased risk of transition to higher doses or more potent opioids. Higher doses are associated with an increased risk of opioid-related morbidity and mortality.</p>
                        <p>Although there is little trial evidence regarding harms of opioids that is specific to psoriatic arthritis, data are available regarding harms in patients with chronic non-cancer pain from trials of medium-term use of opioids (2 weeks to 13 months) [18]: opioid use is associated with an increased risk of any adverse event (RR versus placebo 1.42, 95% CI 1.22, 1.66) and serious adverse events (RR 2.75, 95% CI 2.06, 3.67). Adverse effects that occurred at significantly increased rates in opioid users included nausea and vomiting, constipation, dizziness, drowsiness and fatigue, pruritus, hot flushes and sweating.</p>
                        <p>Evidence for opioid harms in the longer term comes from observational studies. Data from a study of almost 100,000 UK patients treated with opioids for musculoskeletal conditions and followed for a median of 3.4 years indicate that long-term opioid use is associated with a dose-dependent increase in the risk of fractures and other major trauma, overdose, falls, gastrointestinal pathology and addiction [19]. Episodes of major trauma increased by 84 for every 10,000 person-years of use of low-dose opioids (equivalent to &lt;20mg morphine per day) and by 139/10,000 for doses equivalent to at least 50mg morphine per day. While the risk of dependence, addiction and overdose is generally well recognised, the potential for other important harms associated with opioid use, including fractures, endocrine dysfunction, and worsening of chronic pain (opioid-induced hyperalgesia), is frequently underestimated.</p>
                        <p>Opioid prescription is also associated with an increased risk of mortality. Treatment with opioids for chronic non-cancer pain is associated with a 58% increase in the risk of all-cause mortality compared with other analgesic therapies (HR 1.58, 95% CI 1.38 to 1.82), equivalent to 148 excess deaths per 10,000 person-years of treatment [20].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very Low</span></div><div class="etd-domain-text"><p>No studies addressing this question were identified.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>A 2018 systematic review of patient values and preferences regarding chronic non-cancer pain [8] included 6 studies involving patients with various forms of chronic non-cancer pain (CNCP). While none of the included studies specifically recruited patients with psoriatic arthritis, one included patients with other forms of musculoskeletal pain, including osteoarthritis and fibromyalgia. It is likely that the preferences and values of patients with various forms of CNCP are broadly applicable to people with psoriatic arthritis pain.</p>
                        <p>Across the included studies, pain relief was consistently reported as being of high importance to patients. The most important adverse effects were nausea/vomiting and alteration of mental state. Other adverse effects, including risk of addiction, were of lesser importance.</p>
                        <p>Included studies that evaluated the trade-off between benefits and harms indicated that substantial pain relief (at least 2 points on a 10-point numerical scale) would be required for a net benefit in the presence of adverse effects (particularly nausea or vomiting).</p>
                        <p>No studies considered the risk of overdose or death, although these outcomes and deliberate misuse or diversion of prescription opioids are common concerns at a societal level. Similarly, while opioid prescribers also view CNCP as an important problem, they are more likely to report concerns about the risk of opioid misuse or addiction [10].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Direct costs of prescription opioid analgesics to individuals are generally relatively low, although prescribing rules in Australia require frequent visits to healthcare providers for ongoing prescriptions which may result in higher out-of-pocket costs or may have an impact on work.</p>
                        <p>The societal costs of chronic non-cancer pain are significant. Approximately 3 million Australian adults use prescription opioids [13]. The majority of these are people with non-cancer pain, although it is likely that opioid use for psoriatic arthritis represents only a small fraction of these cases. Potential costs to society of widespread use of opioids for chronic non-cancer pain include direct and indirect costs relating to overdose, misuse, dependence and altered productivity. There was concern among some panellists that the societal costs of opioid therapy may be disproportionately high compared with other analgesic strategies in psoriatic arthritis, and that this may therefore represent an important argument against the use of opioids in this setting.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Socioeconomic factors are important determinants of chronic pain, opioid use and opioid-related adverse outcomes[11] [22]. Variation in access to rheumatologists for people with psoriatic arthritis may lead to delayed diagnosis and treatment in some settings, which may increase the risk of persistent pain throughout the disease course.</p>
                        <p>Access to comprehensive and multidisciplinary chronic pain management services varies within Australia. In particular, access may be limited for socially-disadvantaged people and those in regional and remote areas [12]. This may affect pain management strategies in general and, specifically, may alter the balance of potential benefits and harms of opioid analgesics.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>It is likely that the option of short-term use of opioids guided by an explicit management plan in a shared decision-making framework would be acceptable to both patients and prescribers. Evidence from qualitative studies in patients with musculoskeletal disease suggests that while patients strongly value relief of pain, this is balanced by concerns about adverse effects (particularly nausea and vomiting) and that patients feel that opioids should be used with caution [14]. Given the potential net harms of opioids use at the population level, widespread use of opioids for psoriatic arthritis pain may be less acceptable to policy-makers.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Opioids are generally a widely-available and feasible treatment option. In some settings, alternatives to opioids, particularly for chronic pain, including multidisciplinary and multimodal pain management services, may be difficult to access or implement. This may particularly be the case in rural or remote areas [12], among socially-disadvantaged individuals, or in primary care settings where resources or access to multidisciplinary or specialist services are limited. In such cases the barriers to opioid avoidance or deprescribing may make a recommendation against opioid use difficult to implement without additional resources. The panel strongly supported the development of implementation initiatives that seek to facilitate either avoidance of opioid initiation or deprescribing in those already using opioids.</p></div></div>
                </div>
                <div class="tab-content" id="rec-14-practical">
                    <div class="content-section"><p>Any decision regarding the use of opioids should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances (including comorbidities and concomitant medications)</p>
                        <p>In patients who are already using opioids, the lowest effective dose should be sought, and opportunities for reduction in dose or cessation should be considered at each visit</p>
                        <p><strong>In all patients for whom opioids are being considered or currently prescribed:</strong></p>
                        <ul>
                            <li>Consider age, other pharmacotherapy and important comorbidities (e.g., cognitive impairment, falls risk, active mental illness, history of drug or alcohol misuse) and avoid any opioid use in individuals at increased risk of harm from opioids</li>
                            <li>Actively enquire about the individual patient’s prior or current experience with opioid analgesics (including effectiveness, adverse effects, and dose used), and current use of other centrally-acting drugs</li>
                            <li>Consider the pain phenotype: make sure inflammatory pain is adequately treated, and be alert for comorbid fibromyalgia or nociplastic pain (for which opioids are generally not recommended). Ensure that other treatable or reversible pathology (e.g., occult insufficiency fracture) has been adequately considered and investigated</li>
                        </ul>
                        <p><strong>In patients for whom a trial of opioids is being considered:</strong></p>
                        <ul>
                            <li>Ensure that appropriate non-pharmacological therapies (e.g. physiotherapy) and other analgesic strategies have been optimised prior to consideration of opioid prescription</li>
                            <li>Before commencing treatment with opioids, the prescriber and patient should agree on the goals of therapy and the method for measuring outcomes</li>
                        </ul>
                        <p><strong>If a decision is made to proceed with a trial of opioids, the following should be considered:</strong></p>
                        <ul>
                            <li>Commence at a low dose of a short-acting opioid</li>
                            <li>A written treatment plan should be agreed upon by the patient and prescriber, and this should be provided to other relevant parties (e.g., the GP)</li>
                            <li>Discuss the risks of driving a motor vehicle and operating heavy machinery during initiation and dose adjustment of opioids, and develop a plan to mitigate this risk</li>
                            <li>The primary prescriber and the dispensing pharmacy should also be identified in the written plan and all parties should be informed</li>
                            <li>Establish a clear plan for discontinuation of opioids if the treatment goals are not met</li>
                        </ul></div>
                </div>
                <div class="tab-content" id="rec-14-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-14-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-14-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: December 2024</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Short" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Short-term use of glucocorticoids for treating fla -->
    <div class="modal-overlay" id="modal-rec-15">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Glucocorticoids</div>
                    <h2 class="modal-title">Short-term use of glucocorticoids for treating flare in RA</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-15', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-15', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-15', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-15', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-15', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-15', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-15-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>Consider using short-term glucocorticoids for the treatment of rheumatoid arthritis flare in people with previously well-controlled disease, via either a systemic (oral, intramuscular or intravenous) or intra-articular route, in the lowest possible dose for the shortest possible time.</p>
                        <p>Any flare should prompt consideration of the need for adjustment of the DMARD regimen.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For this recommendation, the panel focused on the short-term use of glucocorticoids for the management of RA flares only. Other potential short-term indications for glucocorticoids in RA were not considered, in particular the use of glucocorticoids alone or in combination with DMARDs for the induction of remission or low disease activity during treatment initiation, or for the management of persistent synovitis in one or more joints despite DMARD therapy. The former will be the topic of a separate living recommendation in this guideline.</p>
                        <p>Glucocorticoids via any route were considered, including intra-articular or systemic therapy. A broad definition of flare was used for the literature search, but for the purpose of the panel discussion, flare was considered to represent a new increase in disease activity on a background of well-controlled RA. Such an increase in disease activity was considered to align with the OMERACT operational definition that a flare represents “any worsening of disease activity that would, if persistent, in most cases lead to initiation or change of therapy” [98].</p>
                        <p>The panel elected not to create a strict definition of “short-term” glucocorticoid therapy. In general, the lowest cumulative dose of glucocorticoid required to treat the symptoms of the flare ought to be used. For parenteral routes of administration (e.g., intra-articular or intramuscular), this would typically be a single dose. For oral glucocorticoids, the dose and duration may vary depending on the clinical circumstances but the panel emphasised that the duration should be clearly defined prior to commencement of treatment in order to reduce the risk of transition to long-term use or of adrenal suppression.</p>
                        <p>Using these definitions, no randomised controlled trials (RCTs) were found that addressed the primary question of the benefits and harms of glucocorticoids for RA flare. The panel was of the opinion that this remains an important question and therefore proceeded to formulate a recommendation. The panel also emphasised that RCTs that address this question ought to be prioritised.</p>
                        <p>The panel discussed the likely benefits of short courses of glucocorticoids in RA, based on widespread clinical experience, and extrapolation from the known beneficial effects on RA inflammation more broadly. The potential adverse effects of short-term glucocorticoid use were also discussed, based on observational data in patients with various inflammatory diseases, including inflammatory arthritis. Given the likely short-term benefits on inflammatory symptoms and function and the widespread use of glucocorticoids for flares in routine RA practice, the panel unanimously voted for a recommendation in favour of short-term glucocorticoids. However, the recommendation is conditional, noting that there is potential for harm (including serious harms such as infection and fracture) and that glucocorticoids may not be the preferred option for many people. In all cases, the use of glucocorticoids should be considered within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances (including comorbidities, concomitant medications, and the functional impact of the flare). In cases where there has been a clear reversible cause for the flare (e.g., a recent reduction in DMARD dose), some people may prefer to address the cause and await resolution of the flare, rather than attempt to treat the flare with glucocorticoids.</p>
                        <p>Importantly, the recommendation also asserts that any RA flare may indicate an inadequate disease-modifying regimen. Flares are known to be associated with an increased long-term risk of joint damage, disability and cardiovascular disease [96][97]. Therefore, all episodes of flare should prompt a review of the potential causes (and, if identified, the potential reversibility of the cause), the individual treat-to-target goals, and the current DMARD regimen.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-15-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>In people with rheumatoid arthritis (RA), we are uncertain whether the short-term use of glucocorticoids for disease flare is safe or effective as no studies addressing the primary question were identified. We did not include trials of short-term glucocorticoids for the treatment of persistent synovitis in one or more joints, or for the induction of remission in recent-onset RA. The latter will be addressed in a separate living recommendation in this guideline.</p>
                        <p>Anecdotal evidence supports the efficacy of short-term or single doses of glucocorticoids, administered either systemically (orally, intramuscularly or intravenously) or via intra-articular injection, but there are no reliable estimates of the relative benefits and harms. Many of the recognised adverse effects of long-term systemic glucocorticoid therapy (including endocrine disturbance, weight gain, thin skin, easy bruising, osteoporosis and atherosclerotic vascular disease) are unlikely to be associated with very short-term glucocorticoid use however some adverse effects may plausibly occur even with short-term use. The effect of different doses and routes of administration of glucocorticoids on the short-term risk of adverse effects is unknown.</p>
                        <p>There is little observational evidence available regarding the specific risks of short-term glucocorticoids in people with RA, however data from the general population are consistent with a small increase in the risk of serious adverse events. In a study using data from the Taiwanese National Health Insurance Research Database (n = 15,859,129 adult participants), brief courses (14 days or fewer) of oral glucocorticoids were associated with an approximate doubling of the risk of GI bleeding, sepsis or heart failure in the subsequent month [94]. Similarly, a study using a US insurance database found that a short course (less than 30 days) of systemic glucocorticoids was associated with an increased risk of sepsis, venous thromboembolism and fracture in the subsequent 30 days [95]. The estimated absolute risk of any of these serious adverse events is approximately one per 1,000 short courses of glucocorticoid [93].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very Low</span></div><div class="etd-domain-text"><p>No studies addressing the primary question were identified.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>Among patients with RA, outcomes ranked as being of high importance include pain, joint damage, fatigue, daily functioning and mobility [77]. A systematic review of 36 studies of patient preferences for RA outcomes with disease-modifying therapies found that, in general, treatment benefits were considered more important than risks (including serious adverse events). However there was heterogeneity among included studies and variation between patients, suggesting that individual values and preferences are likely to be an important determinant of treatment decisions in people with rheumatoid arthritis [35].</p>
                        <p>For glucocorticoid therapy in particular, tradeoffs between benefits and risks may vary between patients and within the same person over time, depending on a variety of factors including individual preferences and values, age, comorbidities, disease activity, concurrent medications, social, work and family roles, and risk tolerance.</p>
                        <p>Beneficial and harmful effects often coexist in patients who use glucocorticoids for RA. Data on this topic primarily relate to long-term users of glucocorticoids and it is unclear to what extent the findings can be extrapolated to the short-term use of glucocorticoids for the treatment of flares.</p>
                        <p>Among Australian patients with rheumatoid arthritis who responded to an online survey regarding glucocorticoid use (n=804), adequate disease control and adverse effects were both important considerations for patients using prednisolone. The most common adverse effects reported by those who had discontinued glucocorticoid therapy were weight gain (27.5%), osteoporosis (14.7%) and neuropsychiatric symptoms (13.8%) [83].</p>
                        <p>In another survey of 124 patients with RA, 62% felt that glucocorticoids “helped their disease a lot”, but 86% reported at least one adverse effect. Two-thirds of participants reported that the benefits of glucocorticoids were greater than the adverse effects [82]. The adverse effects identified as “worst” were symptomatic experiences such weight gain, sleep disturbance, gastrointestinal upset and muscle weakness, rather than other physiological effects such as osteoporosis, hypertension and hyperglycaemia. Similarly, in an online survey of glucocorticoid users in a social network, the most important adverse effects were weight gain, insomnia and change in facial appearance [78].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Glucocorticoids are widely available and low-cost, particularly for short-term use.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Glucocorticoids are a low-cost, familiar and accessible intervention. Most panellists felt that there were no important equity concerns related to the use of glucocorticoids as a treatment for RA flare in Australia. However, some panellists noted that there remains some potential for variation in the use of glucocorticoids between different groups, particularly in regard to availability of intra-articular therapy for people who may have difficulty accessing specialist care (e.g., those living in rural or remote locations, or those with lower socioeconomic status). Similarly, it is plausible that people who are less able to access timely specialist care may be at a higher risk of over-treatment with glucocorticoids rather than adjustment of DMARD therapy. Overall the panel felt that for this intervention, these potential differences in access were unlikely to result in important inequity in health outcomes.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The short-term use of glucocorticoids to treat RA flares is likely to be generally acceptable to patients, clinicians and other stakeholders. However, there is a risk of adverse effects in the short-term (e.g., disordered glycaemic control in people with diabetes, or neuropsychiatric effects) that may reduce acceptability in people who are susceptible to such effects. In addition, some people with RA - particularly those who have previously been treated with glucocorticoids for longer periods or who have experienced adverse effects related to glucocorticoids - may be unwilling to accept any use of glucocorticoids, even brief courses.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>There are likely to be no important feasibility issues as glucocorticoids have been in common use for the treatment of rheumatoid arthritis for several decades.</p></div></div>
                </div>
                <div class="tab-content" id="rec-15-practical">
                    <div class="content-section"><p>Consider the use of other symptomatic treatments for RA flares, particularly NSAIDs, depending on the individual clinical circumstances.</p>
                        <p>Opioids are not recommended for the treatment of RA pain, including during a flare.</p>
                        <p>The choice of route of glucocorticoids should be a shared decision that explicitly considers the individual clinical context (including the severity of the flare, the joint(s) involved, functional impact, and comorbidities) and the patient’s values and preferences.</p>
                        <p>Intra-articular glucocorticoids may be preferred in some cases (for example, in flares that affect a small number of accessible joints) but this has not been shown to be superior to systemic treatment in the setting of RA flares. Therefore systemic therapy (e.g., oral or intramuscular) is also a suitable choice depending on the patient’s preferences regarding injections, the nature of the joints involved, and access to a clinician with expertise in joint injection.</p>
                        <p>The use of imaging to guide injection placement is typically unnecessary as in most instances it adds to the costs without contributing additional benefits over anatomically-guided injections.</p>
                        <p>Injectable glucocorticoids should generally be used at the lowest dose expected to be sufficient to treat the flare.</p>
                        <ul>
                            <li>Oral glucocorticoids should be used at the lowest effective dose for the shortest possible time.</li>
                            <li>Care should be taken to ensure that short courses of oral glucocorticoids do not lead to persistent use, which is associated with the risk of additional harms including adrenal suppression.</li>
                        </ul>
                        <p>Any use of glucocorticoids should be accompanied by appropriate monitoring for adverse effects, including infection.</p></div>
                </div>
                <div class="tab-content" id="rec-15-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-15-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-15-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: September 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Long" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Long-term use of low dose glucocorticoids in RA -->
    <div class="modal-overlay" id="modal-rec-16">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Glucocorticoids</div>
                    <h2 class="modal-title">Long-term use of low dose glucocorticoids in RA</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-16', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-16', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-16', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-16', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-16', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-16', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-16-recommendation">
                    <span class="strength-badge conditional-against">⊖ Conditional Recommendation Against</span>
                    <div class="recommendation-box"><p>Do not routinely use glucocorticoids as a long-term (&gt;6 months) adjunct to DMARDs for the treatment of rheumatoid arthritis.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For this question, the panel reviewed evidence from randomised controlled trials (RCTs) in which treatment with low-dose glucocorticoids (up to 15mg per day prednisolone equivalent) used in addition to DMARDs for more than six months was compared with placebo plus DMARDs or DMARDs alone. The short-term use of glucocorticoids for the treatment of RA flare and the use of glucocorticoids for the induction of remission in RA are the subject of separate recommendations. The panel also suggested that tapering of low-dose glucocorticoids in patients with RA who are in remission or low disease activity ought to be considered as a separate recommendation topic.</p>
                        <p>Importantly, the studies included in the evidence summary were performed before the advent of biological and targeted synthetics drugs (b/tsDMARDs) and therefore the existing evidence may not be directly applicable to patients in the current era, in whom prompt abrogation of inflammation with conventional and b/tsDMARDs (alone or in combination) is the usual treatment goal. However, the panel also noted that although the use of glucocorticoids has declined in recent years, up to 1 in 3 Australian patients with RA continue to take oral glucocorticoids [85].</p>
                        <p>The panel noted that there was evidence for a beneficial effect of glucocorticoid for several outcomes, including pain, mean disease activity, and radiographic progression, however the magnitude of the estimated benefit was small for each of these outcomes. Indeed, none of the confidence intervals for the estimate of effect for these outcomes included the minimal clinically important difference. This suggests that, on average, any benefits associated with long-term use of low-dose glucocorticoids for people with RA are unlikely to be of clinical relevance.</p>
                        <p>The panel also noted that the harmful effects of interventions can be difficult to estimate from RCTs, which are typically powered for efficacy outcomes and which may not detect longer-term harms. In this case, there was little difference between those who were randomised to receive glucocorticoids versus those who did not receive glucocorticoids in terms of the number of total adverse events, withdrawal due to adverse events, and serious adverse events. However, adverse events deemed by the study authors to be those typically associated with glucocorticoid therapy (for example, osteoporosis) were more common in those who received glucocorticoids.</p>
                        <p>The panel also discussed data from observational studies of the harmful effects of glucocorticoids in people with RA. While the potential harms of glucocorticoids (such as osteoporosis, weight gain, hyperglycaemia, adrenal suppression, cataracts, altered wound healing and increased risk of infection) are widely recognised by consumers and prescribers, the absolute risk of these effects has proven to be difficult to estimate. Observational studies are at risk of various confounding factors, particularly confounding by indication (in which patients at a higher risk of poor outcomes may be more likely to be prescribed glucocorticoids), which may overestimate the true risk attributable to glucocorticoids.</p>
                        <p>Observational data suggest that the risk of many of the harmful effects of glucocorticoids increases with cumulative dose and is therefore of particular relevance to this recommendation. Major harmful effects, including death and major vascular events, were considered by the panel to be of high importance. The weight of evidence suggests that long-term glucocorticoid use in people with RA may be associated with an increased risk of death and vascular disease. While some studies have suggested a threshold dose (either cumulative or current) below which the risk is not elevated, estimates of this threshold vary and would be difficult to apply to decision-making in the individual patient.</p>
                        <p>The panel also noted that the adverse effects of most importance to consumers (including change in appearance, thin skin, sleep disturbance and neuropsychiatric effects) are often poorly captured in research studies, which often preference readily-measurable physiological outcomes such as blood pressure and bone density, and are therefore also an important consideration in decision-making about the use of long-term glucocorticoids.</p>
                        <p>In light of the body of evidence that suggests that any potential benefits of long-term glucocorticoids in RA are likely to be of negligible clinical importance, and the potential for a variety of harmful effects, the panel made a recommendation against the use of low-dose glucocorticoids in this setting. The recommendation is conditional due to uncertainty regarding the precise balance of benefits and harms and the likely impact of contextual factors on the individual patient’s treatment decision, including their goals, preferences and values, disease course, age and comorbidities. A shared decision-making framework that takes into account all of these factors is of paramount importance. In the absence of definitive data for a safe threshold dose, any plan to use glucocorticoids in RA should aim for the lowest dose and shortest duration that achieves the individual patient’s treatment goals, and should include a plan to monitor for and attempt to mitigate long-term harmful effects.</p>
                        <p>The panel also noted that people with RA who are already using low-dose glucocorticoids as part of their treatment regimen are likely to make different decisions about their ongoing use based on both their own individual goals and preferences and also their lived experience of the balance of benefits and harms of glucocorticoid therapy.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-16-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>Based on data from eight randomised controlled trials (RCTs), in adults with rheumatoid arthritis (RA) receiving DMARD therapy, compared to a placebo (or DMARD-only control), use of low dose glucocorticoids for longer than six months:</p>
                        <p>Probably results in a small improvement in mean disease activity and mean pain Probably results in a very small reduction in radiographic disease progression (mean x-ray changes) May result in more people reporting glucocorticoid-specific adverse events  May have little or no effect on the number of people achieving low disease activity, or on mean function May have little or no effect on the number of people withdrawing due to adverse events, the number of people reporting serious adverse events, or the number of people reporting any adverse event</p>
                        <p>Adverse effects related to glucocorticoid use have long been recognised, however the absolute risk of these effects may be difficult to estimate. RCTs are typically not powered to estimate differences in adverse events and may not have long enough follow-up periods to detect important long-term harms. Observational studies may supplement data from RCTs but are at risk of bias, particularly confounding by indication, which may overestimate the risk of adverse events that is attributable to glucocorticoids. There is continued debate in the literature regarding the relative safety of low-dose glucocorticoids in RA, particularly whether there might be a &#x27;safe&#x27; threshold dose below which the risks of long-term glucocorticoid therapy become negligible and the putative benefits might be retained [71].</p>
                        <p>Observational data suggest that long-term glucocorticoid use for RA may be associated with an increased risk of major adverse effects, including death. One observational study of 779 people with RA followed for an average of nine years found an increased risk of death in those who were exposed to glucocorticoids (IRR 1.77, 95% CI 1.36 - 2.32), equivalent to a 7% increase in the risk of death for each one milligram increase in the daily dose of prednisolone [80]. In this study, a threshold dose was detected: daily doses below 8mg and a cumulative dose below 40g were not associated with an increased mortality risk, and a cumulative dose below 9g was associated with a reduced mortality risk (adjusted HR 0.59, 95% CI 0.36 - 0.95). Similarly, one cohort study of RA patients that included a stricter adjustment for potential confounding by indication found an increase in all-cause mortality risk with glucocorticoid use (HR 1.64, 95% CI 1.50–1.79), and a threshold daily prednisolone dose of 5mg below which there was no increase in mortality [76]. Another demonstrated an increased mortality risk in RA patients who had received a cumulative dose of at least 700mg of prednisolone [72].</p>
                        <p>Data from observational studies of glucocorticoid use in people with RA are also consistent with a dose-dependent increased risk of major adverse effects, including osteoporosis and fracture [72][73], type 2 diabetes mellitus [72][74], serious infection [72], cataracts [70] and cardiovascular events [72][75]. 10-year follow-up of participants in an RCT that compared prednisolone 7.5mg/day versus placebo in addition to DMARDs for the first two years of RA demonstrated an increased risk of cerebrovascular events in those who had been randomised to prednisolone (HR 3.7, 95% CI 1.2 - 11.4) but did not find a difference in coronary events (HR 0.98, 95% CI 0.4 - 2.6) [69].</p>
                        <p>There is some evidence that the risk of some adverse effects that are important to consumers, including thin skin, easy bruising, and change in appearance, may occur even at very low daily doses of glucocorticoids (i.e., less than 5mg prednisolone per day) [79]. The risk of incident type 2 diabetes has also been reported to be elevated (HR 1.66, 95% CI 1.37 - 2.02) in people with RA treated with prednisolone at doses below 5mg per day [74].</p>
                        <p>Adrenal suppression can be demonstrated in at least one-third of RA patients treated with low-dose prednisolone [68], although estimates of the rate of clinically-important episodes of adrenal insufficiency vary [67].</p>
                        <p>The panel debated the balance of benefits and harms at length. Some panellists were of the view that the known harms of glucocorticoids outweigh the benefits, particularly as the benefits demonstrated in RCTs of long-term use were of very low magnitude (generally less than the minimal clinically-important difference for each of the important outcomes). However, the panel also recognised that while the potential harmful effects of glucocorticoids are well-known, the absolute magnitude of these effects is difficult to estimate from either RCTs (which may not adequately detect uncommon or long-term adverse events) or observational studies (which are subject to various confounding factors) and, as such, the balance of benefits and harms may vary between individual patients. Therefore, the panel agreed on a judgment of “small net benefit, or little difference between alternatives” but noted that for many patients, the important potential harmful effects of long-term low-dose glucocorticoids may outweigh the marginal potential clinical benefits.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>There was MODERATE certainty evidence for mean pain, disease activity and radiographic disease progression.</p>
                        <p>There was LOW certainty evidence for the number of people achieving low disease activity, the number of adverse events of special interest, the number of people withdrawing due to adverse events, the number of serious adverse events, and the number of people reporting adverse events and mean function.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>Among patients with RA, outcomes ranked as being of high importance include pain, joint damage, fatigue, daily functioning and mobility [77]. A systematic review of 36 studies of patient preferences for RA outcomes with disease-modifying therapies found that, in general, treatment benefits were considered more important than risks (including serious adverse events). However there was heterogeneity among included studies and variation between patients, suggesting that individual values and preferences are likely to be an important determinant of treatment decisions in people with rheumatoid arthritis [35].</p>
                        <p>For glucocorticoid therapy in particular, tradeoffs between benefits and risks may vary between patients and within the same person over time, depending on a variety of factors including individual preferences and values, age, comorbidities, disease activity, concurrent medications, social, work and family roles, and risk tolerance.</p>
                        <p>Beneficial and harmful effects often coexist in patients who use glucocorticoids for RA. Among Australian patients with rheumatoid arthritis who responded to an online survey regarding glucocorticoid use (n=804), adequate disease control and adverse effects were both important considerations for patients using prednisolone. The most common adverse effects reported by those who had discontinued glucocorticoid therapy were weight gain (27.5%), osteoporosis (14.7%) and neuropsychiatric symptoms (13.8%) [83].</p>
                        <p>In another survey of 124 patients with RA, 62% felt that glucocorticoids “helped their disease a lot”, but 86% reported at least one adverse effect. Two-thirds of participants reported that the benefits of glucocorticoids were greater than the adverse effects [63]. The adverse effects identified as “worst” were symptomatic experiences such weight gain, sleep disturbance, gastrointestinal upset and muscle weakness, rather than other physiological effects such as osteoporosis, hypertension and hyperglycaemia. Similarly, in an online survey of glucocorticoid users in a social network, the most important adverse effects were weight gain, insomnia and change in facial appearance [78].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Direct costs to patients due to glucocorticoids are low. The direct cost to the healthcare system is also lower than some other treatments for RA (particularly biological and targeted synthetic DMARDs), however there are also potential additional costs to the individual and society related to some of the recognised adverse effects of long-term glucocorticoid use, including osteoporosis, cardiovascular disease and cataracts.</p>
                        <p>The panel debated this issue at some length. While some felt that there are likely to be few resource implications of treatment with glucocorticoids, which is a low-cost intervention at the individual level, there was some concern within the panel that the long-term adverse effects of glucocorticoids (e.g., cataracts and fractures) may result in an additional resource burden on the healthcare system as a whole. Therefore, the panel agreed on a judgment of “important issues, or potential issues not investigated”.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Glucocorticoids are a low-cost, familiar and accessible intervention. In contrast, in Australia csDMARDs are typically prescribed under the supervision of a rheumatologist and high-cost interventions (i.e., b/tsDMARDs) must be prescribed by a specialist. Therefore it is plausible that glucocorticoid therapy may be offered in preference to other DMARDs to some people who may have difficulty accessing specialist care (e.g., those living in rural or remote locations, or those with lower socioeconomic status), or in some other groups of patients, such as those who are older or who have lower health literacy.</p>
                        <p>Most panellists felt that there were no important equity concerns related to the use of glucocorticoids in Australians with RA. However, some panellists expressed concern that there remains some potential for variation in the use of glucocorticoids between different groups that may result in inequity in health outcomes. After some discussion, the panel agreed on a judgment of “important issues, or potential issues not investigated”.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>A study of treatment preferences among patients with RA commencing one of four different initial DMARD regimens in a clinical trial setting found that while over a third of participants had hoped to avoid a treatment strategy that included a tapering high-dose glucocorticoid component, this preference was much stronger in those who had no experience of using glucocorticoids for their RA [66]. This suggests that for a proportion of patients, the benefits of glucocorticoids may be sufficient to increase acceptability despite concerns about adverse effects, although this may vary according to dose and duration of treatment.</p>
                        <p>In current practice, glucocorticoids are often used for longer periods or at higher doses than generally recommended, suggesting that prescribers and patients may make judgments about glucocorticoid risk-benefit trade-offs in daily practice that indicate relatively higher acceptability than anticipated [81].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>There are likely to be no important feasibility issues as glucocorticoids have been in common use for the treatment of rheumatoid arthritis for several decades.</p></div></div>
                </div>
                <div class="tab-content" id="rec-16-practical">
                    <div class="content-section"><p>A treat-to-target approach is recommended for all patients with RA, irrespective of any decision to include glucocorticoids in the treatment regimen</p>
                        <p>Any decision regarding the use of glucocorticoids should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances (including comorbidities and concomitant medications)</p>
                        <p>In general, for patients who are already using glucocorticoids, the lowest effective dose should be sought, and opportunities for reduction in dose should be considered at each visit</p>
                        <p>In patients who are using glucocorticoids in combination with DMARDs, reduction or cessation of glucocorticoids should be considered before an attempt at dose reduction of b/tsDMARDs or csDMARDs.</p>
                        <p>See also the recommendation “Rheumatoid Arthritis: Dose reduction or discontinuation of bDMARDs and tsDMARDs”</p>
                        <p>In patients who are treated with glucocorticoids, take steps to estimate the risk of modifiable adverse consequences of treatment (e.g., fracture, cardiovascular disease) and, where appropriate, treat modifiable risk factors (e.g., bone density, blood pressure, lipids).</p></div>
                </div>
                <div class="tab-content" id="rec-16-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-16-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-16-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: September 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%3A%20Short" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <!-- MODAL: Short-term bridging glucocorticoids in addition to -->
    <div class="modal-overlay" id="modal-rec-17">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Glucocorticoids</div>
                    <h2 class="modal-title">Short-term bridging glucocorticoids in addition to DMARD therapy in RA</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('rec-17', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('rec-17', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('rec-17', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('rec-17', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="consumer" onclick="switchTab('rec-17', 'consumer')">For Consumers</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('rec-17', 'moreinfo')">More Info</button>
            </div>
            <div class="modal-body">
                <div class="tab-content active" id="rec-17-recommendation">
                    <span class="strength-badge conditional-for">⊕ Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>Consider using a short course of glucocorticoids in people with active rheumatoid arthritis who are initiating, switching or adding DMARD therapy, using the lowest effective dose until DMARDs take effect.</p>
                        <p>Inability to achieve the treatment target should imply the need for escalation of DMARD therapy rather than the use of additional glucocorticoids.</p></div>
                    <div class="remark-box"><p>A shared plan for dose reduction and discontinuation of bridging glucocorticoids should be developed at the start of the treatment course and regularly reviewed.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For the purpose of this recommendation, we considered ‘bridging’ glucocorticoids to be the use of a short course of glucocorticoids (via any route), administered concurrently with new or additional DMARDs in the setting of newly-diagnosed or poorly-controlled RA, with the intention of achieving rapid disease control (“induction”) while awaiting the maximum effect of the DMARDs. While our evidence summary included glucocorticoid courses of up to 52 weeks, the duration of the course of oral glucocorticoids in the included studies ranged between 12 weeks and 52 weeks, and parenteral courses were generally relatively brief. The panel noted that in most cases a short course is likely to be sufficient to act as a bridge to the onset of action of slower-acting DMARDs.</p>
                        <p>The panel considered the overall body of evidence from RCTs, which provided mostly low- to medium-certainty evidence of a beneficial effect of bridging glucocorticoids on disease activity (including achievement of remission), pain and function, and mostly low-certainty evidence of little difference in adverse effects compared with placebo or no glucocorticoids. However, the panel noted that adverse effects may not be fully captured in RCTs, and discussed the broader observational evidence base regarding the short-term and long-term harms of glucocorticoids (summarised in the Benefits and Harms domain in the Evidence to Decision section). While the majority of the adverse effects of glucocorticoids are related to the cumulative dose, some harmful or unpleasant effects may be associated with brief exposure to glucocorticoids. The panel also noted that the adverse effects of most importance to consumers (including change in appearance, thin skin, sleep disturbance and neuropsychiatric effects) are often poorly captured in research studies, which often preference readily-measurable physiological outcomes such as blood pressure and bone density, and may be experienced during short courses of glucocorticoids.</p>
                        <p>In addition, the panel highlighted the risk that some patients may have difficulty tapering glucocorticoids, which may lead to the unintended use of a prolonged course. There is limited evidence regarding the rate of transition from bridging therapy to long-term therapy, although data from RCTs suggest that 22% of participants who commenced bridging glucocorticoids were still taking glucocorticoids at 12 months, and 10% had not discontinued by 24 months [160]. Although the use of glucocorticoids has reduced slightly in recent years, up to 1 in 3 Australian patients with RA continue to take oral glucocorticoids [85]. The balance of benefits and harms is less favourable with longer courses of glucocorticoids, as discussed in our conditional recommendation against the use of glucocorticoids for longer than 6 months in people with RA.</p>
                        <p>The panel noted that some of the included studies did not incorporate DMARD regimens that are typically used for induction in the modern era (e.g., early use of methotrexate alone or in combination with other csDMARDs and rapid escalation of therapy in a treat-to-target paradigm) and therefore some of the evidence considered may not be directly applicable to current treatment methods. However studies were only included if glucocorticoids were commenced concurrently with DMARDs, and the majority of included studies used methotrexate as the initial DMARD. It was also noted that all csDMARDs have a relatively slow onset of action and therefore a strategy that involves bridging with a rapid-acting therapy remains relevant in the current era.</p>
                        <p>The panel also discussed the impact of bridging glucocorticoids on structural outcomes (i.e., joint erosion). While radiographic outcomes were not included in the evidence summary for this recommendation due to the short-term intervention, the panel noted that there is evidence to suggest that, in general, glucocorticoids may reduce the risk of radiographic progression in RA [65] and that the rapid induction of remission in people with early RA also results in a lower risk of structural damage [161].</p>
                        <p>Ultimately, the panel unanimously agreed on a conditional recommendation in favour of short-term bridging glucocorticoids that acknowledges that the decision for the individual patient will be dependent on a variety of contextual factors, including disease activity, disease impact, comorbidity, access to care, and individual values and preferences. In general, use of the lowest dose and briefest course of glucocorticoids that achieves the treatment goal while awaiting the intended effect of the DMARD regimen is likely to optimise the balance of glucocorticoid benefits and harms. A lower cumulative dose of glucocorticoids is likely to minimise adverse effects. The presence of persistent active RA or the inability to successfully taper the glucocorticoid dose should imply the need for escalation of DMARD therapy rather than continuation or escalation of glucocorticoids.</p>
                        <p>Given the risk of transition to long-term glucocorticoid use, a clear shared plan for discontinuation of glucocorticoids should be developed at the time of treatment initiation. While existing evidence does not demonstrate a difference in efficacy or safety of oral versus parenteral glucocorticoids as a bridging therapy, the panel considered that the use of parenteral glucocorticoids (in particular, intramuscular depot preparations) may in theory reduce the risk of continued glucocorticoid use. Similarly, the use of intra-articular glucocorticoids where feasible (e.g., in people with a small number of active joints that are amenable to injection), may limit systemic exposure to glucocorticoids.</p>
                        <p>Some suggestions regarding glucocorticoid doses have been made in the Practical Information section of this recommendation, although this represents broad guidance based on the clinical experience of the panellists rather than additional evidence-based recommendations, and the choice of dose, duration and route remains an individual clinical decision. The panel deliberately chose the term “short course” rather than “low-dose” for this recommendation as it was felt that, in some instances, initiation of bridging glucocorticoids with a relatively high dose followed by a rapid taper may achieve the treatment goal more rapidly and may ultimately result in a lower cumulative dose than a more prolonged course at a lower dose.</p>
                    </div>
                </div>
                <div class="tab-content" id="rec-17-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>In adults with active rheumatoid arthritis who are initiating DMARD therapy, the addition of glucocorticoids (compared to a glucocorticoid placebo):</p>
                        <p>improves mean function and slightly improves mean disease activity probably slightly improves the number of people achieving remission and probably slightly improves mean overall pain probably results in little or no difference in the number of people withdrawing due to adverse events. may result in little or no difference in the number of people reporting serious adverse events or the number of serious adverse events reported no placebo-controlled studies were found that looked at the number of people achieving low disease activity. No placebo-controlled studies were found that included people adding or switching DMARD therapy.</p>
                        <p>In adults with active rheumatoid arthritis who are initiating, adding or switching DMARD therapy, the addition of glucocorticoids compared to DMARD therapy alone (i.e. without a placebo):</p>
                        <p>may increase the number of people achieving remission, and may improve mean function and mean disease activity. may have little or no effect on the number of people achieving low disease activity and the number of people withdrawing due to adverse events. we are uncertain whether bridging glucocorticoid therapy results in more people with serious adverse events as the certainty of the evidence is very low. No studies were found that looked at mean overall pain.</p>
                        <p>In adults with active rheumatoid arthritis who are initiating, adding or switching DMARD therapy, compared to oral bridging glucocorticoid therapy, parenteral bridging glucocorticoid therapy:</p>
                        <p>may have little or no effect on mean pain, function, disease activity and the number of people achieving remission and low disease activity. we are uncertain whether parenteral bridging glucocorticoid therapy results in more people reporting serious adverse events and withdrawing due to adverse events compared with oral bridging glucocorticoid therapy, as the certainty of the evidence is very low.</p>
                        <p>We are uncertain of the benefits and harms of additional bridging glucocorticoid therapy in adults with active rheumatoid arthritis who are on background glucocorticoid therapy and are adding or switching DMARD therapy, due to a lack of RCT evidence.</p>
                        <p>Adverse effects related to glucocorticoid use have long been recognised, however the absolute risk of these effects may be difficult to estimate. RCTs are typically not powered to estimate differences in adverse events and may not have long enough follow-up periods to detect important long-term harms. Observational studies may supplement data from RCTs but are at risk of bias, particularly confounding by indication, which may overestimate the risk of adverse events that is attributable to glucocorticoids. There is continued debate in the literature regarding the relative safety of low-dose glucocorticoids in RA, particularly whether there might be a &#x27;safe&#x27; threshold dose below which the risks of long-term glucocorticoid therapy become negligible and the putative benefits might be retained [71].</p>
                        <p>Observational data suggest that long-term glucocorticoid use for RA may be associated with an increased risk of major adverse effects, including death. One observational study of 779 people with RA followed for an average of nine years found an increased risk of death in those who were exposed to glucocorticoids (IRR 1.77, 95% CI 1.36 - 2.32), equivalent to a 7% increase in the risk of death for each one milligram increase in the daily dose of prednisolone [80]. In this study, a threshold dose was detected: daily doses below 8mg and a cumulative dose below 40g were not associated with an increased mortality risk, and a cumulative dose below 9g was associated with a reduced mortality risk (adjusted HR 0.59, 95% CI 0.36 - 0.95). Similarly, one cohort study of RA patients that included a stricter adjustment for potential confounding by indication found an increase in all-cause mortality risk with glucocorticoid use (HR 1.64, 95% CI 1.50–1.79), and a threshold daily prednisolone dose of 5mg below which there was no increase in mortality [76]. Another demonstrated an increased mortality risk in RA patients who had received a cumulative dose of at least 700mg of prednisolone [72].</p>
                        <p>Data from observational studies of glucocorticoid use in people with RA are also consistent with a dose-dependent increased risk of major adverse effects, including osteoporosis and fracture [72][73], type 2 diabetes mellitus [72][74], serious infection [72], cataracts [70] and cardiovascular events [72][75]. 10-year follow-up of participants in an RCT that compared prednisolone 7.5mg/day versus placebo in addition to DMARDs for the first two years of RA demonstrated an increased risk of cerebrovascular events in those who had been randomised to prednisolone (HR 3.7, 95% CI 1.2 - 11.4) but did not find a difference in coronary events (HR 0.98, 95% CI 0.4 - 2.6) [69].</p>
                        <p>There is some evidence that the risk of some adverse effects that are important to consumers, including thin skin, easy bruising, and change in appearance, may occur even at very low daily doses of glucocorticoids (i.e., less than 5mg prednisolone per day) [79]. The risk of incident type 2 diabetes has also been reported to be elevated (HR 1.66, 95% CI 1.37 - 2.02) in people with RA treated with prednisolone at doses below 5mg per day [74].</p>
                        <p>Adrenal suppression can be demonstrated in at least one-third of RA patients treated with low-dose prednisolone [68], although estimates of the rate of clinically-important episodes of adrenal insufficiency vary [67].</p>
                        <p>There is little observational evidence available regarding the specific risks of short-term glucocorticoids in people with RA, however data from the general population are consistent with a small increase in the risk of serious adverse events. In a study using data from the Taiwanese National Health Insurance Research Database (n = 15,859,129 adult participants), brief courses (14 days or fewer) of oral glucocorticoids were associated with an approximate doubling of the risk of GI bleeding, sepsis or heart failure in the subsequent month [94]. Similarly, a study using a US insurance database found that a short course (less than 30 days) of systemic glucocorticoids was associated with an increased risk of sepsis, venous thromboembolism and fracture in the subsequent 30 days [95]. The estimated absolute risk of any of these serious adverse events is approximately one per 1,000 short courses of glucocorticoid [93].</p>
                        <p>The panel also noted the important current concern during the COVID-19 pandemic regarding the potential harmful effects of both glucocorticoids and uncontrolled disease activity on the risk of COVID-19 (including severe outcomes) and the negative impact of glucocorticoids on the immunogenicity of COVID-19 vaccines [33][159][162]. While COVID-19 infection rates remain high, the balance of risks and harms of induction glucocorticoid regimens may be altered, particularly in people who are at increased risk of exposure to COVID-19 or of severe COVID-19 disease outcomes.</p>
                        <p>Given the above, the panel agreed that the likely benefits of induction glucocorticoids may be offset by the risk of harms, but that this balance is likely to vary importantly between individuals.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>1.  For adults with active RA who are initiating DMARD therapy, addition of glucocorticoids versus placebo:</p>
                        <p>There was HIGH certainty evidence that bridging glucocorticoid therapy improves mean function (i.e. lower HAQ score) and slightly improves mean disease activity.   There was MODERATE certainty evidence that bridging glucocorticoid therapy probably slightly improves the number of people achieving remission and mean overall pain (i.e. lower VAS score), and probably has little or no difference on the number of people withdrawing from adverse events.   There was LOW certainty evidence that bridging glucocorticoid therapy may have little or no difference on either the number of people reporting serious adverse events or the number of serious adverse events reported.   No studies reported data on the number of people with low disease activity.</p>
                        <p>2. For adults with active RA who are initiating, adding or switching DMARDs, addition of glucocorticoids (versus no additional glucocorticoids):</p>
                        <p>There was LOW certainty evidence the bridging glucocorticoid therapy may improve the number of people achieving remission, mean function and mean disease activity; but may have little or no effect on the number of people achieving low disease activity or the number of people withdrawing due to adverse events.   There was VERY LOW certainty evidence regarding whether or not bridging glucocorticoid therapy results in more people with serious adverse events.   No studies reported data on mean pain.</p>
                        <p>3. For adults with active RA who are initiating, adding or switching DMARDs, parenteral (IV or IM) bridging glucocorticoids versus oral bridging glucocorticoids:</p>
                        <p>There was LOW certainty evidence for the number of people achieving remission, the number of people achieving low disease activity, mean overall pain, function and mean disease activity.   There was VERY LOW certainty evidence for the number of people withdrawing due to adverse events and the number of people reporting serious adverse events.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>Among patients with RA, outcomes ranked as being of high importance include pain, joint damage, fatigue, daily functioning and mobility [77]. A systematic review of 36 studies of patient preferences for RA outcomes with disease-modifying therapies found that, in general, treatment benefits were considered more important than risks (including serious adverse events). However there was heterogeneity among included studies and variation between patients, suggesting that individual values and preferences are likely to be an important determinant of treatment decisions in people with rheumatoid arthritis [35]. Similarly, people with early RA prioritise the rapid relief of symptoms and restoration of function, however there is evidence of variation in priorities and preferences, both between individuals and within individuals over time [157][158].</p>
                        <p>For glucocorticoid therapy in particular, tradeoffs between benefits and risks may vary between patients and within the same person over time, depending on a variety of factors including individual preferences and values, age, comorbidities, disease activity, concurrent medications, social, work and family roles, and risk tolerance.</p>
                        <p>The consumer panellist noted that values and preferences are likely to differ between people with recent onset RA versus those who have had RA for some time. For example, people who have had prior experience with glucocorticoids for RA (particularly those who have previously experienced adverse effects) may weigh the potential benefits and harms differently from those with early RA.</p>
                        <p>Among Australian patients with RA who responded to an online survey regarding glucocorticoid use (n=804), adequate disease control and adverse effects were both important considerations for patients using prednisolone. The most common adverse effects reported by those who had discontinued glucocorticoid therapy were weight gain (27.5%), osteoporosis (14.7%) and neuropsychiatric symptoms (13.8%) [83].</p>
                        <p>In another survey of 124 patients with RA, 62% felt that glucocorticoids “helped their disease a lot”, but 86% reported at least one adverse effect. Two-thirds of participants reported that the benefits of glucocorticoids were greater than the adverse effects [82]. The adverse effects identified as “worst” were symptomatic experiences such weight gain, sleep disturbance, gastrointestinal upset and muscle weakness, rather than other physiological effects such as osteoporosis, hypertension and hyperglycaemia. Similarly, in an online survey of glucocorticoid users in a social network, the most important adverse effects were weight gain, insomnia and change in facial appearance [78].</p>
                        <p>The panel agreed unanimously that there is likely to be substantial variability in values and preferences, and that there remains an important need for further research on the impact of different glucocorticoid regimens on the outcomes that are of highest importance to consumers, and how these may vary in the setting of short-term bridging therapy versus long-term use.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Glucocorticoids are widely available and low-cost, particularly for short-term use. However the panel noted that there might be some indirect costs (to individuals and society) related to the recognised adverse effects of glucocorticoid use, although these are likely to be more important with long-term use. We are not aware of any data regarding the impact of short-term glucocorticoid therapy on the environment, however a major negative impact is unlikely.</p>
                        <p>The panel debated this issue at some length. While some felt that there are likely to be few resource implications of treatment with glucocorticoids, which is a low-cost intervention at the individual level, there was some concern within the panel that the potential adverse effects of glucocorticoids may result in an additional resource burden on the healthcare system as a whole. Therefore, the panel agreed on a judgment of “important issues, or potential issues not investigated&quot;.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Glucocorticoids are a low-cost, familiar and accessible intervention. There is a theoretical risk of some variation in the use of glucocorticoids between different groups, particularly people who may have difficulty accessing specialist care (e.g., those living in rural or remote locations, or those with lower socioeconomic status). It is plausible that people who are less able to access timely specialist care may be at a higher risk of over-treatment with glucocorticoids rather than adjustment of DMARD therapy.</p>
                        <p>The panel discussed this issue at length and reiterated that a recommendation in favour of bridging glucocorticoids should not permit or encourage the use of glucocorticoids in place of the appropriate use of DMARDs. The panel also noted that in Australia there is variation in timely access to specialist rheumatology care. While glucocorticoids may help to reduce health inequity in people with RA by enabling suppression of disease activity in those who face delayed access to specialist care, there is also a risk of prolonged use of glucocorticoids or delayed use of adequate DMARD therapy in this group, which may create inequity in long-term outcomes.</p>
                        <p>Overall, the panel agreed that there are likely to be effects on health equity related to glucocorticoid use that are complex and poorly understood, and for this reason the panel voted for &#x27;important issues, or potential issues not investigated&#x27;.</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>There is likely to be some variation among patients, clinicians and other stakeholders in the acceptability of the addition of glucocorticoids to the initial DMARD regimen in people with RA.</p>
                        <p>A study of treatment preferences among patients with RA commencing one of four different initial DMARD regimens in a clinical trial setting found that while over a third of participants had hoped to avoid a treatment strategy that included a tapering high-dose glucocorticoid component, this preference was much stronger in those who had no experience of using glucocorticoids for their RA [66]. Similarly, a qualitative study of participants in a clinical trial of combination csDMARD and glucocorticoid therapy in early RA found that concerns about glucocorticoid adverse effects were common at the start of the trial, however these concerns diminished over the course of the trial as beneficial effects were experienced or expected side-effects did not occur [155]. This suggests that for a proportion of patients, the benefits of glucocorticoids may be sufficient to increase acceptability despite concerns about adverse effects, although this may vary according to dose and duration of treatment.</p>
                        <p>A study of rheumatologists in Belgium found variation in the acceptability of a regimen of combination DMARDs and glucocorticoids for the treatment of early RA [156]. The most important barriers to the rheumatologists&#x27; implementation of such a regimen were the increased risk of adverse effects (particularly in patients with comorbidity) and perceived reluctance of their patients to take combination therapy. Notably, two of the six highest-ranked barriers to implementation related to the use of glucocorticoids (specifically, concerns about use of prednisolone for longer than 28 weeks or at a dose higher than 10mg/day).</p>
                        <p>In current practice, glucocorticoids are often used for longer periods or at higher doses than generally recommended, suggesting that prescribers and patients may make judgments about glucocorticoid risk-benefit trade-offs in daily practice that indicate relatively higher acceptability than anticipated [81].</p></div></div>
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>There are likely to be no important feasibility issues as glucocorticoids have been in common use for the treatment of rheumatoid arthritis for several decades.</p></div></div>
                </div>
                <div class="tab-content" id="rec-17-practical">
                    <div class="content-section"><p>A treat-to-target approach is recommended for all patients with RA, irrespective of any decision to include glucocorticoids in the treatment regimen.</p>
                        <p>Any decision regarding the use of glucocorticoids should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual’s circumstances (including comorbidities and concomitant medications).</p>
                        <p>DMARDs, rather than glucocorticoids, remain the preferred long-term treatment for RA.</p>
                        <p>The long-term use (&gt;6 months) of glucocorticoids for the treatment of RA is not recommended.</p>
                        <p>Bridging glucocorticoids are intended to achieve prompt control of disease activity while awaiting the effect of DMARDs.</p>
                        <p>Failure to achieve the treatment target within an appropriate timeframe should imply the need for escalation of DMARD therapy rather than the use of additional glucocorticoids.</p>
                        <p>Glucocorticoids may be administered via the oral, intramuscular, intra-articular or intravenous routes. Tailor the route of administration to the individual clinical circumstances, including patient preferences, disease activity, and pattern of involved joints.</p>
                        <p>Parenteral routes of administration (particularly intramuscular depot preparations and, where appropriate, intra-articular injections) may reduce the risk of unintended transition to chronic glucocorticoid use.</p>
                        <p>The use of imaging to guide intra-articular injection placement is typically unnecessary as in most instances it adds to the costs without contributing additional benefits over anatomically-guided injections.</p>
                        <p>Aim for the lowest cumulative dose of glucocorticoids that achieves the treatment goal while DMARDs are taking effect.</p>
                        <p>A typical dose for intramuscular therapy is 120mg of methylprednisolone acetate, repeated once at 6-12 weeks if necessary.</p>
                        <p>For oral glucocorticoids, a starting dose of 15 to 25mg of prednis(ol)one once daily is typically sufficient, aiming to reduce the dose approximately weekly to cessation within 8-12 weeks or as soon as possible thereafter.</p>
                        <p>A shared plan for dose reduction and discontinuation of bridging glucocorticoids should be developed at the start of the treatment course and regularly reviewed.</p>
                        <p>Any use of glucocorticoids should be accompanied by appropriate monitoring for adverse effects, including infection.</p></div>
                </div>
                <div class="tab-content" id="rec-17-data">
                    <div class="data-placeholder"><p>📊 Links to GRADE evidence tables, systematic reviews, and other supporting data will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-17-consumer">
                    <div class="data-placeholder"><p>👥 A plain-language version of this recommendation for patients and carers will be added here.</p></div>
                </div>
                <div class="tab-content" id="rec-17-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members">
                            <span class="panel-member">To be added</span>
                        </div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Meeting Date</div>
                            <div class="info-value">To be added</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: September 2025</span>
                    <a href="mailto:sam@whittle.au?subject=Feedback%20on%20Recommendation" class="feedback-link"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/><path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/></svg> Suggest feedback</a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/LqRV3n" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
            </div>
        </div>
    </div>
    <script>
        let activeCondition = 'all';
        let activeTag = null;
        let searchQuery = '';

        function filterCards() {
            let visibleCount = 0;
            document.querySelectorAll('.recommendation-card').forEach(card => {
                const conditions = card.dataset.conditions || '';
                const tags = card.dataset.tags || '';
                const title = card.querySelector('.card-title')?.textContent.toLowerCase() || '';
                const recommendation = card.querySelector('.card-recommendation')?.textContent.toLowerCase() || '';
                const category = card.querySelector('.card-category')?.textContent.toLowerCase() || '';
                
                const matchesCondition = activeCondition === 'all' || conditions.includes(activeCondition);
                const matchesTag = !activeTag || tags.includes(activeTag);
                const matchesSearch = !searchQuery || 
                    title.includes(searchQuery) || 
                    recommendation.includes(searchQuery) || 
                    category.includes(searchQuery) ||
                    tags.includes(searchQuery);
                
                const isVisible = matchesCondition && matchesTag && matchesSearch;
                card.classList.toggle('hidden', !isVisible);
                if (isVisible) visibleCount++;
            });
            
            // Show/hide no results message
            let noResults = document.getElementById('no-results');
            if (visibleCount === 0) {
                if (!noResults) {
                    noResults = document.createElement('div');
                    noResults.id = 'no-results';
                    noResults.className = 'no-results';
                    noResults.innerHTML = '<h3>No recommendations found</h3><p>Try adjusting your search or filters</p>';
                    document.getElementById('recommendations-grid').after(noResults);
                }
                noResults.style.display = 'block';
            } else if (noResults) {
                noResults.style.display = 'none';
            }
        }

        // Search functionality
        const searchInput = document.getElementById('search-input');
        const searchClear = document.getElementById('search-clear');
        
        searchInput.addEventListener('input', function() {
            searchQuery = this.value.toLowerCase().trim();
            searchClear.classList.toggle('visible', searchQuery.length > 0);
            filterCards();
        });
        
        function clearSearch() {
            searchInput.value = '';
            searchQuery = '';
            searchClear.classList.remove('visible');
            filterCards();
        }

        document.querySelectorAll('.condition-tab').forEach(tab => {
            tab.addEventListener('click', function() {
                document.querySelectorAll('.condition-tab').forEach(t => t.classList.remove('active'));
                this.classList.add('active');
                activeCondition = this.dataset.condition;
                filterCards();
            });
        });

        document.querySelectorAll('.tag-filter').forEach(btn => {
            btn.addEventListener('click', function() {
                if (this.classList.contains('active')) {
                    this.classList.remove('active');
                    activeTag = null;
                } else {
                    document.querySelectorAll('.tag-filter').forEach(b => b.classList.remove('active'));
                    this.classList.add('active');
                    activeTag = this.dataset.tag;
                }
                filterCards();
            });
        });

        function openModal(modalId) {
            const modal = document.getElementById('modal-' + modalId);
            if (modal) { modal.classList.add('active'); document.body.style.overflow = 'hidden'; }
        }
        
        function closeModal() {
            document.querySelectorAll('.modal-overlay').forEach(modal => modal.classList.remove('active'));
            document.body.style.overflow = '';
        }
        
        function switchTab(modalId, tabId) {
            const modal = document.getElementById('modal-' + modalId);
            if (!modal) return;
            modal.querySelectorAll('.modal-tab').forEach(tab => tab.classList.toggle('active', tab.dataset.tab === tabId));
            modal.querySelectorAll('.tab-content').forEach(content => content.classList.remove('active'));
            const tabContent = document.getElementById(modalId + '-' + tabId);
            if (tabContent) tabContent.classList.add('active');
        }
        
        document.querySelectorAll('.modal-overlay').forEach(modal => {
            modal.addEventListener('click', function(e) { if (e.target === this) closeModal(); });
        });
        document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeModal(); });
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function(e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) target.scrollIntoView({ behavior: 'smooth', block: 'start' });
            });
        });
    </script>
</body>
</html>
